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Abstract 
 
Exploration of neuromuscular plasticity: an examination of acetylcholine receptor 
and skeletal muscle fiber adaptations. 
 
Ewa M. Kulig, PhD 
Concordia University, 2012 
 
 
Muscle is an example of a beautifully orchestrated biological system whose main role is 
to convey a chemical stimulus into a mechanical response. Skeletal muscles carry out the 
function of moving the bones of the skeleton. Skeletal muscles display remarkable levels 
of adaptability and plasticity. The regulation of neuromuscular plasticity is influenced by 
signals coming from the motor neuron and from within the muscles. In this thesis, 
different transgenic and surgical mice models are used to investigate key aspects of 
muscle plasticity. Firstly, transgenic mice expressing a calmodulin-binding peptide are 
used to demonstrate that calmodulin regulates the aggregation of acetylcholine receptors. 
Secondly, the roles of Nuclear Factor of activated-Tcells (NFAT) transcription factors are 
investigated in adaptive muscle growth using mice knockouts for these transcription 
factors. The results presented indicate that NFATc2 and NFATc3 are essential for muscle 
hypertrophy and that they have distinct roles in the regulation of muscle growth. Thirdly, 
novel roles for the nerve-derived trophic factor agrin are explored in healthy and 
deteriorating muscles. Overall, the results presented in this thesis provide original 
information on the regulation of muscle plasticity and serve to point to novel potential 
targets in the regulation of various neuromuscular diseases.  
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Chapter 1: General Introduction 
 2 
 
1.1 Skeletal muscle development and structure 
1.1.1 Muscle structure 
Muscle is an example of a beautifully orchestrated biological system whose main 
role is to convey a chemical stimulus into a mechanical response. Three types of muscle 
tissues exist: skeletal, cardiac and smooth. These three categories differ in their 
microscopic anatomy, location and control by the nervous and endocrine systems 
(Jenkins et al., 2010). Skeletal muscles contract voluntarily, are striated and carry the 
function of moving the bones of the skeleton. Cardiac muscles are also striated and form 
the heart wall. These muscles carry heart contractions that serve to propel blood into the 
body’s circulatory system. Finally, smooth muscle tissue is located in the walls of hollow 
internal structures such as blood vessels, the respiratory and the gastrointestinal track. 
Smooth muscles lack striations and perform involuntary movements that regulate the 
movement of liquids in internal body structures.   
 Skeletal muscle fibers are made up of bundles of myofibrils composed of a 
network of contractile myofilaments. The sacromere is the functional unit of muscle 
contraction (Jenkins et al., 2010) and it is defined as the region between successive  Z-
discs (also called Z-bands or Z-lines) (Figure 1.1). The Z-disc structural backbone is 
formed by α-actinin dimers where structural and signaling proteins, such as actin 
filaments, titin or nebulin, are inserted (Frank et al., 2006). The thick filaments of the 
sarcomere are composed of myosin and are situated in the central portion of the 
sacromere, while the thin actin containing filaments are situated toward the extremities of 
 3 
 
the functional unit with one end attached to the Z line and the other binding myosin.  
Myosin and actin are contractile proteins of skeletal muscle that carry out the process of 
skeletal muscle contraction. More specifically, myosin is the motor protein that converts 
the chemical energy of ATP into the mechanical energy of motion, while using the actin 
filaments to perform a sliding motion that leads to muscle contraction (Jenkins et al., 
2010). This cycle of sarcomere contraction and relaxation is repeated to achieve muscle 
movement. 
 




Muscle contraction events are initiated by electrical signals coming from the 
nerve: a process referred to as excitation-contraction coupling (Jenkins et al., 2010). 
Briefly, a nerve impulse will trigger the release of the neurotransmitter acetylcholine 
(Ach) from the presynaptic terminal into the synaptic cleft. Acetylcholine will bind to its 
receptor (AChR), situated on the postsynaptic muscle surface, and induce a 
conformational change opening this channel and allowing ion exchange. Most notably, 
the influx of Na
+
 will lead to membrane depolarization and the propagation of an action 
potential. This action potential will travel down the muscle sarcolemma (muscle fiber 
plasma membrane) into the T-tubules (special extensions of the sarcolemma) where it 




 moving into the sarcoplasm 
(muscle fiber cytoplasm) will bind to the troponin-tropomyosin protein complex and 
move this complex away from the myosin binding site on actin. This process allows free 
myosin heads to bind and initiate the sliding motion cycle of muscle contraction.  
In addition to muscle contractile proteins and their regulatory proteins, skeletal 
muscle also consists of a vast number of structural proteins that contribute to stability, 
elasticity, extensibility and alignment of muscle myofibrils (Jenkins et al., 2010; Singhal 
& Martin, 2011). Some of these proteins assemble the extracellular matrix (ECM), while 
others form the muscle basement membrane that is linked to the muscle sarcolemma. The 
list of these proteins is extensive but includes agrin, laminin, collagen, perlecan, integrin, 
dystroglycan, rapsyn, and dystrophin (Pilgram et al., 2010; Singhal & Martin, 2011). 
ECM proteins can form signaling complexes, for example laminins regulate, via 
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dystroglycan and integrins, the Akt signaling cascade (Langenbach & Rando, 2002). 
Furthermore, agrin and rapsyn modulate post-synaptic receptor density at muscle 
synapses (Moransard et al., 2003). The complexity of the ECM highlights its essential 
roles in muscle development, muscle growth, neuromuscular junction formation and 
synaptic transmission (Singhal & Martin, 2011).  
The most extensive and well-characterized complex formed by some of these 
proteins is the dystrophin-associated glycoprotein complex (DGC) (Figure 1.2). This 
complex links the sarcomere actin filaments to the integral membrane proteins of the 
sarcolemma, which in turn is connected to the connective tissue in the ECM, providing 
reinforcement to muscle structure.  
 
Figure 1.2: Dystrophin associated protein complex (Blake et al., 2002) 




This DGC is formed by proteins highly conserved between species and this highlights its 
important role in the maintenance of muscle fiber integrity (Pilgram et al., 2010). A lack 
of, or mutation in, almost any of these proteins leads to muscular dystrophies such as 
Duchenne Muscular Dystrophy (characterized by the absence of functional dystrophin) or 
Limb Girdle Muscular Dystrophy (characterized by the absence of functional 
sarcoglycan). Moreover, it is now established that the DGC also serves as a platform for 
the proteins calmodulin and insulin, involved in muscle signaling (Pilgram et al., 2010). 
Additionally, the DGC provides a scaffold for anchoring and regulating calcium 
transporters such as the store-operated channel (SOC) or the stretch-activated channel 
(SAC) regulating intracellular calcium concentration (Constantin et al., 2006). As such, a 
better understanding of muscle structure can also provide a better comprehension of 
muscle and nerve communication.    
 
1.1.2 Development of skeletal muscle 
Skeletal muscles carry out numerous essential functions in the body including 
locomotor activity, posture and breathing. The development of skeletal muscle involves 
the simultaneous processes of myogenesis that forms muscle cells, and synaptogenesis 
that forms neuromuscular junctions (NMJ).  
Skeletal muscle cells are derived from mesodermal precursor cells of the 
embryo’s somites (Figure 1.3). All myogenic precursor cells express the transcription 
factor Pax7 (Seale et al., 2000; Yokoyama & Asahara, 2011). During the process of 
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myogenesis, the expression of Pax7 decreases and myogenic precursor cells are 
determined to become myoblasts through the signaling of transcription factors myoD 
(myogenic determination) and myf5 (myogenic factor 5) (Sabourin & Rudnicki, 2000; 
Charge & Rudnicki, 2004; Lieber, 2010; Yokoyama & Asahara, 2011). Myoblasts are 
primitive, proliferating, mononucleated muscle fiber precursor cells that differentiate into 
myocytes. This differentiation of myoblasts into myocytes is promoted by the expression 
of two other myogenic regulator factors, mrf4 and myogenin (Sabourin & Rudnicki, 
2000; Charge & Rudnicki, 2004; Lieber, 2010). This controlled timing of expression of 
the myogenic factors leads to clustering and fusion of myocytes into multinucleated 
myofibers. Myofibers continue their maturation into contractile muscle fibers that express 
muscle-specific genes such as the ones encoding myosin heavy chains (MyHC).  
 
Figure 1.3: Myogenesis (Sabourin & Rudnicki, 2000) 
 
Alternatively, a subpopulation of muscle precursor cells do not differentiate into 
myoblasts but form muscle stem cells termed satellite cells. Satellite cells are localized 
within the basal lamina surrounding muscle fibers. Satellite cells remain mitotically 
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quiescent and become activated under conditions of muscle growth or repair (Charge & 
Rudnicki, 2004; Al-Shanti & Stewart, 2009; Yokoyama & Asahara, 2011).  Activated 
satellite cells divide and differentiate into myoblasts. These myoblats can fuse with pre-
existing myofibers, or they can fuse together and give rise to new muscle fibers.    
Synaptogenesis starts with axonal outgrowth arising from the ventral horn of the 
spinal cord. Axons grow towards the location of a specific target muscle, following a pre-
determined direction but also being guided by additional cues coming from muscle cells. 
This process will lead to the formation of a NMJ where a motor neuron innervates 
specific muscle fibers. The formed end plate is a cholinergic synapse since the 
presynaptic nerve releases the chemical neurotransmitter acetylcholine (ACh) that 
conveys information through a synaptic cleft to a postsynaptic muscle fiber. The NMJ is 
the site of communication between the nerve and the muscle and where excitation-
contraction coupling events are initiated. 
 
1.1.3 Acetylcholine Receptors  
Acetylcholine receptors (AChR) mediate the communication between motor 
neurons and skeletal muscle fibers, and thus the levels, distribution and properties of 
these receptors influence the efficacy of synaptic transmission. The importance of these 
receptors is highlighted in Myasthenia Gravis, a disease characterize by defects in NMJ 
synaptic transmission. This disease is caused by an autoimmune response against AChR 
or other important proteins found at the NMJ (McConville & Vincent, 2002; Newsom-
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Davis, 2007). This autoimmune response leads to the inhibition and loss of AChR at the 
muscle surface. This in turn leads to a defective communication between the nerve and 
the muscle. Muscles do not respond adequately to the nerve signals, and muscles become 
weaker and unable to sustain to the mechanical demands of the body.  A combination of 
mechanisms influences the density of AChR at endplates, ranging from increase in 
mRNA synthesis, protein translation, and increase in protein stability to the lateral 
migration of receptors, receptors insertion, degradation, and recycling. AChR dynamics 
are controlled by muscle nerve activity, by phosphorylation events and by the action of 
scaffolding proteins (Bruneau & Akaaboune, 2006b; Bruneau et al., 2009).  
 
Figure 1.4: Crystal structure of muscle AChR (Lindstrom, 2010) 
On left is presented a top view illustrating the channel formed by the assembly of AChR subunits: αβαγδ. 
On right is depicted the side view of the pentameric structure. Here the embryonic form in shown, in adults 




AChRs are ligand-gated ion channels composed of four different subunits that 
assemble to form a pentameric structure (Figure 1.4). The neurotransmitter Ach binds at 
the interface formed between α / γ and α / δ subunits. Viewed from the side, each receptor 
subunit consists of a large extracellular amino-terminal domain, four helical 
transmembrane domains and a cytoplasmic domain formed between the third and fourth 
transmembrane helices (Lindstrom, 2010).  
Early in development, the entire muscle surface expresses AChR however these 
receptors will become localized to junctional regions. Various factors are thought to 
regulate the decrease in extrajunctional receptors and the increase in junctional receptors. 
For instance, it has been proposed that nerve endplate potential or electrical activity 
clusters receptors under the muscle-nerve contacts through a dispersal of extrajunctional 
receptors mediated by the neurotransmitter acetylcholine (Sanes et al., 1991; Misgeld et 
al., 2002; Misgeld et al., 2005). Expression of ACh was shown to promote the signaling 
of cyclin-dependent kinase 5 (cdk5), which acts to inhibit AChR expression (Fu et al., 
2005; Cheung et al., 2006). Concurrently, a local increase in the synthesis of receptors is 
observed at junctional regions (Sanes & Lichtman, 2001; Lieber, 2010). Skeletal muscles 
and motor nerves also secrete various ECM proteins (eg. agrin, rapsyn, laminin and 
dystroglycan) that act to stabilize the formed NMJ (Singhal & Martin, 2011).   
Moreover, synaptogenesis transforms the NMJ, structurally and functionally, to 
ensure that synaptic transmission occurs with high fidelity each time the motor nerve is 
excited. A change in AChR subunit composition occurs to allow the expression of 
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receptors with shorter open times and higher conductance in adult muscles as compared 
to embryonic muscles (Mishina et al., 1986; Martinou & Merlie, 1991). In neonatal, 
embryonic and denervated muscles the subunits are assembled in the order αβαγδ, but in 
the first two post-natal weeks the fetal γ subunit is replaced by the adult ε subunit 
(Mishina et al., 1986; Gu & Hall, 1988; Martinou & Merlie, 1991). In addition, during 
NMJ maturation, the aggregation of AChRs becomes more complex and the endplate 
topography is transformed from an oval “plaque-like” structure to a branched “pretzel-
like” structure (Figure 1.5) (Balice-Gordon & Lichtman, 1993; Sanes & Lichtman, 1999, 
2001). This transformation occurs independently of nerve activity, by mechanisms 
regulated by postsynaptic muscle cell signaling (Kummer et al., 2004). All of these 
changes, reorganize the localization and concentration of AChR to a density of 10 000-20 
000/μm2 in a synaptic region, as compared to only 10/μm2 in an extrajunctional region 
(Fertuck & Salpeter, 1976; Kummer et al., 2006; Singhal & Martin, 2011); thus ensuring 
efficient and adequate nerve to muscle communication.  
 
Figure 1.5: AChR aggregates topographic maturation (Kummer et al., 2004) 
AChR aggregates at the NMJ are initially plaque-shaped (A), perforated or ring (B), C-shaped or broken-





1.1.4 Muscle fiber types 
Skeletal muscle fibers differ in their biochemical and physiological properties. 
Muscle fibers are divided into types based on their metabolic, contractile and electrical 
properties. Muscle fibers contract and relax at different speeds and these properties of 
muscles result from to the ability of different isoforms of myosin heavy chain ATPase to 
perform the chemical breakdown of ATP with different speeds. Hence, a reliable method 
of muscle fiber classification is based on the type of myosin heavy chain (MyHC) 
isoform it expresses (Pette & Staron, 2001; Schiaffino et al., 2007). This method of 
classification is readily used since it defines muscle fibers specifically on various 
characteristics, some of which are summarized in Figure 1.6. According to this 
classification system, muscles used for posture or regular aerobic endurance activities are 
predominantly high endurance, oxidative fibers consisting of MyHC type I and IIa, 
whereas muscles used for rapid, intense movements of short duration are predominantly 
formed by glycolytic, low endurance MyHC type IIb expressing fibers.   
 




A motor axon innervates many muscle fibers within a single muscle forming a 
motor unit. An important characteristic of motor units is that the properties of each motor 
neuron are matched to those of the muscle fibers it innervates.  For example, slow motor 
neurons release neurotransmitters continuously at low rates, and are matched to slow 
muscle fibers, which are fatigue resistant and contract slowly. By contrast, fast motor 
neurons release neurotransmitters intermittently in high-frequency bursts and, are linked 
to fast muscle fibers, which contract rapidly and are fatigue susceptible (Mendell et al., 
1994; Gundersen, 2010). This motor unit homogeneity is influenced by both anterograde 
(from the nerve) and retrograde (from the muscle fiber) mechanisms (Chakkalakal et al., 
2010), further illustrating the importance of the communication that occurs at the NMJ. 
Moreover, skeletal muscles possess the remarkable ability to adapt to increased load or 
neural input by increasing fiber size and/or by undergoing fiber type switching (Pette & 
Staron, 2001; Schiaffino et al., 2007). For instance, endurance/aerobic exercise training 
promotes muscle fiber type remodeling from fast glycolytic to slow oxidative fibers, 
whereas strength/resistance exercise training promotes the opposite conversion. Muscle 
fiber type remodeling usually occurs following a sequential transition in order from 
I↔IIa↔IIx↔IIb fiber types and is also accompanied by increased expression of hybrid 
fibers which express more than one MyHC isoform (Pette & Staron, 2001). A better 
understanding of mechanisms that regulate muscle ability to respond to functional 




1.2 Skeletal muscle plasticity and signal transduction 
1.2.1 Calmodulin  
Skeletal muscle cell survival and normal function depend on the strict regulation 
of intracellular calcium (Ca
2+
) levels. In fact, calcium is the main regulatory and 
signaling molecule in skeletal muscle. While the fluctuation of Ca
2+ 
levels determines the 




serves as a second messenger molecule that interacts with specific targets to initiate 
cascades of biochemical events. Information encoded in transient Ca
2+
 signals is decoded 
by various intracellular Ca
2+
 binding proteins, and converted to biochemical signaling 
events.  
Calmodulin (CaM) is a small 17kDa, evolutionarily highly conserved, calcium 
binding protein (Chin & Means, 2000; Al-Shanti & Stewart, 2009). This protein is 
composed of four EF hand motifs, a signature helix-loop-helix structure which is found in 
numerous other Ca
2+
 binding proteins such as parvalbumin and troponin C (Chin & 
Means, 2000; Al-Shanti & Stewart, 2009). Specifically, each pair of EF hand motifs is 
associated with the amino- or carboxy-terminal domain of the protein. Respective 
terminal regions are tethered together by a long central helix hinge region. In the absence 
of Ca
2+
, the protein amino-terminus adopts a closed conformation, where the two EF 
hand motifs are tightly packed together (Al-Shanti & Stewart, 2009). In contrast, the 
carboxy-terminus adopts a “semi-open” conformation partly exposing hydrophobic 
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residues and allowing for the binding of some targets under resting conditions (Figure 
1.7A) (Chin et al., 1997; Al-Shanti & Stewart, 2009).  
 
Figure 1.7: Calmodulin secondary structure (Al-Shanti & Stewart, 2009) 
On the left calmodulin is shown (A) in the closed conformation while on the right (B) calmodulin is 








binds to the central loop of each EF 
hand motif, leading to a more “open” protein confirmation that exposes additional 
hydrophobic regions, further promoting the binding of other target proteins (Figure 1.7B) 
(Chin & Means, 2000; Al-Shanti & Stewart, 2009). In skeletal muscle, these target 
proteins include ion channels (ryanodine receptors), kinases (calcium-calmodulin kinase), 
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phosphatases (calcineurin) and structural proteins (dystrophin) (Berchtold et al., 2000; 
Chin & Means, 2000). The vast list of CaM targets, coupled with different mechanisms 
of calcium interaction and modes of regulation (Chin & Means, 2000), provide CaM with 
the ability to play various roles in the cell by activating numerous signaling molecules in 
response to calcium influx. 
 
1.2.2 Calcium/calmodulin dependent protein kinase  
A distinct group of CaM effectors is the calcium-calmodulin dependent protein 
kinase (CaMK) family (Hanson & Schulman, 1992; Braun & Schulman, 1995; Chin & 
Means, 2000; Means, 2000; Hook & Means, 2001). The CaMK family consists of four 
serine threonine kinases: CaMKI, II and IV are multifunctional kinases possessing 
several substrate proteins, while CaMKIII is a dedicated kinase that recognizes a single 
substrate; elongation factor-2 (Hanson & Schulman, 1992; Braun & Schulman, 1995). All 
three multifunctional kinases share a similar general structure (Figure 1.8): an amino-
terminal catalytic domain followed by an autoinhibitory domain and an overlapping CaM 
binding site (Means, 2000; Hook & Means, 2001). CaMKII also possesses, at its 
carboxy-terminal region, an additional association domain essential for its 
oligomerization. CaM activates the CaMK family of enzymes by binding to them and 
removing the autoinhibitory domain from the catalytic pocket, thus promoting substrate 
protein binding (Hook & Means, 2001). Furthermore, CaMKI and CaMKIV are 
phosphorylated (at Thr177 and Thr196, respectively) in their activation loops by CaMK 
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kinases (CaMKK) leading to enhanced activity (Means, 2000; Hook & Means, 2001). 
CaMKII and CaMKIV also possess autophosphorylation sites (Thr286) within their 
autoinhibitory regions. Upon phosphorylation at these sites, these kinases can acquire an 
autonomous, Ca
2+
 independent, activity (Means, 2000; Hook & Means, 2001). Table 1.1 
summarizes the main differences between these multifunctional kinases.  
 
 
Figure 1.8: Schematic of multifunctional CaMK structure (Hook & Means, 2001) 
In red are indicated important residues for CaMK activation and/or regulation by CaM (for details see 
Hook & Means, 2001). Numbers indicate the positions of these residues in these kinases. Within the 
catalytic domain of CaMKI and CaMKII is the activation loop. CaMKII alone possesses a C-terminal 
association domain essential for its multimerization. This C-terminal region also contains an NLS that can 







 CaMKI CaMKII CaMKIV 
Tissue 
Distribution 



















Ca2+/CaM binding;  
autophosphorylation 






No Yes (up to 80%) Yes (up to 20%) 
Table 1-1: Properties of multifunctional CaMK: adapted from (Hook & Means, 2001) 
 
CaMKII is the most well characterized multifunctional kinase of the CaMK 
family. This kinase is recognized to regulate various cellular events including neuronal 
plasticity, myofilament contraction, and gene expression (Braun & Schulman, 1995; 
Means, 2000; Chin, 2004). In skeletal muscle, CaMKII was shown to be the predominant 
isoform activated by exercise in humans (Rose & Hargreaves, 2003; Rose et al., 2006; 
Rose et al., 2007a; Rose et al., 2007b). Similar results were observed in rodent models, 
leading to the hypothesis that CaMKII signaling is important in mediating contractile 
adaptation associated with muscle hypertrophic growth (Fluck et al., 2000). CaMKII is a 
very sensitive calcium sensor that can detect not only the concentration of Ca
2+
 but also 
the frequency, amplitude and duration of Ca
2+
 oscillations (De Koninck & Schulman, 
1998; Dupont & Goldbeter, 1998). This enzyme is encoded by four separate genes (α, β, 
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γ, δ) that undergo alternative splicing to generate up to 24 distinct splice variants (Braun 
& Schulman, 1995; Carafoli & Klee, 1999; Hook & Means, 2001). CaMKII is the sole 
kinase of this family that requires homo- or hetero- oligomerization of 8 to 12 subunits 
into a pinwhell-like structure for activity (Kanaseki et al., 1991; Means, 2000; Hook & 
Means, 2001). Moreover, it does not require the presence of CaMKK for its activity since 
it can undergo inter-subunit phosphorylation. CaMKII modulates its own activity levels 
due to its multimerization and autophosphorylation abilities. Indeed, CaMKII 
autophosphorylation of Thr286 requires both inter-subunit interactions and cooperative 
calmodulin binding. These events increase the enzyme’s affinity for CaM and partly 
disrupt the enzyme autoinhibitory domain. Both of these events allow the kinase to retain 
partial, Ca
2+ 
- independent activity (Hanson & Schulman, 1992; Braun & Schulman, 
1995). These unique mechanisms allow this kinase to potentiate transient increases in 
Ca
2+
 levels and make CaMKII a very sensitive sensor of Ca
2+ 
frequency oscillations in 
the cell. 
  
1.2.3 Ca2+ /CaM regulation of neuromuscular junction  
As described previously, CaM acts as a very efficient second messenger of Ca
2+
 
signaling. In this section, CaM regulation of neuromuscular junction development, 
stability and plasticity will be discussed. 
 In the 1980s, experiments conducted in vitro using calcium-coated beads showed 
that, by a CaM-mediated mechanism, Ca
2+
 induces the formation of new AChR clusters 
 20 
 
without major effects on existing clusters (Peng, 1984). Similar results were observed 
when monitoring AChR clustering induced by the nerve-derived trophic factor agrin 
(AGR) (Megeath & Fallon, 1998). Some data have implicated the Ca
2+
/CaM dependent 
phosphatase calcineurin in this process (Madhavan et al., 2003). Subsequently, it was 
shown that Ca
2+
 binds the nerve-derived trophic factor agrin (AGR) and alters its 
conformation, leading to activation of its biological activity (Tseng et al., 2003; Stetefeld 
et al., 2004; Tseng et al., 2011). Specifically, AGR was shown to regulate 
phosphorylation of the AChRβ subunit, which promotes AChR binding to the scaffolding 
protein rapsyn, and this in turn induces stabilization of the receptor clusters increasing 
receptor density at the synapse (Borges & Ferns, 2001; Borges et al., 2002; Moransard et 
al., 2003; Borges et al., 2008). This AGR clustering activity was shown to signal through 
LRP4/MuSK receptor complex (DeChiara et al., 1996; Glass et al., 1996a; Glass et al., 
1996b; Kim et al., 2008; Zhang et al., 2008; Wu et al., 2010). In addition, nerve-activity 
independent AChR clustering was shown to be activated by two other important ECM 
proteins: dystroglycan and laminin (Jacobson et al., 2001; Kummer et al., 2004; Bruneau 
et al., 2005b; Tremblay & Carbonetto, 2006; Nishimune et al., 2008). 
A key aspect of AChR redistribution during NMJ maturation involves the 
selective accumulation of AChR subunits in junctional regions, with simultaneous 
suppression of expression in extrajunctional regions. Nerve-electrical activity leads to a 
rise in intracellular Ca
2+
 levels that acts to suppress expression of AChR genes in the 
extrajunctional regions (Walke et al., 1994). Calcium signaling through CaMKII can 
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repress AChR promoter activity by inhibiting myogenin transcriptional activity (Tang et 
al., 2001). CaMKII phosphorylates myogenin, decreasing myogenin’s ability to bind to 
DNA and reducing myogenin’s activity, and leading to a decrease in AChR gene 
expression (Macpherson et al., 2002; Tang et al., 2004). These results were further 
expanded and shown to implicate the signaling of a histone deacetylase pathway: the 
HDAC4 – Dach2 – Mgn loop (Figure 1.9) (Tang & Goldman, 2006; Cohen et al., 2007; 
Tang et al., 2009). This signaling pathway was shown to specifically coordinate 
phenotypic changes in muscle following denervation (Tang et al., 2009), but could 
potentially regulate gene expression in conditions of synaptic adaptation. 
 
 
Figure 1.9: CaMKII-HDAC4-Mgn signaling loop (Tang et al., 2009) 
In conditions of normal innervations, Ca
2+
 activates CaMKII promoting downstream signaling that 
decreases synaptic gene expression and promotes glycolytic genes. During denervation, Ca
2+ 
levels 




Additionally, the nerve-derived trophic factor neuregulin (NRG) (also called 
ARIA or heuregulin) has been identified as a key factor that promotes expression of 
synaptic genes independently of nerve electrical activity (Martinou et al., 1991; Martinou 
& Merlie, 1991; Jo et al., 1995). NRG acts through receptors of the ErbB family and 
activates the expression of AChR subunit genes through an ERK signaling cascade that 
recruits the activation of the Ets transcription factor GABP (GA-binding protein) (Tansey 
et al., 1996; Sapru et al., 1998; Briguet & Ruegg, 2000; Lacazette et al., 2003). Similarly, 
AGR/MuSK signaling was shown to converge on this signaling pathway and 
cooperatively regulate GABP activation through JNK signaling (Lacazette et al., 2003).  
AChR density also can be regulated by mechanisms that involve receptor 
dynamic movements and/or recycling. Extensive fluorescence labelling experiments have 
shown that AChR receptors can be recycled in conditions of nerve activity (Bruneau et 
al., 2005a; Bruneau & Akaaboune, 2006a). Under conditions of muscle stimulation, 
intracellular Ca
2+
 levels increase and prevent AChR removal from the muscle surface. 
This is achieved by promoting receptor recycling, and maintaining the synthesis and 
insertion of new receptors (Bruneau & Akaaboune, 2006a). It has been shown that 
muscle activity regulates the recycling process through CaMKII activity (Martinez-Pena 
y Valenzuela et al., 2010). It is proposed that CaMKII might modulate proteins involved 
in sorting, targeting and/or fusion of endocytic vesicles with the muscle membrane or that 
it itself acts as a scaffolding protein as suggested by its localization at the NMJ (Fertuck 
& Salpeter, 1976; Martinez-Pena y Valenzuela et al., 2010).  
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Consequently, current research has identified some possible pathways that can 
regulate AChR expression. It appears the muscle fiber’s intrinsic signaling contributes to 
the formation of NMJ structures (Kummer et al., 2006; Wu et al., 2010). Nevertheless, an 
in depth understanding of the events that regulate AChR density, and in turn synaptic 
communication, still requires further investigation since parallel and complementary 
mechanisms exist and need to be fully explained in the perspective of disease or 
compromised signaling models.     
 
1.2.4 Calcineurin 
Calcineurin (Cn), a Ca
2+
/CaM-dependent phosphatase, is another well- 
characterized modulator of skeletal muscle phenotypes. Cn (Figure 1.10) is a 
heterodimeric serine / threonine protein phosphatase comprised of a catalytic A subunit 
(CnA) of ~60 kDa and a calcium-binding regulatory B subunit (CnB) of ~19 kDa 
(Sakuma & Yamaguchi, 2010). An amino-terminal catalytic domain and a carboxy-
terminal regulatory domain form the CnA subunit. The regulatory domain of CnA 
contains a CnB interacting domain, a calmodulin binding site and an autoinhibitory 
domain (Al-Shanti & Stewart, 2009; Li et al., 2011). The CnB subunit has four EF-hand 
motifs: the two carboxy-terminal motifs bind Ca
2+ 
with high affinity and serve to stabilize 
the heterodimeric structure, while the two amino-terminal motifs bind Ca
2+ 
with low 




Figure 1.10: Calcineurin structure (Al-Shanti & Stewart, 2009) 
 
The proposed model of calcineurin activation involves a series of conformational 
changes illustrated in Figure 1.11. In resting skeletal muscle cells, intracellular Ca
2+ 
levels are low and the Cn heterodimer adopts an inactive conformation state (Form I). In 
this state, A) the autoinhibitory domain of CnA masks the catalytic site of the protein and 
B) the calmodulin binding site is associated with CnB. During physical activity, 
intracellular levels of Ca
2+ 
increase and bind the low affinity EF-hand motifs on CnB 
inducing a conformational change that unmasks the catalytic site and exposes the 
calmodulin binding site (Form II). This process promotes calmodulin binding to CnA 
(Form III) which is followed by a displacement of the CnA autoinhibitory domain (Form 




Figure 1.11: Model of Cn activation (Li et al., 2011) 
CnA is color coded in red; CnB in green; CaM in orange, Ca
2+
 as black circles.  
Ca
2+
 binds EF-hand motifs of CnB. CaM interacts with the carboxy-terminal of CnA and leads to the 
displacement of the autoinhibitory domain from the catalytic site.  
 
Three genes have been identified for CnA: CnAα and CnAβ that are both 
ubiquitously expressed and CnAγ which is expressed in brain and testes (Guerini & Klee, 
1989; Lara-Pezzi et al., 2007). The CnAβ isoform exists in two splice variants, CnAβ1 
and CnAβ2, which differ in their carboxy-terminal regions (Guerini & Klee, 1989). 
Specifically, the CnAβ1 isoform lacks the typical autoinhibitory domain and has a novel 
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unrelated carboxy-terminal domain that allows this isoform to be constitutively active 
(Lara-Pezzi et al., 2007).  
Calcineurin regulates a vast number of functions in various cell types because it 
interacts with numerous substrates, such as transcription factors, scaffolding proteins, ion 
channels, cell cycle regulators, and cytoskeleton proteins (Li et al., 2011). As such, 
dysregulation of calcineurin signaling is associated with numerous diseases, for instance 
cardiac disorders, osteoporosis, Alzheimer’s, Down syndrome, autoimmune diseases and 
cancer (Li et al., 2011). One of the most recognized targets of calcineurin is the Nuclear 
Factor of Activated T cells (NFAT) family of transcription factors and these transcription 
factors have been used as models of signal transmission in various cell types. 
 
1.2.5 Nuclear Factor of Activated T-cells  
The NFAT protein was originally identified as an inducible factor of T cell 
activation (Shaw et al., 1988). Subsequently, a whole family of these transcription factors 
was identified and its members were found  to regulate the development and function of 
various tissues including the cardiovascular, musculoskeletal and nervous systems 
(Crabtree & Olson, 2002). Each NFAT protein exists as multiple isoforms and splice 
variants that share a conserved DNA binding domain (DBD) (Jain et al., 1995) and an 
NFAT homology region (NHR) (Luo et al., 1996a). The nomenclature of these proteins is 
confusing due to various names given to distinct isoforms through time. For simplicity, 
this nomenclature was standardized by the Human Genome Organization (HUGO) Gene 
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Nomenclature Committee (HGNC) in 2000 to define the proteins as NFATc1, NFATc2, 
NFATc3, NFATc4 and NFAT5. Table 1-2 presents a summary of all alternative names 
used in the literature. All NFAT proteins, for the exception of NFAT5 (that lacks the “c” 
annotation in its name), are found in the cytoplasm until activated by dephosphorylation. 
Current Name Alternative Names 
NFATc1 NFAT2; NFATc; NF-ATC 
NFATc2 NFAT1; NFATp; NF-ATP 
NFATc3 NFAT4; NFATx;  
NFATc4 NFAT3 
NFAT5 TonEBP; OREBP; NFATz, NF-AT5; NFATL1; KIAA0827 
Table 1-2: NFAT protein nomenclature (from HGNC and PubMed). 
 
As indicated above, NFAT proteins share sequence similarity and functional 
domain homology. The region of highest sequence similarity within the NFAT protein 
family is the DBD, which also shares moderate similarity with the Rel-family of 
transcription factors (Rao et al., 1997). The NHR, situated amino-terminal to the DBD, 
shows a strong conservation of sequence motifs (Rao et al., 1997). The NHR is also often 
called the regulatory domain since it contains the nuclear localization signal (NLS), a 
possible nuclear export signal (NES), numerous phosphorylation sites (serine-rich region 
and SP-motifs) and the calcineurin binding sites (Figure 1.12) (Rao et al., 1997; Hogan et 
al., 2003). In fact, NFAT proteins contain two conserved calcineurin binding sites: a 
conserved sequence of PxIxIT at the N-terminal end of the NHR and an LxVP motif 
located closer to the DBD site (presented using amino acid single letter code where x is 
any amino acid):  (Hogan et al., 2003; Li et al., 2011). The LxVP site shows different Cn 
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binding strengths and could be a source of differential regulation between the NFAT 
isoforms (Rodriguez et al., 2009). Finally, NFAT proteins also contain an amino-terminal 
transactivation domain (and possibly another one at the carboxy-terminal end) (Luo et al., 
1996b). This region of variable sequence provides an additional site for distinct 
regulation and distinct interaction with co-activators or other components of the 
transcriptional machinery.  
 
Figure 1.12: Schematic structure of NFAT protein (Hogan et al., 2003) 
NFATc2 is shown as a model. Regulatory-domain phosphorylation sites are shown as circles under the 
scheme. In red are serine residues regulated by Cn, while the black circle is a Cn-independent serine site. 
Black bars under the scheme indicate the two Cn binding regions. The conserved sequences are shown with 
the amino acid single letter code where x represents any amino acid. Region A is the PxIxIT sequence, 
while region B is the LxVP sequence. The transactivation domain is indicated by AD (activation domain).    
 
Fianlly, it is worth noting that the NFAT5 isoform lacks the PxIxIT calcineurin binding 
site, the transactivation domain and is constitutively nuclear in localization (Lopez-
Rodriguez et al., 1999). This isoform is not regulated by calcium / Cn signaling and will 
not be further considered here. 
NFAT protein activation occurs in three steps: dephosphorylation, nuclear 
translocation and increased affinity for DNA binding (Rao et al., 1997). In resting cells, 
NFAT proteins are phosphorylated at multiple sites in their regulatory domain, are 
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localized to the cytoplasm and show a low affinity for DNA binding. Upon physical 
activity, intracellular Ca
2+
 levels increase and activate calcineurin, the major phosphatase 
that dephosphorylates NFATs. This process exposes the NLS, promotes NFAT’s nuclear 
translocation and increases DNA binding affinity. Alternatively, NFATs can be 
phosphorylated by various kinases to be exported back out of the nucleus. Four kinases 
are known to phosphorylate NFATs: the constitutive kinases casein kinase-1 (CK1) and 
glycogen synthase kinase-3 (GSK3), and the inducible kinases MAPK p38 and JNK 
(Hogan et al., 2003).  The selective activation of these export kinases provides an 
additional level of regulation of NFAT proteins. Furthermore, NFAT transcriptional 
activity also can be regulated by modification of the TA domain. Less information is 
available on this mechanism, but inducible activation of the TA domain has been shown 
(Okamura et al., 2000; de Gregorio et al., 2001; Rainio et al., 2002). Additionally, NFAT 
transcriptional activity also can be regulated by cooperative binding with other 
transcription factors. Indeed, NFAT can bind DNA as monomers, as homo- or hetero-
dimers with other NFAT isoforms, or as cooperative complexes with other transcription 
factors such as the AP-1 family (Fos and Jun), GATA or MEF2 family (Hogan et al., 
2003)  
 
1.2.6 Cn / NFAT signaling in muscle fiber remodelling 
Calcium signaling plays crucial roles in determining, maintaining and 
transforming muscle fiber types (Bassel-Duby & Olson, 2003) and Cn acts as an 
intermediate factor in this process. Numerous groups have shown the importance of Cn in 
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the regulation of skeletal muscle fiber remodeling. For instance, the overexpression of 
activated Cn in muscle cell culture myocytes was shown to promote the slow muscle, 
oxidative gene program (Chin et al., 1998). Furthermore,  in vivo over-expression of 
activated Cn, driven by a muscle specific promoter, was shown to upregulate endogenous 
oxidative proteins such as myoglobin or troponin I slow (Naya et al., 2000). In contrast, 
transgenic mice lacking CnA showed decreased expression of slow fiber types (Parsons 
et al., 2003). Similarly, blocking Cn activity in vivo, using the specific pharmacological 
Cn inhibitor cyclosporine (CsA), led to transformation towards fast, glycolytic muscle 
profiles (Chin et al., 1998; Bigard et al., 2000). It is important to point out that the 
regulation of muscle fiber metabolic profiles by Cn does not induce a fiber type 
remodeling displaying a complete sequential transition of MyHC (in order from 
IIb→IIx→IIa→I fiber types). Instead Cn seems to regulate fibers type remodeling of 
slow oxidative (type I) and fast oxidative (type IIa) MyHC profiles (Bigard et al., 2000). 
In addition, muscles with different metabolic properties display a different response to Cn 
activity (Bigard et al., 2000; Talmadge et al., 2004). This observation indicates that Cn 
can distinguish between fiber types and offers distinct regulation based on their metabolic 
profiles. These results imply that other calcium-regulated pathways also play important 
roles in the process of fiber type remodeling. Nevertheless, the importance of Cn 
signaling in oxidative fibers is defined.  
In contrast, while Cn appears to play defined roles in muscle fiber type 
remodelling, its function in skeletal muscle fiber growth is more controversial (Schiaffino 
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& Serrano, 2002; Bassel-Duby & Olson, 2003; Tidball, 2005; Sakuma & Yamaguchi, 
2010). The contribution of Cn alone to skeletal muscle fiber hypertrophy is supported by 
three main observations. Firstly, Cn was shown to mediate skeletal muscle hypertrophy 
induced by IGF treatment in skeletal muscle cell cultures (Musaro et al., 1999; Semsarian 
et al., 1999). Secondly, Cn has been shown to mediate muscle hypertrophy in vivo, in a 
model of adaptive muscle growth: the functional overlaod model. In this model, Cn 
activity was blocked using pharmacological inhibitors (FK506 and CsA), and in the 
absence of Cn activity overload induced hypertrophy was prevented in both fast plantaris 
and slow soleus muscles (Dunn et al., 1999; Sakuma et al., 2008). Thirdly, numerous 
groups showed that Cn is important for growth recovery following atrophy (Mitchell et 
al., 2002; Miyazaki et al., 2006; Oishi et al., 2008). In contrast, other results suggest that 
Cn is not mediating fiber hypertrophy alone and that it requires collaborative signaling 
events. For instance, transgenic mice over-expressing an activated Cn did not display 
fiber hypertrophy under normal weight-bearing conditions (Dunn et al., 1999; Naya et 
al., 2000). Similarly, a genetic loss of Cn did not block skeletal muscle hypertrophy 
induced by functional overload (Parsons et al., 2004). Meanwhile, in vitro experiments 
that induced skeletal muscle hypertrophy by IGF, but performed in different cell cultures 
lines than Musaro et al. (1999) and Semsarian et al. (1999) , failed to show an activation 
of Cn (Bodine et al., 2001; Rommel et al., 2001). These same experiments also used 
different dosages of pharmacological Cn inhibitors (CsA or FK506) and failed to prevent 
IGF induced hypertrophy. The observed contradicting results are probably due to the 
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usage of different cell line backgrounds or by smaller dosages of Cn pharmacological 
inhibitors. Additionally, the vehicle for CsA drug delivery was also different and might 
further explain the observed discrepancies (Sanchez et al., 2000). Overall, it appears the 
Cn has a certain ability to regulate muscle fiber hypertrophy but the exact signaling 
pathways are not clearly defined. Cn regulation of muscle growth differs between muscle 
types (Mitchell et al., 2002; Talmadge et al., 2004) or growth model used, and is 
probably necessary but not sufficient alone to mediate muscle fiber hypertrophy (Naya et 
al., 2000).  
Involvement of Cn signaling in the regulation of the skeletal muscle fiber 
phenotype is recognized, however the elucidation of the roles of Cn-regulated NFAT 
isoforms in this process remains rudimentary. Previous literature has reviewed in detail 
the phenotypes of NFAT-deficient mice (Crabtree & Olson, 2002; Horsley & Pavlath, 
2002), but it appears important to briefly highlight the importance of some NFAT 
isoforms in the regulation of skeletal muscle. NFATc1-deficient mice have deficient heart 
valve development and abnormalities in heart septum, which leads to embryonic death. 
Nevertheless, cell culture work, has identified a potential role for NFATc1 in the 
regulation of Myf5 expression (Friday & Pavlath, 2001). In addition, NFATc2-deficient 
mice display defects in the recruitment of myoblasts to fuse with multinucleated 
myofibers; a process required for postnatal myotube growth (Horsley et al., 2001). On the 
other hand, NFATc3-deficient mice show defects in development of myoblasts; thus 
NFATc3 seems to regulate primary myogenesis (Kegley et al., 2001). Finally, NFATc4-
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deficient mice did not show any abnormalities in skeletal muscles (Graef et al., 2001), 
but overexpression of NFATc4 induced hypertrophy of the heart (Molkentin et al., 1998).  
At last, the involvement of Cn in regulation of muscle phenotypes is documented. 
Cn is involved in the regulation of oxidative remodeling and seems to have the potential 
to regulate muscle growth. NFAT proteins are recognized as the main transcriptional 
targets downstream of Cn, yet the importance and exact roles of NFAT protein isoforms 
in the regulation of skeletal muscle adaptive remodeling still awaits further investigation. 
 
1.2.7 Agrin  
Agrin (AGR) is a large (~225 kDa) heparan sulfate proteoglycan. This protein is 
widely expressed in different tissues such as brain, spinal cord, retina, muscle, liver, 
kidney and lung (Ferns et al., 1993; Hoch et al., 1993). Agrin exists in numerous 
different splice variants displaying different biological activities and tissue distributions 
(Ferns et al., 1993; Hoch et al., 1993). Agrin has been extensively studied in the context 
of NMJ regulation but its broad expression indicates that it also can regulate other 
processes. For instance, agrin is necessary for hypertrophic differentiation of 
chondrocytes (Hausser et al., 2007) and it can regulate blood vessel angiogenesis (Iozzo 
et al., 2009). Agrin is also important in the activation of the T cell immune response 
(Khan et al., 2001; Jury & Kabouridis, 2010). In addition, agrin mediates axonal 
guidance in the CNS (McCroskery et al., 2006; McCroskery et al., 2009) and controls the 
maintenance of the blood-brain barrier (Rascher et al., 2002). The best characterized role 
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for agrin is its involvement in the stabilization of neuromuscular junctions (Bezakova & 
Ruegg, 2003; Lin et al., 2008). Indeed, agrin was discovered as a trophic factor sufficient 
to instruct pre- and post-synaptic NMJ assembly (Godfrey et al., 1984; Nitkin et al., 
1987) and later it was shown that agrin induces the clustering of AChR aggregates (Ferns 
et al., 1992; Ferns et al., 1993). The clustering of AChR at NMJ is the predominant 
biological activity of agrin. 
 The recognition of the varied functions of agrin led to the implication of  this 
protein in several diseases (Williams et al., 2008) such as cancer (Iozzo et al., 2009; 
Somoracz et al., 2010), Alzheimer’s (Verbeek et al., 1999; Reilly, 2000; Rauch et al., 
2011), Myasthenia Gravis (MG) (Hoch et al., 2001; McConville & Vincent, 2002; Romi 
et al., 2008), various forms of Congenital Myasthenia Syndrome (CMS) (Moll et al., 
2001; Meinen & Ruegg, 2006; Maselli et al., 2011; Meinen et al., 2011) and some forms 
of muscular dystrophy (Moll et al., 2001; Bentzinger et al., 2005; Qiao et al., 2005; 
Meinen & Ruegg, 2006; Meinen et al., 2011). Yet, precise and exact details about agrin’s 
roles and/or regulation in these varied contexts still require more in depth research. 
 
1.2.8  Agrin structure 
The agrin gene shares high sequence similarity between different species ranging 
from chicks to mice, rats and humans (Bezakova & Ruegg, 2003). Agrin is a large protein 
containing numerous functional domains (Figure 1.13) homologous to motifs found in 
other proteins of the ECM (Bezakova & Ruegg, 2003; Ngo et al., 2007). These conserved 
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motifs present in agrin can regulate agrin’s ability to bind numerous proteins of the ECM 
such as dystroglycan, laminins and integrins (Bezakova & Ruegg, 2003). The N-terminus 
of agrin can be N- and O- glycosylated. The glycolysation sites serve as docking sites for 
glycoaminoglycan (GAG) groups and increase the size of the protein to ~400-600kDa 
(Winzen et al., 2003). These modifications probably induce conformational changes in 
the protein structure that regulate agrin interactions with its binding partners, or the 
stability of the protein by preventing rapid degradation (Winzen et al., 2003).  
Agrin transcripts can be alternatively spliced at four different sites (Ferns et al., 
1993; Bezakova & Ruegg, 2003; Iozzo et al., 2009). The N-terminal end of agrin can be 
spliced to generate a short or long protein isoform that displays differential localization 
(Burgess et al., 2000) (Figure 1.13). The longer form is able to bind laminin and is 
localized to the basal lamina of the ECM while the shorter form is a Type II 
transmembrane protein expressed in the central nervous system (Burgess et al., 2000; 
Bezakova & Ruegg, 2003; Iozzo et al., 2009). Additionally, agrin has three alternative 
splice sites localized at its C-terminus: X, Y and Z sites (Figure 1.13). Alternative 
splicing of the C-terminal end of agrin forms protein isoforms that differ in localization 
and/or ability to cluster AChR receptors (Ferns et al., 1992; Ferns et al., 1993). At the X 
position, alternative splicing can lead to insertion of 3 or 12 amino acids (Rupp et al., 
1991; Ferns et al., 1993), the Y site can contain an insert of 4 amino acids (Ferns et al., 
1993) and the Z site can include or exclude two separate exons, and lead to possible 




Figure 1.13: Agrin functional domains (Ngo et al., 2007) 
Agrin contains follistatin-like cysteine-rich repeats (F), repeats homologous to epidermal growth factor 
EGF (E), laminin B (LB) and laminin AG domains (G). Agrin also has two serine/threonine (S/T) rich 
regions and glycosaminoglycan side chains (GAG). Alternative RNA splice sites (X, Y and Z) are 
indicated. Alternative transcriptional start sites give rise to short and long N-terminal (SN and LN) agrin 
variants.  
 
not tissue specific and does not regulate agrin biological activity (Ferns et al., 1993). The 
insert at the Y site shows tissue specific expression and is found predominantly in 
neuronal tissues (Ferns et al., 1993; Hoch et al., 1993). Finally, alternative splicing at the 
Z site controls agrin biological activity that mediates the assembly and stabilization of 
NMJ (Ferns et al., 1993; Hoch et al., 1993). An insert of 8 amino acids at the Z site is 
essential to the formation of AChR aggregates at the postsynaptic muscle surface (Ferns 
et al., 1993). The agrin isoforms that include the 8, 11 or 19 amino acid inserts at the Z 
site are called “neural agrin”. These neural isoforms of agrin are secreted by the motor 
neurons and they display different biological activities. The rank order for the efficacy in 
AChR clustering activity of the Z splicing variants is 8 ≥ 19 > 11 > 0 (Ferns et al., 1993). 
Muscles synthesize the isoform lacking the insert at the Z site and this isoform is called 
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“muscle agrin”. The function of muscle agrin still remains unclear but it might act to 
amplify and/or sustain the activity of neural agrin (Ferns et al., 1993; Bezakova & Lomo, 
2001; Williams et al., 2008). Currently, neural agrin is the sole isoform recognized to 
display biological activity.  
 
1.2.9 Agrin in skeletal muscles 
In skeletal muscles agrin is crucial for the organization and stabilization of the 
NMJ where it functions to assemble diverse molecules required for efficient nerve-
muscle communication. Agrin is released from the motor neuron into the presynaptic 
cleft where it binds the muscle surface. On the muscle surface, agrin interacts with two 
receptors (Hoch, 1999): α-dystroglycan (α-DG) (Gee et al., 1994) and LDL-receptor 
related protein 4 (LRP4) (Kim et al., 2008; Zhang et al., 2008). Over the past two 
decades, work carried out by varied groups elucidated some major signaling partners for 
agrin signaling in skeletal muscles. In addition, recent discoveries indicate that agrin 
might have novel, yet unidentified roles, in skeletal muscles. 
Firstly, the association of agrin with α-DG serves to aggregate the dystrophin-
associated glycoprotein complex (DGC) (Figure 1.14) (Campanelli et al., 1994; Hoch, 
1999). The main function of this complex is to stabilize skeletal muscle structure but it 
also serves as a scaffold for various signaling molecules (Pilgram et al., 2010). The 
assembly of this structural complex at the NMJ concentrates synaptic molecules such as 
AChR (Campanelli et al., 1994). Dystroglycan is synthesized as a precursor propeptide 
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that is post-translationally cleaved to generate α- and β-DB (Holt et al., 2000). Agrin 
binds the C-terminal end of α-DG that interacts with β-DG, which in turn binds rapsyn 
(Figure 1.14) (Hopf & Hoch, 1996; Bartoli et al., 2001).  Rapsyn is a peripheral protein 
expressed on the muscle surface that binds the actin cytoskeleton and facilitates AChR 
attachment to the muscle surface (Peng & Froehner, 1985). 
 
Figure 1.14: Agrin and α-DG signaling (Pilgram et al., 2010) 
Figure legend:  DG, dystroglycan; AChR, acetylcholine receptor complex; NOS, nitric oxide synthase  
 
In addition, the amino-terminal end of agrin interacts with laminins, that in turn bind 
integrins (Denzer et al., 1997) and this further stabilizes the formed DGC ensuring 
adequate force transmission between the ECM and the muscle actin cytoskeleton. In 
summary, agrin interaction with α-DG functions to stabilize the NMJ by concentrating 
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protein found in the DGC and by promoting the concentration of AChR aggregates at 
synaptic sites (Apel et al., 1995; Fuhrer et al., 1999; Moransard et al., 2003). 
Secondly, agrin interacts with the LRP4/MuSK receptor complex to initiate a 
signaling cascade that drives the aggregation of AChR. Specifically, agrin directly 
interacts with LRP4 which in turn binds the muscle specific kinase (MuSK) co-receptor 
(Figure 1.15) (Kim et al., 2008; Zhang et al., 2008). MusK is as a tyrosine kinase 
receptor specifically localized at the NMJ of adult skeletal muscles (Valenzuela et al., 
1995). The first suggestion that it might act as a receptor for agrin came from the 
similarity in NMJ defects observed in MuSK-deficient mice (DeChiara et al., 1996) and 
agrin-deficient mice (Gautam et al., 1996). Subsequently, MuSK was shown to mediate 
the agrin induced phosphorylaytion of AChR β-subunit (Wallace et al., 1991) but this 
signaling was demonstrated to occur without direct binding between agrin and MuSK 
(Glass et al., 1996a; Glass et al., 1996b). Recently, LRP4 was shown to be the receptor 
that binds directly to agrin and is necessary and sufficient for agrin-induced tyrosine 
phosphorylation of MuSK and downstream AChRβ (Kim et al., 2008; Zhang et al., 
2008). The signaling events downstream of agrin/LRP4/MuSK are beginning to be 
elucidated (Figure 1.15) and involve the adaptor protein downstream of tyrosine kinase-7 
(Dok-7) (Okada et al., 2006) that binds directly to MuSK and promotes activation of 
timorous imaginal disc-1 (Tid1) (Linnoila et al., 2008). Tid1 activity regulates the 
phosphorylation of AChRβ and modulates cytoskeletal dynamics to promote clustering of 
AChR through cytoskeleton protein adenomatous polyposis coli (APC) (Wang et al., 
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2003), by regulating the activity of small GTPases (Weston et al., 2000; Weston et al., 
2003; Linnoila et al., 2008) and by activating heat shock proteins (Liang & MacRae, 
1997; Linnoila et al., 2008). The phosphorylation of AChRβ regulates the binding to the 
scaffolding protein rapsyn and acts to further stabilize AChR clusters (Borges & Ferns, 
2001; Borges et al., 2002; Moransard et al., 2003; Friese et al., 2007; Borges et al., 
2008).  
 
Figure 1.15: Agrin and LRP4/MuSK signaling (Song & Balice-Gordon, 2008) 
Downstream of agrin/LRP4/MuSK proteins Dok-7 and Tid1 regulate postsynaptic reorganization by 
regulating (A) APC, (B) heat-shock proteins, (C) and by activating small GTPase Rac1, Cdc42 and RhoA. 
The neurotransmitter ACh acts to disperse non-synaptic clusters through Cdk5 signaling. Legend:  APC, 




Alternatively, agrin promotes the expression of AChR genes by localizing the 
trophic factor neuregulin (NRG) at synaptic sites (Meier et al., 1998; Rimer et al., 1998). 
Recently, the protein erbin was demonstrated to interact with MuSK and erbin was shown 
to regulate signaling events between AGR and NRG (Simeone et al., 2010). At the NMJ, 
NRG binds the ErbB family of receptors and signals to activate the expression of AChR 
subunit genes through an ERK signaling cascade that recruits the activation of the Ets 
transcription factor GABP (GA-binding protein) (Tansey et al., 1996; Sapru et al., 1998; 
Briguet & Ruegg, 2000; Lacazette et al., 2003). In summary, signaling downstream of 
agrin/LRP4 influences skeletal muscle properties by regulating the clustering of AChR 
aggregates through rearrangement of the cytoskeleton and by promoting expression of 
AChR genes.  
Finally, studies have indicated that agrin also can regulate aspects of skeletal 
muscles other than the maintenance and development of nerve-muscle communication. 
As such, agrin treatment was sufficient to improve dystrophic muscle pathology observed 
in congenital muscular dystrophy (Moll et al., 2001; Bentzinger et al., 2005; Qiao et al., 
2005; Meinen & Ruegg, 2006). This disease is characterized by the absence of the ECM 
structural protein laminin-α2. In this dystrophic model, using transgenic mice expressing 
a miniagrin gene or using adeno-associated virus mediated-overexpression of miniagrin, 
it was shown that agrin can restore muscle structure, improve whole body growth, and 
ameliorate locomotor and contractile functions of the dystrophic muscles (Moll et al., 
2001; Bentzinger et al., 2005; Qiao et al., 2005). In addition, whole-cell patch-clamp 
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experiments have demonstrated that agrin regulates the electrical properties of skeletal 
muscle cells in vitro by altering excitation-contraction coupling and regulating ion 
channels expression (Bandi et al., 2008; Jurdana et al., 2009). In addition, recent data 
showed that agrin can enhance the contractile functions of an engineered aneural muscle 
tissue system (Bian & Bursac, 2011). These novel roles of agrin are still emerging and 
more research is required in this field.  
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1.3 Thesis organization, scope and hypotheses 
The ability of skeletal muscle and nerve to adapt to functional demand is a 
noteworthy characteristic that can be viewed as a significant evolutionary achievement. 
Future research is needed to better understand the underlying mechanisms and molecular 
elements responsible for mediating the remarkable neuromuscular adaptation.  
In this thesis, using transgenic and surgical models, we seek to explore some of 
the signaling components of neuromuscular plasticity. 
Chapter 2: The function of calmodulin in the regulation of AChR density at the adult 
NMJ is investigated using a transgenic mouse model that expresses an inhibitor peptide 
for CaM. We hypothesize that calmoduin can influence endplate morphology by 
regulating the expression of AChR. 
Chapter 3: The specific functions of NFAT transcription factors are investigated in 
adaptive growth of adult muscles using a surgical synergistic ablation overload model. 
Muscle growth is compared between wild-type mice and mice deficient for NFATc2 or 
NFATc3 isoforms. We hypothesize that NFATc2 and NFATc3 have essential and distinct 
functions in adaptive growth of skeletal muscles. 
Chapter 4: The roles of the nerve-derived trophic factor agrin in the regulation of muscle 
growth are revealed, in healthy muscles and in models of muscle aging and Duchenne 
muscular dystrophy. We hypothesize that agrin can regulate signaling events that regulate 
skeletal muscle mass. 
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2.1 Background  
In this Chapter we seek to better understand the regulation of acetylcholine 
receptors (AChR) density at the adult neuromuscular junction (NMJ) using an in vivo 
transgenic mouse model. The results provide novel findings illustrating that calmodulin 
(CaM) alter AChR aggregate morphology in a transgenic mouse model. Our findings 
suggest that CaM regulates adult NMJ morphology through mechanisms independent of 
synaptic transcription and translation.  
 
The results of this chapter are to be submitted for publication in Muscle & Nerve. 
This journal specializes in original research studies focused on neuromuscular disorders 
and/or on their treatment options. Our work provides new insights into the regulation of 
NMJ morphology in adult mice and identifies a new direction for future research. A 
better understanding of mechanisms that regulate AChR maintenance and recruitment is 





The NMJ is the interface between motor neurons and their target muscle fibers. 
AChR mediate nerve-muscle communication, and the density and properties of these 
receptors regulate synaptic efficiency. The density and morphology of AChR aggregates 
can change based on functional demands, as is seen during muscle development and 
growth. Adequate expression and recruitment of AChR are important for appropriate 
synaptic communication and normal muscle function.  
The calcium-regulated protein CaM, by modifying its downstream signaling 
events, has the potential to alter AChR expression. In the present study, a transgenic 
mouse model that displayed a decrease in CaM activity was used to evaluate the role of 
CaM in the regulation of AChR expression in adult muscles. Larger and more complex 
endplates were observed in the muscles of transgenic mice as compared to wild-type 
mice. The data showed that the increased complexity of endplates is most likely regulated 
by post-translational mechanisms in transgenic mice since two major signaling pathways 
that regulate AChR expression were not altered in transgenic mice. Consistent with this, 
the results did not indicate increased expression for AChR genes and proteins. These 
collective findings present new insights into the regulation of AChR density in vivo in 
adult muscles and suggest that CaM regulates adult NMJ morphology by regulating 





Acetylcholine receptors (AChR) mediate the communication between the motor 
neuron and skeletal muscle fibers. These ligand-gated ion channels are made of four 
different types of subunits that form a pentameric structure. In neonatal, embryonic and 
denervated muscle the subunits are assembled in the order αβαγδ, whereas in the first 
post-natal week the fetal γ subunit is replaced by the adult ε subunit. This γ- to ε- subunit 
conversion during muscle development allows for the expression, in adult muscles, of 
receptors with shorter open times and higher conductance (Mishina et al., 1986; Gu & 
Hall, 1988). In addition, during NMJ maturation, the aggregation of AChRs becomes 
more complex and the endplate topography is transformed from an oval “plaque-like” 
structure to a branched “pretzel-like” structure (Balice-Gordon & Lichtman, 1993; Sanes 
& Lichtman, 1999, 2001). 
The density of AChRs at the postsynaptic muscle membrane influences the 
efficacy of synaptic transmission. Various diseases illustrate the importance of adequate 
AChR maintenance and recruitment for the appropriate synaptic function of the adult 
NMJ. For instance, the main symptoms of Myasthenia Gravis are muscle fatigue and 
muscle weakness. This autoimmune disease is characterized by an inhibition and loss of 
AChR at the surface of muscle which leads to defects in neuromuscular communication 
(Strochlic et al., 2005). Additionally, recent data have shown that AChR expression is 
also reduced in certain forms of muscular dystrophies (Lane et al., 2011). Finally, 
decreased expression of AChR is also seen in aging muscles (Doran et al., 2009; 
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McMullen & Andrade, 2009) and this further highlights the importance of an in-depth 
understanding of the regulation of AChR expression.  
The localization of AChRs at the neuromuscular junction (NMJ) appears to be 
regulated by mechanisms that reorganize AChR proteins within the muscle fiber 
membrane and directs them to synaptic regions (reviewed in (Wu et al., 2010)). Nerve 
activity is known to regulate the levels, distribution and properties of the AChR. Previous 
research has identified some signaling pathways that influence the expression of synaptic 
genes. For instance, the HDAC4/myogenin cascade drives activity-dependent gene 
expression of AChR subunits (Tang et al., 2004; Tang & Goldman, 2006; Tang et al., 
2009). Similarly, signaling pathways downstream of agrin (AGR) or neuregulin (NRG), 
act through the transcription factor GA-binding protein (GABP) to regulate transcription 
of AChR and other synapse-specific genes (Schaeffer et al., 1998; Briguet & Ruegg, 
2000; Schaeffer et al., 2001; Lacazette et al., 2003; Mejat et al., 2003). Additionally, 
several calcium-sensitive molecules can regulate synaptic receptor density by activating 
downstream signaling pathways, after detecting even subtle changes in calcium 
concentration inside the cell (Peng, 1984; Malenka et al., 1989; Walke et al., 1994; 
Borges et al., 2002; Madhavan et al., 2003).  
One such calcium-sensitive molecule is calmodulin (CaM). CaM is a protein with 
four EF hand calcium-binding motifs (Chin & Means, 2000; Al-Shanti & Stewart, 2009) 
that readily detects calcium oscillations in skeletal muscle. In this study, we used an in 
vivo transgenic mouse model to determine the influence of decreased calmodulin 
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signaling on the expression of AChR. More specifically, transgenic mice used express a 
small peptide inhibitor for CaM, known as the CaM-binding protein (CaMBP), under the 
control of the slow fiber-specific troponin I slow (TnIs) promoter (Corin et al., 1994; 
Corin et al., 1995; Levitt et al., 1995; Wang et al., 1995; Dunn et al., 2000). In these 
transgenic CaMBP-expressing mice, downstream pathways involving Ca
2+
/CaM-
regulated enzymes such as calcineurin and CaMKII are attenuated (Wang et al., 1995; 
Dunn et al., 2000).  
We hypothesized that a reduction of calmodulin would alter AChR aggregates 
morphology and could regulate synaptic plasticity. The involvement of a transcriptional 
signaling mechanism was explored in this study. Our results indicate that in the CaMBP 
transgenic mouse model, the reduced calmodulin activity decreases CaMKII signaling 
and leads to an increased density of AChR at the NMJ. CaM regulation of AChR 
aggregates does not alter the levels of the AChR gene or protein. The data suggest that 
CaM likely regulates NMJ morphology by mechanisms that regulate the distribution and 
localization of receptors at the muscle surface. These results identify a new transgenic 
model that should be further investigated to better understand mechanisms that regulate 
the expression and density of AChR at the adult NMJ. This in turn could help in the 




2.4 Methods  
2.4.1 Animal Care, Protocols and Extractions 
All animal care and experimental procedures were performed in
 
accordance with 
the guidelines established by the Canadian Council
 
of Animal Care. These procedures 
were approved by the University Animal Research Ethics Committee (UAREC) of 
Concordia University. Animals were housed in temperature and humidity controlled 
conditions on a 14:10 hour light: dark cycle and had access to water and food ad libitum. 
Mice were bred using standard breeding methods and identified to express the calmodulin 
binding peptide (CaMBP) transgene through PCR screening of genomic DNA extracted 
from tails (Dunn et al., 2000). The expression of CaMBP was also confirmed in the 
soleus muscle using genotyping cycling conditions and primers: Fwd 5’– 
cctttacttctaggcctgtagg -3’and Rvs 5’- gcatttttttcactgcattctagttgt -3’. In all experimental 
procedures, male mice aged between 3-9 months were used. Mice were anesthetized by 
intramuscular injection (1.2 μl/g) of 100 mg/ml ketamine hydrochloride and 10 mg/ml 
xylazine in a volume ratio of 1.6:1 and selected muscles were extracted for biochemical 
analysis. Muscles were either fixed in 4% paraformaldehyde for histological analysis or 
frozen directly in liquid nitrogen for RT-PCR and Western blotting purposes.  Upon 
completion of tissues extraction, mice were euthanized by cervical dislocation under 




2.4.2 Cell culture 
 Primary mouse myoblast cultures were prepared from postnatal day 1 mice that 
were euthanized by asphyxiation with carbon dioxide. Using surgical scissors, the skin 
around the ankles of their hindlimbs was cut and stripped off to expose the muscles of the 
limbs. Special attention was given to keep the muscles moist at all times with Dulbecco’s 
Phosphate Buffered Saline (DPBS). The muscles were minced to slurry in a culture dish 
using a razor blade. The slurry was transferred to a 15 ml conical vial containing 5 ml of 
a 0.25% Trypsin/EDTA solution at 37°C and incubated at 37°C for 5 minutes and 
vortexed until the solution became cloudy. The solution was transferred to a new 15 ml 
conical vial and the trypsin inhibited with proliferation media. The dissociation procedure 
was repeated using the leftover tissue and fresh 0.25% Trypsin/EDTA solution. The two 
dissociation solutions were combined and filtered through a 70 mm nylon mesh to 
remove large pieces of tissue. The suspension of cells was centrifuged at 1000 rpm for 5 
minutes and the pellet was resuspended in 20 ml of proliferation medium (80% 
Dulbecco’s Modified Eagle Medium (DMEM) high glucose supplemented with 20% fetal 
bovine serum and 1% Penicillin/Streptomycin) and cultured in a flask. The cells were 
incubated in a 37°C incubator with 5% carbon dioxide overnight. In order to purify the 
myoblast culture and eliminate fibroblasts, after 12-18 hours of culture, we collected the 
medium that contained the yet unattached myoblasts from the flask. The myoblasts were 
resuspended in 8-10 ml of growth medium and seeded on gelatin-coated substrate. The 
cultures were left incubating for 2 days before substituting the medium to fresh 
proliferation medium. When myoblasts reached confluence, the medium was changed to 
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fusion medium (98% DMEM high glucose supplemented with 2% horse serum and 1% 
penicillin/streptomycin) and incubated for 3 day.  
 These myotubes grown on gelatin substrate were then used to assay the formation 
of complex AChR aggregates in response to laminin as previously described (Vogel et 
al., 1983). All cell samples were incubated with soluble laminin for 18 hours and 
subsequently AChR aggregates visualized. 
This section is adapted from Vezina-Audette (2009).  
  
2.4.3 RNA extraction and semi-quantitative RT-PCR 
Total RNA was extracted from soleus (SOL) and extensor digitorum longus 
(EDL) muscles as previously described (Gauthier et al., 1997; Dunn et al., 1999). RNA 
concentration and purity were determined using an Eppendorf Biophotometer. 
Subsequently, RT-PCR was carried using 2 μg of each RNA sample. The final volume of 
the RT mixture (40 μl) contained of 0.625 μM random primer hexamers (Invitrogen, 
Burlington, ON, Canada), 1 X RT buffer (Ambion, Streetsville, ON, Canada), 0.5 μM 
dNTP mix (Invitrogen, Burlington, ON, Canada), 40U of RNase inhibitor (Ambion, 
Streetsville, ON, Canada), and 100U of MMLV reverse transcriptase (Ambion, 
Streetsville, ON, Canada). Subsequently, PCR amplifications were carried out using 1.5 
μl of the cDNA generated in a master mix containing 1X Taq buffer with KCl 
(Fermentas, Burlington, ON, Canada), 1.5 mM MgCl2 (Fermentas, Burlington, ON, 
Canada), 0.1 mM dNTP mix (Invitrogen, Burlington, ON, Canada), 0.2 mM primers 
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(custom synthesized by Sigma Genosys, St-Louis, MO, USA) and 0.05U/μl of Taq DNA 
polymerase (Fermentas, Burlington, ON, Canada) yielding a total volume of 25 μl.  
GENE 
NAME 












132 55 16 NR_003279.1 
HDAC4
1
 Fwd:  5'-CAGGAGATGCTGGCCATGAA-3' 
Rvs: 5'-GCACTCTCTTTGCCCTTCTC-3' 




 Fwd:  5'-ACTGAAAGTGGCTTTGGATAA-3' 
Rvs: 5'- TTCAGACGCTTTTGCATTGTA-3' 




 Fwd:  5'-CTCAGCTTAGCACCGGAAGCCCGA-3' 
Rvs: 5'-ATTGCCCCACTCCGGAGCGCAGGAG-3' 
392 55 36 NM_031189.1 
AGR
3
 Fwd:  5'- CAGTGGGGGACCTAGAAACA -3' 
Rvs: 5'- GCCATGTAGTCTGCACGTTCT-3' 
181 60 40 NM_021604.2 
NRG Fwd: 5'-ACTCGCCTGCTACTCGCCC-3' 
Rvs: 5'-CGCCGCTGCCTCACACTTG-3' 
457 55 45 NM_001167891.1 
GABP
4
 Fwd: 5'- GGGGAACAGAACAGGAAACA-3' 
Rvs: 5'- CCGTAATGCACGGCTAAGTT-3' 
208 55 36 NM_008065.2 
MuSK Fwd:  5'-ATGCTGTTTCTTCAGGTTCC-3' 
Rvs: 5'-CTTCCATTGCCAGCCATTCC-3' 





AChRα2 Fwd: 5'-CGTCTGGTGGCAAAGCT-3' 
Rvs: 5'-CCGCTCTCCATGAAGTT-3' 
506 55 28 NM_007389.4  
AChRγ2 Fwd:  5'-ACGGTTGTATCTACTGGCTG-3'  
Rvs: 5'-GATCCACTCAATGGCTTGC-3' 
176 55 45 NM_009604.3 
AChRε2 Fwd:  5'-AGACCTACAATGCTGAGGAGG-3' 
Rvs: 5'-GGATGATGAGCGTATAGATGA -3' 
204 55 30 NM_009603.1 
Table 2-1: Primers and RT-PCR conditions 
Superscript number following a gene name indicates the paper from which the sequences were obtained.  
When no number is indicated, primers were designed by our lab. 1) (Tang et al., 2009)  2) (Tang & 
Goldman, 2006)  3) (Hausser et al., 2007) 4) (Angus et al., 2005)  
 
Amplification conditions consisted of an initial denaturation at 95
o
C for 3 minutes, 
followed by cycles of 1 minute denaturation at 94°C, 1 minute annealing at primer 
specific temperature and 1 minute extension at 72°C (Table2-1), followed by a final 
extension at 72
o
C for 10 minutes. For each set of primers, cycle number was adjusted to 
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permit comparison of PCR products within their linear range of amplification across 
samples (Table 2-1). Amplification of the ribosomal 28S RNA was used as an internal 
control. PCR products were separated by electrophoresis on 1.5% agarose gels and 
visualized with ethidium bromide. Band intensities were quantitated by densitometry 
with the AlphaInnotech system and FluorChem software (San Leonardo, CA, USA).    
 
2.4.4 Histochemistry of NMJ 
Muscle tissues, fixed with paraformaldehyde (4%), were used to carry out the 
staining for cholinesterase (Karnovsky & Roots, 1964). Following fixation, muscles were 
washed with distilled water (dH20) and placed in an incubation medium until the 
endplates became visible as white areas on the muscle surface. All muscle samples were 
treated in the same incubation solutions in order to stain acetylcholinesterase uniformly 
across samples. The incubation medium was prepared from 1.6 ml of a solution of 0.5 M 
glycine and 0.1 M copper sulfate pentahydrate, 3.2 ml of substrate solution consisting of 
0.05 M acetylthiocholine iodide and 0.025 M copper sulfate, 20 ml of 0.2 M acetate 
buffer (pH 4.8) and 15.2 ml of dH20. Following the incubation period, samples were 
washed in dH20, stained for 2 minutes in 1% ammonium sulfide and washed once more. 
ImageJ software was used with the MultiCell outliner plug-in to outline and measure the 
size of endplates detected with the cholinesterase staining.  
Additionally, AChRs were labeled using fluorescent rhodamine-conjugated α- 
bungarotoxin (r-BTX). Myotubes or muscle bundles were incubated with 1 μg/ml r-BTX 
for 15 minutes at 37°C. Tissues were then washed twice in PBS and mounted with a 
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glycerol solution containing 1,4-diaminobutane dihydrochloride (P5780, Sigma) to 
reduce bleaching of fluorescent samples. Pictures of AChR endplates were acquired using 
a Zeiss axioskop epifluorescence microscope with a X63 objective (Zeiss). The system 
was equipped with a Retiga 1300R camera (Qimaging) and images were captured using 
Northern Eclipse software (Empix). All pictures were acquired at a fixed exposure for all 
specimens. Fluorescence analysis was carried out using ImageJ software to compare the 
fluorescence intensity of r-BTX staining across samples. 
 All histochemistry images were quantified using NMJ randomly selected from 5 
experimental samples per condition. All quantifications were performed blind to the 
experimental condition. 
 
2.4.5 Protein Extraction and Western Blotting 
Muscles were homogenized using a hand-held Tissue Tearor homogenizer 
(ColeParmer, Montreal, QC, Canada) in RIPA buffer consisting of 1XPBS, 1% Igepal, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.001 M sodium 
orthovanadate, 0.01 M sodium fluoride, 0.01 mg/ml aprotinin, 0.01 mg/ml leupetin and 1 
mM phenylmethanesulfonyl fluoride (all reagents from Sigma-Aldrich, St-Louis, MO, 
USA).  Homogenates were incubated on ice for 30 minutes followed by two 4
o
C 
centrifugations at 15 000 x g for 20 minutes. The supernatants were collected and protein 
concentration determined using Quick Start Bradford dye reagent (Bio-Rad, Mississauga, 
ON, Canada).  
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For protein expression analysis, 150 μg of protein were separated by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) on a gel consisting of a 5% stacking gel 
and an 8% separating gel. Samples were electrophoresed at 120V and Amersham Full-
Range Rainbow (GE Healthcare, Baie d’Urfe, QC, Canada) molecular weight markers 
were used to define the protein sizes. Subsequently, proteins were transferred to a PVDF 
membrane (Millipore, Billerica, MA, USA) at 100V for one hour and a successful 
transfer was confirmed using Ponceau S staining. Membranes were blocked for one hour 
using 5% non-fat milk in 0.1% Tween-Tris Buffered Saline (T-TBS) and incubated with 
primary antibody overnight at 4
o
C on a shaker as indicated in Table 2-2. The following 
day the membranes were washed three times for five minutes each using 0.1% T-TBS 
and were then incubated with the appropriate horseradish peroxidase-conjugated 
secondary antibody: anti-rabbit IgG  #7074 (Cell Signaling Technology, Danvers, MA, 
USA) or anti-mouse IgG #A8924 (Sigma-Aldrich, St-Louis, MO, USA). Subsequently, 
membranes were developed using the chemiluminescent Immobilon HRP substrate kit 
(Millipore, MA, USA) as per the manufacturer’s instructions. Images were captured and 
protein expression quantified by densitometry with the AlphaInnotech system and 







PROTEIN NAME SUPPLIER SIZE (kDa) 1OANTIBODY 2OANTIBODY 
α-tubulin Cell Signaling 
#2125 






α = 50 
γ,δ = 55-60 
βM = 73 
1:1000 in 5% BSA 1:2000 in 5% milk for 
1hr (anti-rabbit) 
CaMKII Cell Signaling 
#4436 
α = 50 
γ,δ = 55-60 
βM = 73 






42/44 1:1000 in 5% BSA 1:1000 in 5% milk for 
1hr (anti-rabbit) 
ERK1/2 Cell Signaling 
#9696 






54 1:500 in 5% BSA 1:2000 in 5% milk for 
1hr (anti-mouse) 
JNK Santa Cruz 
#sc-827 




54 1:1000 in 5% milk 1:1000 in 5% milk for 
1hr (anti-rabbit) 
Table 2-2: Western Blotting Conditions 
 
2.4.6 Statistical Analysis 
All data were analyzed using independent samples two-tailed Student’s T-test.  
All statistics were performed using SPSS statistics software version 17.0 (IBM SPSS, 
Chicago, IL, USA).  
 
2.5 Results 
2.5.1 Characterization of CaMBP-TG mice  
In this study, transgenic mice used express a small peptide inhibitor for CaM, 
known as the CaM-binding protein (CaMBP) under the control of the slow fiber-specific 
promoter troponin I slow (TnIs). (Corin et al., 1994; Corin et al., 1995; Levitt et al., 
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1995; Wang et al., 1995; Dunn et al., 2000). RNA was extracted from selected muscles 
and RT-PCR was carried out to validate the expression of the inhibitory peptide 
exclusively in transgenic muscles. The 28S ribosomal RNA served as a loading control. 
Results confirmed the expression of CaMBP predominantly in the slow fiber expressing 
muscle soleus (SOL), with very little in the fast fiber expressing muscle extensor 
digitorum longus (EDL) (Figure 2.1A). To further demonstrate alterations in CaM 
signaling, immunoblotting for CaMKII phosphorylated at Thr286 was performed. This 
phosphorylation provides CaMKII with the ability to be autonomously active and it is the 
form of CaMKII displaying maximal activity (Means, 2000; Hook & Means, 2001). The 
SOL muscle of CaMBP-TG mice displayed a 30% decrease in the level of this active 
pCaMKII form (Figure 2.1B and C). Several bands, corresponding to different isoforms 
of CaMKII were detected on this Western blot (Figure 2.1B), however as CaMKIIβM is a 
skeletal muscle specific isoform (Bayer et al., 1998; Rose et al., 2006), found localized at 
endplates regions (Martinez-Pena y Valenzuela et al., 2010), it was the sole isoform 
quantified (Figure 2.1C). Note that changes in the amount of the other CaMKII isoforms 
followed a similar trend to the response observed for CaMKIIβM (Figure 2.1B). The 
results did not indicate a significant alteration of pCaMKII levels in the fast muscle EDL, 
supporting the fact that the observed changes are mediated by the expression of CaMBP 
under the control of a slow fiber-specific promoter. Additionally, no alterations levels of 
total CaMKII were observed between the wild-type and transgenic muscles (Figure 2.1B 







Figure 2.1: Decreased calmodulin signaling in CaMBP-TG mice 
A) Representative agarose gel images comparing the expression of CaMBP in SOL and EDL muscles of 
wild-type and transgenic mice. Shown are images for two mice per group. Ribosomal 28S RNA served as a 
loading control. B) Representative Western blot images C) and quantifications of relative protein 
expression for pCaMKII and total CaMKII in SOL and EDL muscles of wild-type and transgenic mice. All 
quantifications were standardized to tubulin loading control and are expressed as mean ±SE. (* sig. diff. 




pCaMKII to total CaMKII) indicated a 35% drop of protein activity in CaMBP-TG mice 
as compared to wild-type mice. In contrast, the EDL muscle only displayed a 20% drop 
of protein activity in CaMBP-TG mice as compared to wild-type mice. These results 
confirmed the expression of CaMBP in the SOL muscle of transgenic mice and showed a 
compromised CaM signaling, as detected by decreased levels of pCaMKII in CaMBP-
expressing mice. 
 
2.5.2 Transgenic expression of CaMBP increases endplate complexity 
Previous research has implicated calcium in the modulation of AChR aggregates 
formation (Peng, 1984) and in AChR gene expression (Walke et al., 1994). In this study 
the hypothesis that calmodulin is altering the morphology of AChR aggregates on the 
muscle surface was further explored.  
Initial experiments were performed in vitro on muscle cell cultures using a 
simplified model that used soluble laminin, an extracellular matrix protein, to induce 
AChR aggregates. The clustering of AChR induced on cultured myotubes by soluble 
laminin occurs independently of nerve activity (Vogel et al., 1983; Sugiyama et al., 1997; 
Montanaro et al., 1998; Kummer et al., 2004). The formation of AChR aggregates was 
observed using bungaratoxin (BTX) staining after 18 hours of incubation with soluble 
laminin. The complexity of endplates was compared between myotubes produced from 
wild-type or CaMBP-expressing myoblasts. Wild-type myotubes formed simple, “plaque-
like” AChR aggregates (Figure 2.2A). In contrast, CaMBP-expressing myotubes formed 
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complex, branched, “pretzel-like” AChR aggregates (Figure 2.2A). These results suggest 
that calmodulin can regulate the complexity of AChR aggregates in vitro independently 




Figure 2.2: Expression of CaMBP leads to larger endplate structures in vitro and in vivo.  
Figure modified from (Vezina-Audette, 2009) as authorized per author. 
A) Primary myotubes were stained for AChR using BTX. Formation of AChR aggregates was induced by 
incubation with soluble laminin. Shown are myotubes from wild-type mice and myotubes prepared from 
CaMBP-TG mice. B) Representative images of SOL muscle bundles isolated from mice and stained using 
BTX. The quantification of the fluorescent intensity of the BTX stain is presented. Additionally, staining 
for acetylcholinesterase identified the surface area of endplates and the quantification is shown. All 
quantification are expressed as mean ±SE (* sig. diff. from WT, p < 0.05, N = indicates the number of NMJ 




To investigate if a similar response was observed in vivo, muscle fiber bundles 
were teased from adult soleus muscles and their NMJ were visualized by staining AChR 
using bungaratoxin (BTX); a toxin that binds specifically AChRs. Additionally, staining 
for acetylcholinesterase identified the surface area of endplates. Acetylcholinesterase is 
the enzyme that degrades the neurotransmitter acetylcholine and it is localized at endplates. A 
comparison of soleus muscles of wild-type and transgenic mice indicated that a reduction of 
calmodulin signaling leads to more complex AChR clusters (Figure 2.2B). The fluorescence 
intensity of bungaratoxin staining was greater in transgenic muscles and the surface area of 
endplates was increased in transgenic mice. Taken together these findings indicate that CaM 
regulates the density of AChR aggregates both in vitro and in vivo.     
 
2.5.3 The expression of selected transcripts is not altered in CaMBP-TG mice  
Calmodulin, by altering CaMKII activity, appears as a candidate in the conversion 
of muscle activity into intracellular signaling events that modulate gene expression at the 
neuromuscular junction (Tang et al., 2001; Tang et al., 2004; Tang & Goldman, 2006; 
Tang et al., 2009). We hypothesized that altered gene expression at the NMJ could lead 
to changes in the morphology of AChR aggregates on the muscle surface. Semi-
quantitative RT-PCR analysis was conducted on RNA isolated from SOL muscle of wild-
type and CaMBP-TG mice. The expression of transcripts from the HDAC/myogenin 
pathway was investigated and results failed to detect alterations in the target genes 





Figure 2.3: The expression of selected gene targets is not changed in CaMBP-TG mice 
Representative agarose gel images of PCR products and quantifications are shown for the (A) HDAC/Mgn 
pathway and for (B) AGR and NRG signaling. All quantifications are standardized to ribosomal 28S RNA. 
Data were normalized to wild-type and expressed as mean ± SE. (* sig. diff. from WT, p < 0.05, n = 3 to n 
= 5) 
 
influence AChR aggregates by signaling through the GABP transcription factor 
(Schaeffer et al., 1998; Briguet & Ruegg, 2000; Schaeffer et al., 2001; Lacazette et al., 
2003; Mejat et al., 2003). Thus mRNA levels of these targets were measured and again 
results did not indicate changes in gene expression, as compared to wild-type mice 
(Figure 2.3B). Overall, these findings indicate that genes previously shown to regulate 
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AChR expression are not differentially expressed in CaMBP-TG mice, suggesting a post-
transcriptional regulation of the observed morphological changes in endplate structures. 
 
2.5.4 CaMBP-TG mice do not show altered signaling of JNK and ERK kinase 
Signaling pathways of agrin and neuregulin converge and act cooperatively to 
activate signaling events through MAPK kinases ERK and JNK (Lacazette et al., 2003). 
These pathways have been shown to regulate expression of AChR. Accordingly, it is thus 
possible that levels of ERK and JNK are altered in our transgenic model of compromised 
CaM. Immunoblotting of whole cell muscle protein extracts was performed and protein 
expression analysed. The results indicated a trend towards increased levels of pERK1 and 
pERK2 (Figure 2.4A) without a significant difference, and without changes in total 
protein levels. Similarly, a significant alteration in the levels of pJNK or total JNK 
protein was not observed (Figure 2.4B). These findings indicate that neither ERK nor 
JNK signaling are perturbed in the CaMBP-TG mice model. These outcomes suggest that 






Figure 2.4: Signaling of ERK and JNK are not altered in CaMBP-TG mice 
Representative Western blot images and quantifications for A) phosphorylated ERK1/2 (pERK1/2) and 
total ERK1/2 B) pJNK and total JNK. All quantifications were standardized to tubulin loading control and 
are expressed as mean ± SE (* sig. diff. from WT, p < 0.05, n=3). 
 
2.5.5  Larger AChR aggregates are not caused by increased expression of AChR 
The larger endplates observed in vitro and in vivo in our model of compromised 
CaM (Figure 2.2) could be mediated by remodeling processes that lead to a change in 
AChR localization without a change in the expression of AChR genes and proteins. To 
support the idea that there is no transcriptional mechanism involved, levels of synaptic 
genes were measured in CaMBP-TG mice using semi-quantitative RT-PCR analysis. 
MuSK mRNA levels were also measured as this receptor is found localized at the NMJ, 
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its expression is known to be influence by nerve activity and it is recognized as the 
central organizer of synaptic differentiation. Additionally, mRNA levels of the major 
subunit forming the pentameric receptor structure, subunit α, were determined. Both 
MuSK and AChRα mRNA levels were unchanged in CaMBP-TG mice as compared to 
wild-type mice, (Figure 2.5A). The AChR pentameric structure is formed by distinct 
subunits that differ with respect to their time of expression and their properties. The fetal 
γ subunit and the adult ε subunit are also reported to be regulated by distinct regulatory 
mechanisms (Martinou et al., 1991; Martinou & Merlie, 1991). Measurements of the 
expression levels of these two subunits did not indicate changes of expression between 
the wild-type and CaMBP-TG mice (Figure 2.5A). Overall, these results support the 
conclusion that the observed morphological changes in endplate structures are not 
regulated at the level of transcription. 
To address the possibility that the larger endplates are caused by an overall 
increase of AChR protein level, mediated by an increased efficacy of translation, 
immunoblotting of whole cell muscle protein extract was performed and expression of 
the major AChRα subunit was measured. Similarly to transcript levels, no alteration in 
protein levels was observed between the wild-type and CaMBP-TG mice (Figure 2.5B). 
Note that the commercially available antibodies for AChR subunits recognize 
uncharacterized targets that appear as multiple non-specific bands on the Western blot. 
For this reason, expression analysis of other AChR subunits was not possible. These 
findings indicated that the larger endplate morphology in CaMBP-TG mice was not 
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mediated by changes in AChR transcript or protein levels. The results presented imply 
that CaM regulates AChR aggregate morphology in an in vivo transgenic mouse model 
and suggest involvement of mechanisms independent of synaptic transcription and 
translation as mediators of this remodeling.    
 
 
Figure 2.5: Neither the AChR gene or AChR protein levels are altered in CaMBP-TG mice. 
A) Representative agarose gel images of PCR products and quantifications for synaptic gene levels. All 
quantifications are standardized to ribosomal 28S RNA. Data were normalized to wild-type and expressed 
as mean ± SE. (* sig. diff. from WT, p < 0.05, n = 3 to n = 5). B) Representative Western blot images for 
AChRα subunit and the quantification normalized to tubulin loading control. The arrow points to the 






Research has highlighted the importance of maintaining an adequate density of 
AChR receptor at the NMJ for efficient synaptic communication (reviewed in 
(McConville & Vincent, 2002; Newsom-Davis, 2007)).  In this study, our aim was to 
investigate the regulation of AChR expression by calmodulin, a second messenger of 
Ca
2+
 signaling. We hypothesize that calmodulin can influence expression of AChR at 
adult muscle endplates. This is the first study that uses an in vivo transgenic mouse 
model, displaying compromised CaM signaling, to elucidate CaM involvement in 
regulation of AChR density at the adult NMJ.   
The transgenic mice used express a small peptide inhibitor for CaM, known as the 
CaM-binding protein (CaMBP), under the control of the slow fiber-specific promoter 
troponin I slow (TnIs). (Corin et al., 1994; Corin et al., 1995; Levitt et al., 1995; Wang et 
al., 1995; Dunn et al., 2000). Previous characterization of CaMBP-transgenic mice has 
indicated that under resting conditions, muscles of these animals display a normal 
phenotype (Dunn et al., 2000). In the initial phase of our experiments, we confirmed the 
alteration of CaM signaling in the animals used. The findings presented in Figure 2.1 
indicated that the SOL muscle of transgenic mice was expressing CaMBP at high levels 
and this was leading to decreased expression of active pCaMKII, thus confirming a 
decrease in CaM signaling. CaMKII was chosen as a target since previous data have 
indicated that this kinase is localized at the NMJ (Fertuck & Salpeter, 1976; Martinez-
Pena y Valenzuela et al., 2010), therefore, this suggests CaMKII involvement in the 
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regulation of endplate morphology or function. Additionally, the role of CaMKII in the 
regulation of synaptic plasticity of the central nervous system (CNS) has been shown 
(Lisman et al., 2002) and this also suggests its possible function in the much simpler, 
neuromuscular synapse. 
Next, we sought to determine if calmodulin can lead to alterations in the 
formation of AChR aggregates. Preliminary experiments were conducted in vitro on 
cultured myotubes with AChR aggregation induced using soluble laminin (Vogel et al., 
1983; Sugiyama et al., 1997; Montanaro et al., 1998). Laminin is a potent nerve-
independent model of synaptic development that has the ability to promote formation of 
complex, branched, pretzel-like AChR aggregates that are characteristic of adult NMJ 
(Kummer et al., 2004). Myoblasts from CaMBP-TG mice were isolated and 
differentiated into myotubes. The AChR aggregates formed on CaMBP expressing 
myotubes were larger than wild-type controls and displayed branched like structures 
(Figure 2.2A). These findings suggest that in cultured myotubes, CaM acts to regulate the 
morphology of endplates by suppressing formation of mature pretzel-like structures.  
To determine if a similar response is observed in vivo, we analysed the NMJ on 
muscle bundles isolated from wild-type and CaMBP-TG mice. As in the in vitro results, 
the NMJ of CaMBP-TG muscles displayed larger surface areas, as measured by AChE 
staining, as well as an increased density of AChR at NMJ, as measured by BTX labeling 
experiments. These results (Figure 2.2B) indicated that CaM signaling influences the 
morphology of AChR aggregates both in vitro and in vivo. In wild-type mice, CaM likely 
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serves to suppress the formation of aberrant pretzel-like structures. These results support 
a novel and important regulatory role for CaM.  
A tight regulation of the number and structure of neuromuscular junctions is a 
fundamental aspect of efficient and appropriate synaptic transmission (Sanes & 
Lichtman, 1999, 2001). An inadequate regulation of NMJ formation and the presence of 
aberrant AChR aggregates have been shown in Fukuyama-type congenital muscular 
dystrophy (Taniguchi et al., 2006). In addition, a deregulation in AChR localization or 
expression are the hallmark of numerous neuromuscular junction disorders such as 
Myasthenia Gravis (reviewed in (McConville & Vincent, 2002; Newsom-Davis, 2007). 
Furthermore, more complex NMJ could represent fragmented endplates that are caused 
by a loss of nerve terminals followed by novel nerve sprouting. Overall, the formation of 
more complex NMJ in CaMBP-TG mice may be preliminary symptoms of a disease. 
Muscles of CaMBP-TG mice display a normal phenotype under resting conditions (Dunn 
et al., 2000), but it is possible that under exercise or stress conditions, the muscles of 
these mice are more susceptible to damage or fatigue. Future studies should address these 
questions.  
Subsequent experiments were performed to identify the signaling pathways 
implicated in the observed alteration of AChR aggregate morphology in CaMBP-TG 
mice. The hypothesis that CaM regulates signaling pathways influencing the expression 
of synaptic genes was tested. The first pathway investigated was the HDAC/Mgn 
pathway (Figure 2.6A) that is regulated by CaMKII activity (Tang et al., 2001; Tang et 
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al., 2004; Tang & Goldman, 2006; Tang et al., 2009). Under normal innervation and 
signaling conditions, CaMKII activity induces phosphorylation of HDAC4, which 
promotes HDAC4 shuttling out of the nucleus (Tang et al., 2001; Tang et al., 2004; Tang 
& Goldman, 2006; Tang et al., 2009). This, in turn, stimulates expression of the Dach2 
gene that inhibits expression of Mgn that drives expression of AChR genes (Tang et al., 
2001; Tang et al., 2004; Tang & Goldman, 2006; Tang et al., 2009). Results previously 
discussed (Figure 2.1) indicated that CaMKII signaling is compromised in CaMBP-TG 
mice, thus we hypothesized that similarly to the denervated condition, CaMBP-TG mice 
would display decreased Dach2 and increased Mgn levels, and this in turn would increase 
levels of AChR genes. Results (Figure 2.3A) failed to show alterations in the signaling 
targets of this pathway. Myogenin signaling was previously characterized to regulate 
gene expression in innervated versus denervated muscle (Tang et al., 2009) thus the 
HDAC/Mgn signaling appears important for adaptive fiber remodeling associated with 
denervation, whereas suppression of glycolytic genes and induction of oxidative and 
synaptic genes is observed. This pathway is not regulating expression of AChRs in 
models of normal innervations.  
Alternatively, AGR and NRG, two trophic factors synthesized by the nerve also 
influence AChR clustering and the transcription of AChR genes (Figure 2.6B) (reviewed 
in (Williams et al., 2008)). AGR and NRG interact with distinct receptors and activate 
distinct signaling cascades, but their signaling events converge and cooperatively regulate 
 72 
 
the GABP transcription factor (Lacazette et al., 2003). The mRNA expression of AGR, 




Figure 2.6: Schematic of signaling pathways investigated 
Signaling pathway hypothesized in this study to influence the expression of AChR expression: A) 




and no differences were observed for any target (Figure 2.3B). MAPK kinases ERK and 
JNK are downstream signaling partners of AGR and NRG. ERK and JNK promote 
expression of AChR genes by stimulating GABP binding to promoter regions (Schaeffer 
et al., 2001; Lacazette et al., 2003; Mejat et al., 2003). The levels of phosphorylated and 
total proteins ERK and JNK (Figure 2.4) were not changed in CaMBP-TG mice and are 
in agreement with the absence of modification in the amount of GABP mRNA.  
Collectively, two pathways that regulate the expression of AChR are not modified in 
CaMBP-TG mice and this data suggest that the expression of AChR may not be altered in 
our model. 
These results urged us to measure changes in the expression of synaptic genes in 
CaMBP-TG mice. MuSK mRNA levels were measured since this receptor is recognized 
as a central organizer of synaptic differentiation (reviewed in (Strochlic et al., 2005)) and 
its expression levels correlate with AChR gene expression (Valenzuela et al., 1995; Ip et 
al., 2000; Moore et al., 2001). The mRNA levels of AChR subunits also were measured. 
The fetal γ subunit and the adult ε subunit were chosen since they differ in their 
expression time, properties and also have been shown to be differently regulated 
(Mishina et al., 1986; Gu & Hall, 1988; Martinou et al., 1991; Martinou & Merlie, 1991). 
In addition, AChR α subunit was chosen since it is the main subunit forming the receptor 
pentameric structure. Outcomes did not identify any alteration of expression in these 
targets and indicated that expression of synaptic genes is not altered in CaMBP-TG mice 
(Figure 2.5A). Finally, the larger endplate morphology could be mediated by increased 
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synthesis of AChR protein, but here again our findings did not detect an increase in 
protein levels using immunoblotting analysis (Figure 2.5B). Overall these results suggest 
that neither modifications of signaling events that promote synaptic gene transcription, 
nor variations in AChR protein translation, are the cause for increased NMJ complexity 
in CaMBP-TG mice. These findings are in agreement with published results that indicate 
that AChR density at the muscle surface is regulated by recycling mechanisms (Bruneau 
et al., 2005a; Bruneau & Akaaboune, 2006a). Furthermore, it has been proposed that 
CaMKII could modulate the levels or activities of proteins involved in sorting, targeting 
and/or fusion of endocytic vesicles at the muscle membrane and thus play regulatory 
roles in AChR recycling events (Martinez-Pena y Valenzuela et al., 2010). Given the 
findings presented in this investigation, further research in the CaMBP-TG mouse model 
should aim to study AChR movement and recycling events using techniques such as 
confocal microscopy and selective receptor labeling.   
In conclusion, the results presented here support the idea that CaM regulates 
AChR aggregates morphology. The data imply that transcriptional or translational 
mechanisms are not involved and point toward mechanisms of receptor movement or 
recycling. CaMKII activity is shown to be decreased in CaMBP-TG mice and thus 
CaMKII signaling may be implicated in the organization of AChR at NMJ. Yet, it may 
not be the sole pathway regulating this process since additional pathways downstream of 
CaM have been shown to regulate AChR clustering activity. For instance, calcineurin 
(Cn) is a well known CaM dependent phosphatase (reviewed in (Al-Shanti & Stewart, 
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2009) that has been implicated in the regulation of AChR distribution in vitro (Madhavan 
et al., 2003). The findings presented in this study demonstrate for the first time that a 
transgenic inhibition of CaM signaling has the ability to regulate NMJ morphology. 
These results are important since they identify a new model that should be further 
investigated to better understand mechanisms that regulate the dynamics of AChRs at the 
adult NMJ. This in turn could help in the identification of novel therapeutic targets for the 
treatment of neuromuscular disorders. In addition, many of the molecules expressed at 
NMJ are also expressed in the CNS, and thus studies of NMJ assembly might provide 
information on the mechanisms of synaptogenesis in the brain. 
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2.7 Future Directions 
 In conclusion, it is important to specify the limitations of the experiments 
presented here and to identify additional experiments that would address these 
limitations. The skeletal muscle tissue is heterogeneous and composed of many cell types 
that include muscle fibers, fibroblasts, vascular cells and interstitial space. In addition, 
NMJ assembly has been shown to be regulated by signaling from a specific subtype of 
nuclei situated solely at the motor nerve contact sites (reviewed in (Schaeffer et al., 2001; 
Mejat et al., 2003)). These synaptic nuclei form a small portion of the whole muscle 
tissue investigated. Similarly, synaptic proteins that mediate the assembly and/or 
maintenance of NMJ are localized and concentrated at nerve-muscle contact sites 
(reviewed in (Sanes & Lichtman, 1999, 2001). In this study, whole muscle samples 
analysis were carried out and thus it is possible that alterations in gene and/or protein 
levels in a specific subset of cells are not detected, or only subtle variations are noted. A 
recent and more precise technique called Laser Capture Microdissection (LCM) (Espina 
et al., 2006a; Espina et al., 2006b; Espina et al., 2007; Decarlo et al., 2011) is now 
available in the laboratory. This methodology permits a simple and rapid isolation of 
selected cell types by direct microscope visualization (Espina et al., 2006a; Espina et al., 
2006b; Espina et al., 2007; Decarlo et al., 2011). Subsequently, gene or protein analysis 
can be performed on samples of pure enriched cell populations. This technique can be 
used to selectively isolate NMJ enriched regions (Nazarian et al., 2005; Ketterer et al., 
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2011) and thus an in depth analysis of synaptic genes and proteins of CaMBP-TG mice 
can be carried out and compared to wild-type mice. 
In addition, the data presented in this study suggest that CaM signaling regulates 
movement of AChR at the muscle surface. For this reason, the sequential labeling of 
AChR localized at the surface of wild-type and CaMBP-TG muscles should be carried 
out. Sequential labeling of receptor can be performed using bungaratoxin conjugated to 
different fluorophores as described in detail by Akaaboune group (Bruneau et al., 2005a). 
This technique can distinguish pre-existing, new and recycled receptor aggregates and 
provides information on AChR movement at the muscle surface. Alteration in receptor 
dynamics could contribute to the larger and more complex NMJ observed in CaMBP-TG 
mice as compared to wild-type mice.  
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3.1 Background  
In this Chapter the functions of different isoforms of NFAT transcription factors 
are investigated in the regulation of adaptive muscle growth. A surgical overload growth 
model is used to induce adaptive muscle remodeling. We assessed the expression, 
localization and function of NFAT isoforms in muscle fibers of wild-type, NFATc2 and 
NFATc3 knockout mice under normal weight-bearing or functional compensatory work 
overload conditions. The results provide novel findings that suggest distinct and essential 
roles for the members of the NFAT family of transcription factors in conditions of rapid 
fiber growth. 
These results are to be included in a paper written for future submission to The 
Journal of Physiology. This journal presents original work devoted to demonstrating new 
physiological mechanisms. Alternatively, the work presented in this chapter could be 
separated into smaller studies that might be published separately. Some of the data 
presented has been included in previous poster presentations (Kulig et al., 2009; Kulig et 
al., 2010). Overall, the findings presented here provide new insights into the roles and 




Calcineurin (Cn) is a calcium-regulated serine/threonine phosphatase that acts via 
its substrate the Nuclear Factor of Activated T-cells (NFAT) family of transcription 
factors. Involvement of Cn / NFAT signaling in the regulation of the skeletal muscle fiber 
phenotype is recognized, however, little is known about the roles of the various Cn-
regulated NFAT isoforms (NFATc1-c4) in this process.  
In this study, mice deficient for the NFATc2 or NFATc3 isoform displayed 
blunted muscle growth following functional work overload while maintaining fiber 
remodeling towards oxidative phenotypes. Furthermore, NFATc2 and NFATc3 regulated 
the hypertrophic growth specifically in glycolytic, but not oxidative, muscle fiber types. 
RT-PCR did not reveal compensatory upregulation of any surviving NFAT isoform 
mRNA in knockout mice, but immunofluorescence data showed that the nuclear 
localization of NFAT proteins is differentially regulated during compensatory growth in 
knockout mice. Analysis of the mRNA levels of several myogenic regulatory factors 
indicated that NFATc2 may regulate Myf5 expression during adaptive muscle growth, 
while NFATc3 may control Mgn expression during developmental muscle growth. 
Furthermore, immunoblotting did not detect altered overload-induced Akt signaling in 
NFATc2-/- and NFATc3-/- mice, as compared to wild-type mice. Taken together, these 
results show that members of the NFAT family of transcription factors have distinct roles 
in the remodeling of the muscle fiber phenotype. In addition, the data demonstrate 




Skeletal muscle fibers are composed of myofibers that can adapt and remodel 
their biochemical, physiological and metabolic properties to meet functional demands 
(reviewed in (Bassel-Duby & Olson, 2006)). The remodeling of skeletal muscles results 
from the activation of signaling pathways that reprogram gene and/or protein expression 
to sustain muscle performance. Calcium-dependent signaling is well characterized for 
regulation of muscle function and plasticity (Berchtold et al., 2000) and calcineurin (Cn) 
is a calcium/calmodulin-activated serine-threonine phosphatase that has been implicated 
in modulation of myofiber growth and remodeling (reviewed in (Olson & Williams, 
2000; Bassel-Duby & Olson, 2003, 2006; Michel et al., 2007)). More specifically, 
previous experiments have implicated calcineurin in muscle cell differentiation  (Delling 
et al., 2000; Friday et al., 2000; Friday & Pavlath, 2001; Friday et al., 2003), muscle 
hypertrophy (Dunn et al., 1999; Musaro et al., 1999; Semsarian et al., 1999; Dunn et al., 
2000) and in the regulation of the muscle oxidative gene program (Chin et al., 1998; 
Bigard et al., 2000; Delling et al., 2000; Naya et al., 2000).  
Downstream targets of calcineurin signaling include the nuclear factors of 
activated T-cells (NFAT) family of transcription factors (Crabtree & Olson, 2002; 
Bassel-Duby & Olson, 2003). Originally identified in T cells, NFATs are now also well 
characterized for their roles in various other cell types including skeletal muscles (Rao et 
al., 1997; Crabtree & Olson, 2002; Horsley & Pavlath, 2002). Calcium regulated NFATs 
are activated by a direct calcineurin induced dephosphorylation that promotes nuclear 
translocation, and subsequent DNA binding that activates gene expression. Four different 
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Cn-regulated isoforms: NFATc1, NFATc2, NFATc3 and NFATc4, are expressed in 
skeletal muscles (Hoey et al., 1995; Calabria et al., 2009). Previous research showed that 
a knockout of NFATc1 lead to embryonic lethality due to defects in cardiogenesis (de la 
Pompa et al., 1998). In addition, disruption of NFATc2 or NFATc3 lead to an alteration 
in muscle mass without changes in fiber type proportions (Horsley et al., 2001; Kegley et 
al., 2001). More specifically, this alteration in muscle mass was caused by a reduced fiber 
cross sectional area in NFATc2-/- mice, and a reduced number of fibers in NFATc3-/- 
mice. Meanwhile, mice with an NFATc4 knockout display a normal phenotype without 
evident defects in muscles (Graef et al., 2001).  Furthermore, recently it has been shown 
that NFAT isoforms have differential sensitivity to nerve electrical activity patterns and 
that different combinations of NFAT isoforms are necessary for maintenance of both 
slow and fast muscle fibers (Calabria et al., 2009).   
Various models can be used to induce muscle growth, however, the synergist 
ablation or overload model is a potent and well-characterized model that leads to 
increased muscle load, while simultaneously doubling nerve mediated fiber activation 
(Gardiner et al., 1986). This model has been shown to promote muscle fiber hypertrophy 
(Dunn & Michel, 1997; Dunn et al., 1999) and hyperplasia (Antonio & Gonyea, 1993; 
Kelley, 1996) as well as muscle remodeling toward the oxidative phenotype (Dunn & 
Michel, 1997).  
The aim of the present study was to assess the role of the NFATc2 and NFATc3 
in the regulation of adaptive muscle growth. Results indicate that NFATc2 and NFATc3 
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knockout mice undergo a blunted plantaris muscle hypertrophy, while maintaining 
oxidative fiber type remodeling following 28 days of functional overload. In NFATc2-/- 
or NFATc3-/- mice, nuclear trafficking of NFAT isoforms was altered following 
overload in comparison to wild-type mice. In addition, changes in the expression of 
myogenic regulatory factor (MRF) mRNA levels were observed in NFATc2 and 
NFATc3 knockout mice in comparison to wild-type mice. Taken together, these results 
illustrate that members of the NFAT family of transcription factors have distinct and 
important roles in the regulation of muscle fiber phenotypes in an adaptive growth model. 
 
3.4 Methods  
3.4.1 Animal Care and Protocols 
All animal care and experimental procedures were performed in
 
accordance with the 
guidelines established by the Canadian Council
 
of Animal Care. These procedures were 
approved by the University Animal Research Ethics Committee (UAREC) of Concordia 
University. Transgenic mice models deficient for functional NFATc2 (NFATc2-/-) were 
a gift from Dr. L. Glimcher (Harvard University) whereas mice deficient for functional 
NFATc3 (NFATc3-/-) were a gift from Dr. G. Pavlath (Emory University). Both 
NFATc2 and NFATc3 knockout mice were generated by the insertion of a neomycin 
resistance gene into the Rel homology region leading to a disruption of the DNA-binding 
domain of NFATc2 or NFATc3 protein (Hodge et al., 1996; Oukka et al., 1998). The 
truncated proteins generated in mutant mice are unable to bind DNA but can still 
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potentially interact with other accessory binding partners; however the characterization of 
the mutant mice confirmed a loss of function mutation in these animals (Hodge et al., 
1996; Oukka et al., 1998).  Animals were housed in temperature and humidity controlled 
conditions on a 14:10 hour light: dark cycle and had access to water and food ad libitum. 
Mice were bred using standard breeding methods and identified as deficient for specific 
NFAT isoform by screening of genomic DNA extracted from tails (Dunn et al., 2000). 
For all experimental procedures, male mice aged between 4-8 months were used.   
 
3.4.2 Animal Surgeries and Extractions 
All surgical procedures were performed under aseptic conditions on animals 
anesthetized by intramuscular injection (1.2 μl / g) of 100 mg/ml ketamine hydrochloride 
and 10 mg/ml xylazine in a volume ratio of 1.6:1. Functional compensatory work 
overload of plantaris muscle was induced by bilateral surgical ablation of the synergistic 
muscles: soleus and a major portion of the gastrocnemius muscle (Figure 3.1). The mice 
were overloaded for periods of 7 and 28 days. During these periods, following a period of 
convalescence (3-5 days), the overload mice were exercised daily for 60 minutes by 
placing them in an exercise ball (12 cm diameter). At the end of the experimental period, 
mice were anesthetized as previously described and lower limb muscles of control and 
overloaded animals were extracted, either frozen directly in liquid
 




Figure 3.1: Schematic of the functional overload model (Lieber, 2010) 
In normal conditions, the plantaris, soleus and gastrocnemius muscles carry jointly weight bearing 
functions in mice hindlimbs (the percentage indicate the contribution of each muscle). 
  
in OCT (Tissue-Tek, Torrance, CA, USA) and frozen in melting isopentane cooled in 
liquid nitrogen.At the end of the experimental period, mice were anesthetized as 
previously described and lower limb muscles of control and overloaded animals were 
extracted, either frozen directly in liquid
 
nitrogen or embedded in OCT (Tissue-Tek, 
Torrance, CA, USA) and frozen in melting isopentane cooled in liquid nitrogen. Upon 
completion of tissue extractions, mice were euthanized by cervical dislocation under 





To determine muscle fiber type and size, muscle cryosections (10 μm) were cut 
from each plantaris muscle midbelly anatomical location. Sections were blocked for 30 
minutes in 5% goat serum in a carrier solution consisting of 0.5% bovine serum albumin 
(BSA) in 25 mM phosphate buffer solution (PBS) (pH = 7.4). Subsequently, the sections 
were incubated overnight at 4
o
C in carrier solution with a primary antibody raised against 
the appropriate MyHC type. All antibodies used (MyHC I: A4.840 using 1:25 dilution; 
MyHC IIa: SC71 using 2:25 dilution; MyHC IIx: 6H1 without dilution; MyHC IIb: BF-
F3 using 1:25 dilution) were from the Developmental Study Hybridoma Bank (DSHB, 
University of Iowa, Iowa city, IA). After three 10 minutes rinses in PBS, sections were 
incubated for two hours in secondary antibodies, horseradish peroxidase-conjugated goat 
anti-mouse IgG (MyHC type IIa) or IgM (MyHC type I, IIx, IIb) (Sigma-Aldrich, St-
Louis, MO, USA) using a 1:25 dilution. The sections then were rinsed three times with 
PBS for ten minutes, and the bound antibody complexes were visualized using 1 mg/ml 
of diaminobenzidine tetrahydrochloride (DAB). Slides were analyzed with an Olympus 
BX-60 light microscope. Three distinct regions were selected randomly from the 
midbelly of each plantaris muscle and images were captured across serial sections using a 
Retiga SRV camera (QImaging, Surrey, ON, Canada). All fibers in those regions were 
classified according to the type of MyHC expressed and fiber cross-sectional size was 





To determine NFAT nuclear localization, muscle cryosections (10 μm) were cut 
from each plantaris muscle midbelly anatomical location. Sections were fixed in 2% 
paraformaldehyde (PFA) for 20 minutes, washed three times five minutes with PBS and 
blocked for one hour in PBS containing 1% normal goat serum and 0.2% Triton X-100. 
Slides were subsequently washed and incubated overnight with a primary antibody at 4
o
C 
(1:50 dilution) in an antibody solution of 1% normal goat serum and 0.1% Triton X-100. 
Antibodies (NFATc1 #sc-13033, NFATc2 #sc-13034, NFATc3 #sc-8321 and NFATc4 
#sc-13036) were all from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The 
sections then were rinsed three times five minutes with PBS and incubated with 
secondary anti-rabbit Alexa488 conjugated antibody #A-1108 (Invitrogen, Burlington, 
ON, Canada) using a 1:100 dilution. Slides were mounted using DAPI-Vectashield (#H-
1200 from Vector Laboratories, Burlingame, CA, USA). Three distinct regions were 
selected randomly from each plantaris muscle and images were captured using a Zeiss 
Axioplan fluorescence microscope mounted with a Lumenera Infinity 3-1C1.4 camera 
(Ottawa, ON, Canada). Control slides, omitting primary antibodies revealed the absence 
of background staining at the acquisition time used.  Co-localization analysis of NFAT 
and nuclei was performed using ImagePro Plus version 6.2 software (Olympus, 
Markham, ON, Canada). In all analysis, the researcher was blinded to the experimental 




3.4.5 RNA extraction and semi-quantitative RT-PCR            
Total RNA was extracted from each plantaris muscle as previously described 
(Gauthier et al., 1997; Dunn et al., 1999). RNA concentration and purity were determined 
using the Eppendorf Biophotometer. Subsequently, RT-PCR was carried out using 2 μg 
of each RNA sample. The final volume of the RT mixture (40 μL) contained of 0.625 μM 
of random primer hexamers (Invitrogen, Burlington, ON, Canada), 1X RT buffer 
(Ambion, Streetsville, ON, Canada), 0.5 μM dNTP mix (Invitrogen, Burlington, ON, 
Canada), 40U of RNase inhibitor (Ambion, Streetsville, ON, Canada), and 100U of 
MMLV reverse transcriptase (Ambion, Streetsville, ON, Canada). Subsequently, PCR 
amplification was carried out using 1.5 μl of the cDNA generated in a master mix 
containing 1X Taq buffer with KCl (Fermentas, Burlington, ON, Canada), 1.5 mM 
MgCl2 (Fermentas, Burlington, ON, Canada), 0.1 mM dNTP (Invitrogen, Burlington, 
ON, Canada), 0.2 mM primers (custom synthesized by Sigma Genosys, St-Louis, MO, 
USA) and 0.05 U/μl of Taq DNA polymerase (Fermentas, Burlington, ON, Canada) 
yielding a total volume of 25 μl. Amplification conditions consisted of an initial 
denaturation at 95
o
C for 3 minutes, followed by cycles of 1 minute denaturation at 94°C, 
1 minute annealing at primer specific temperature and 1 minute extension at 72°C (Table 
3-1), followed by a final extension at 72
o
C for 10 minutes. For each set of primers, cycle 
number was adjusted to permit comparison of PCR products within their linear range of 
amplification across animals (Table 3-1). Amplification of the ribosomal 28S RNA was 
used as an internal control. PCR products were separated by electrophoresis on 1.5% 
agarose gels and visualized with ethidium bromide. Band intensities were quantified by 
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densitometry with the AlphaInnotech system and FluorChem software (San Leonardo, 






















Fwd: 5'-GAACCCTCCCAAGTACGACA-3'  
Rvs: 5'-TAAGGGTTGACGGTGACACA-3' 







300 55 20 NM_010855.2 
TnIs Fwd: 5'-TGCTGAAGAGCCTGATGCTA-3' 
Rvs: 5'-GAACATCTTCTTGCGACCTTC-3' 
485 55 32 NM_021467.4 
NFATc1 Fwd: 5'-TTCCAGCACCTTCGGAAGGGT-3' 
Rvs: 5'-AGTGAGCCCTGTGGTGAGAC-3' 






NFATc2 Fwd: 5'-TCTGCTGTTCTCATGGATGCCCC-3' 
Rvs: 5'-GGATGCAGTCACAGGGATGCT-3' 




NFATc3 Fwd: 5'-CGATCTGCTCAAGAACTCCC-3'  
Rvs: 5'-GGCAGATGTAACTGCTGGGT-3' 
246 55 28 NM_010901.2 
NFATc4 Fwd: 5'-CTGAGGATCGAGGTACAGCC-3' 
Rvs: 5'-TTGTTCTCTGGGAGCAAGGT-3' 
293 55 33 NM_023699.3 
NM_001168346.1 
Pax7 Fwd: 5'- GTAAGCAGGCAGGAGCTAAC-3' 
Rvs: 5'- GGTTCATGAAGCTGTCAGAG-3' 
285 55 38 NM_011039.2 
Myf5 Fwd: 5'-CTGTCTGGTCCCGAAAGAAC-3' 
Rvs: 5'-GTCTTTCCTTCAGCTTCAGGGC-3' 
328 55 38 NM_008656.5 
MyoD Fwd:  5'- TACCCAAGGTGGAGATCCT -3' 
Rvs: 5'- GCGGTGTCGTAGCCATTCT -3' 
253 55 32 NM_010866.2 
Mgn
2
 Fwd: 5'-GAAGAAAAGGGACTGGGG-3' 
Rvs: 5'-GGACCGAACTCCAGTGCAT-3' 
392 55 35 NM_031189.1 
Table 3-1:  Primers and cycling conditions 
Superscript number following a gene name indicates the paper from which the sequences were obtained.  
When no number is indicated, primers were designed by our lab. 1) (Murphy et al., 2010) 2) (Tang & 




3.4.6 Protein extraction and Western Blotting 
Muscles were homogenized using a hand-held Tissue Tearor homogenizer 
(ColeParmer, Montreal, QC, Canada) in RIPA buffer consisting of 1XPBS, 1% igepal, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.001 M sodium 
orthovanadate, 0.01 M sodium fluoride, 0.01 mg/ml aprotinin, 0.01 mg/ml leupetin and 1 
mM phenylmethanesulfonyl fluoride (all reagents from Sigma-Aldrich, St-Louis, MO, 
USA). Homogenates were incubated on ice for 30 minutes followed by two 4
o
C 
centrifugations at 15 000 x g for 20 minutes. The supernatants were collected and the 
protein concentration determined using Quick Start Bradford dye reagent (Bio-Rad, 
Mississauga, ON, Canada).  
For protein expression analysis, 150 μg of protein were separated by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) on a gel consisting of a 5% stacking gel 
and an 8% separating gel. Samples were electrophoresed (buffer: 25mM Tris, 192 mM 
glycine, 0.1% SDS, pH 8.3) at 120V and Amersham Full-Range Rainbow (GE 
Healthcare, Baie d’Urfe, QC, Canada) molecular weight markers were used to define the 
protein sizes. Subsequently, proteins were transferred (buffer: 25 mM Tris, 192 mM 
glycine and 20% methanol) to a PVDF membrane (Millipore, Billerica, MA, USA) at 
100V for one hour and a successful transfer was confirmed using Ponceau S staining. 
Membranes were blocked for one hour using 5% non-fat milk in 0.1% Tween-Tris 
Buffered Saline (T-TBS) and incubated with primary antibody overnight at 4
o
C on a 
shaker as indicated in Table 3.2. The following day, the membranes were washed three 
times five minutes using 0.1% T-TBS and were then incubated with the appropriate 
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horseradish peroxidase-conjugated secondary antibody: anti-rabbit IgG  #7074 (Cell 
Signaling Technology, Danvers, MA, USA) or anti-mouse IgG #A8924 (Sigma-Aldrich, 
St-Louis, MO, USA). Subsequently, membranes were developed using chemiluminescent 
Immobilon HRP substrate kit (Millipore, MA, USA) as per the manufacturer’s 
instructions. Images were captured and protein expression quantified by densitometry 
with the AlphaInnotech system and FluorChem software (San Leonardo, CA, USA). 
PROTEIN 
NAME 
SUPPLIER SIZE (kDa) 1OANTIBODY 2OANTIBODY 
α-tubulin Cell Signaling 
#2125 
52 1:2000 in 5% milk 1:2000 in 5% milk for 
1hr (anti-rabbit) 
pAkt (ser473) Cell Signaling 
#4060 





60 1:1000 in 5% milk 1:2000 in 5% milk for 
2hrs (anti-mouse) 
pGSK3β (ser9) Cell Signaling 
#9323 
46 1:1000 in 5% BSA 1:2000 in 5% milk for 
1hr (anti-rabbit) 
GSK3β Cell Signaling 
#9315 
46 1:1000 in 5% BSA 1:2000 in 5% milk for 
1hr (anti-rabbit) 
Table 3-2: Western Blotting Conditions 
 
3.4.7 Statistical Analysis  
The data were tested for homogeneity of variance using Levene’s test. In the case 
where variance between groups was homogenous one-way ANOVA was used followed 
by Tukey HSD (or Tukey-Kramer if uneven sample size) post hoc test.  In the case where 
the variance between groups was not homogenous, the Welch’s T test was used followed 
by Dunnett T3 post hoc test. All statistics were performed using SPSS statistics software 




3.5.1 NFATc2-/-  and NFATc3-/-  mice show blunted muscle growth following 
functional overload 
The hypothesis explored was that an absence of the downstream Cn signaling 
partners NFATc2 or NFATc3 would prevent or blunt overload-induced muscle growth. 
Plantaris muscle weights were measured following 7 and 28 days of functional overload 
in wild-type and NFATc2 or NFATc3 knockout mice. Values were expressed relative to 
total body weight and compared to wild-type mice. Wild-type mice showed a significant 
progressive muscle growth from 7 days to 28 days of overload, reaching a 2.1 fold 
growth after 28 days as compared to control, normal weight-bearing muscles (Figure 
3.2A). On the other hand, NFATc2-/- and NFATc3-/- mice displayed blunted muscle 
growth after 7 and 28 days of functional overload (Figure 3.2A). 
The increase in fiber size (Figure 3.2B) and fiber number at the midbelly area 
(Figure 3.2C) confirms that ablation of synergistic muscles induces a growth 
characterized by both fiber hypertrophy and hyperplasia in wild-type mice. Fiber size and 
number were also measured in the NFATc2 and NFATc3 knockout mice to determine if 
either blocked fiber hypertrophy or blocked fiber hyperplasia are the mechanisms 
responsible for the blunted muscle growth in these mice. The results indicated that the 
plantaris muscles of NFATc2 and NFATc3 knockout mice are not displaying 
hypertrophic fiber growth (Figure 3.2B) but maintain overload induced fiber hyperplasia 






Figure 3.2: Blunted compensatory muscle growth in NFATc2 and NFATc3 knockout mice 
A) Comparison of relative muscle weights following 7 days or 28 days of functional overload in wild-type, 
NFATc2-/- and NFATc3-/- mice B) Measurement of mean fiber cross sectional area size for all fiber types 
comparing control and 28 days overloaded muscles of wild-type, NFATc2-/- and NFATc3-/- mice. C) 
Fiber number count at the midbelly area comparing control and 28 days overloaded muscles of wild-type, 
NFATc2-/- and NFATc3-/- mice. All results are expressed as the mean ±SE. Numbers above bars indicate 
the data value. (* or # sig. diff. from respective normal weight-bearing CTL unless otherwise indicated, * 
p≤0.05, # <0.09 WT: CTL n=6, 7dOV n=3, 28dOV n=4; NFATc2-/-: CTL n=7, 7dOV n=3, 28dOV n=4; 




fibers are significantly smaller than wild-type overloaded fibers, although this is not the 
case of NFATc3 deficient fibers (Figure 3.2B). Additionally, as expected (Kegley et al., 
2001), there was a decrease in the number of fibers in NFATc3-/- mice in the normal 
weight-bearing condition in comparison to wild-type and NFATc2-/- mice (Figure 3.2C). 
These findings show that NFATc2 and NFATc3 transcription factors have essential roles 
in adaptive muscle growth. Additionally, our data suggest that adaptive muscle growth is 
regulated by a distinct mechanism in NFATc2-/- mice than in wild-type or NFATc3 
knockout mice.  
 
3.5.2 NFATc2-/- and NFATc3-/- mice show altered growth that is fiber type specific  
Given the observed reduced hypertrophic growth in both NFATc2 and NFATc3 
knockout mice, we sought to determine if this regulation is fiber type specific. Fiber 
typing was carried out based on the type of MyHC expressed and the fibers cross 
sectional area (CSA) and the percentage expression of fibers were compared between 
experimental groups. Muscle fibers classified as MyHC type IIa are characterized by an 
oxidative metabolism. These oxidative fibers maintained the ability to carry out overload-
induced hypertrophic growth in NFATc2 and NFATc3 knockout mice (Figure 3.3B) but 
this growth was reduced in NFATc2-/- mice as compared to wild-type mice.  Meanwhile, 
a marked but not significant increase in the percentage of fibers expressing MyHC IIa 
was observed in all mice investigated following 28 days of overload (Figure 3.3C). 
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Similar results (data not shown) were obtained for fibers expressing MyHC type I. These 




Figure 3.3: Muscle fibers expressing MyHC IIa maintain their ability to grow in NFATc2 
and NFATc3 knockout mice 
A) Representative images of histological sections stained for MyHC IIa fibers. Scale bar 50 um. 
Quantification of B) fiber cross sectional area and C) percentage of fibers expressing MyHC IIa comparing 
wild-type, NFATc2-/- and NFATc3-/- transgenic mice under control normal weight-bearing and 28 days of 
functional overload conditions. All results are expressed as the mean ±SE. Numbers above bars indicate the 
data value. (* sig. diff. from respective normal weight-bearing CTL unless otherwise indicated, p ≤ 0.05, 
WT: CTL n=3 & 28dOV n=4; NFATc2-/-: CTL n=4 & 28dOV n=4; NFATc3-/- : CTL n=3 & 28dOV 
n=3). 
 
  Next, analysis of glycolytic fibers, classified as expressing MyHC type IIb 
indicated a block of overload-induced hypertrophic growth in NFATc2 and NFATc3 
knockout mice (Figure 3.4B). It should be noted that overloaded muscles of NFATc2-/- 
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mice were significantly smaller then wild-type overloaded muscles, but this was not the 
case for NFATc3-/- overloaded muscles (Figure 3.4B). Meanwhile, all mice displayed a 
marked but not significant decrease in the number of MyHC IIb expressing fibers (Figure 
3.4C) following 28 days of overload (Figure 3.4C). 
 
 
Figure 3.4: Muscle fibers expressing MyHC IIb lose their ability to grow in NFATc2 and 
NFATc3 knockout mice. 
A) Representative images of histological sections stained for MyHC IIb fibers. Scale bar 50 um. 
Quantification of B) fiber cross sectional area and C) percentage of fibers expressing MyHC IIb comparing 
wild-type, NFATc2-/- and NFATc3-/- transgenic mice under control normal weight-bearing and 28 days of 
functional overload conditions. All results are expressed as the mean ±SE. Numbers above bars indicate the 
data value. (* sig. diff. from respective CTL, p≤0.05, WT: CTL n=3 & 28dOV n=4; NFATc2-/: CTL n=4 
& 28dOV n=4; NFATc3-/- : CTL n=3 & 28dOV n=3).  
 
Overall these findings indicate that NFATc2 and NFATc3 isoforms are essential for the 
maintenance of adaptive hypertrophy of fast glycolytic muscle fibers but do not influence 
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the hypertrophic growth of fast oxidative fibers. Also, these data showed differences in 
the hypertrophic growth response between NFATc2-/- and NFATc3-/- mice and suggest 
distinct roles for NFAT transcription factors in muscle adaptive growth.  
 
3.5.3 NFATc2 and NFATc3 knockout mice maintain the ability to remodel muscle 
fibers toward oxidative metabolic profiles 
Based on the observed tendencies for increased MyHC IIa and decreased MyHC 
IIb expressing fibers, we sought to determine if the expected overload-induced oxidative 
fiber type remodeling is maintained in mice deficient for functional NFATc2 or NFATc3. 
First, the levels of slow oxidative fibers, expressing MyHC I, were markedly increase (3-
10%) in all mice investigated following 28 days of overload (data not showed). Next, the 
amount of transcripts coding for MyHC IIa and IIb were measured. Following 7 days of 
functional overload, the levels of MyHC IIa transcripts remained unchanged (Figure 
3.5A) while a marked not significant down-regulation of MyHC IIb transcripts was 
observed in overloaded muscles of all mice investigated (Figure 3.5B). Specifically, all 
animals showed similar decrease of MyHC IIb mRNA levels in the overload condition 
displaying a ~60% decrease in comparison to respective normal weight bearing condition 
(Figure 3.5B). These findings suggest that fiber type remodeling toward oxidative 
metabolism is occurring in NFATc2 and NFATc3 knockout mice, as is observed in wild-





Figure 3.5: Remodeling toward oxidative muscle profiles is maintained in NFATc2 and 
NFATc3 knockout mice   
Representative agarose gel images of PCR products with quantification are shown comparing wild-type, 
NFATc2-/- and NFATc3-/- mice under control normal weight-bearing and 7 days of functional overload 
conditions. A) Expression of mRNA levels for MyHC IIa, B) MyHC IIb and C) TnIs. All quantifications 
are standardized to the ribosomal 28S RNA. Data are expressed as the mean ±SE. Numbers above bars 





Changes in metabolic profiles often precede changes in expression of myosins 
(Gundersen, 1998) hence the amount of mRNA coding for the slow muscle specific 
contractile protein troponin I slow (TnIs) were measured to further validate an increase in 
oxidative muscle profile. The levels of TnIs displayed a large (3 to 5 fold) increase 
following overload in muscles of all genetic backgrounds (Figure 3.5C).  
These collective findings indicate that fiber type remodeling is maintained in the 
NFAT knockout mice. All mice displayed the characteristic muscle metabolic remodeling 
observed in the overload condition, marked by an increase in the oxidative profiles and a 
decrease in the glycolytic profiles. 
 
3.5.4 NFATc2-/-  and NFATc3-/-  mice display distinct nuclear localization of NFAT 
isoforms 
All four isoforms of calcium-regulated NFAT are present in skeletal muscle. To 
determine the ability of NFAT isoforms to compensate for the absence of functional 
NFATc2 or NFATc3 in the knockout mice investigated, RT-PCR analysis was carried 
out (Figure 3.6). It is important to indicate that both NFATc2 and NFATc3 knockout 
mice are capable of producing a mutated transcript for their respective isoforms (Hodge 
et al., 1996; Oukka et al., 1998) and the PCR primers used in this study were designed in 
a manner to detect these mutant transcripts. In addition, it should also be noted that this 
assay is comparing the overall expression of NFAT isoforms between the different 




Figure 3.6: NFATc2 and NFATc3 knockout mice do not display compensatory changes in 
the expression of NFAT mRNA levels. 
A) Representative agarose gel images of PCR products and quantifications comparing mRNA levels for B) 
NFATc1, C) NFATc2, D) NFATc3 and E) NFATc4 under normal weight-bearing or 7 days functional 
overload condition for all genetic background of mice investigated. All quantifications are standardized to 
ribosomal 28S RNA. Data are expressed as the mean ±SE. Numbers above bars indicate the data value.  (p 
≤ 0.05, n=3 per group) 
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plantaris muscle. Overall these data did not indicate that NFAT isoforms have the ability 
to compensate for the absence of functional NFATc2 or NFATc3 at the mRNA levels in 
normal weight bearing or functional overload condition.  
The NFAT transcription factors are found in the cytoplasm in a phosphorylated 
state. The activity of these proteins is controlled through dephosphorylation that leads to 
the translocation of NFATs to the nucleus. In addition, the activity of these transcription 
factors is regulated by selective activation of export kinases. The study of the cellular 
distribution of the members of the NFAT protein family is important to better understand 
the functions and regulation of these transcription factors. Immunofluorescence was 
carried out to assess the nuclear localization of the members of the NFAT protein family 
and to evaluate if compensatory alterations in cellular distribution are observed in 
NFATc2 or NFATc3 knockout mice (Figure 3.7). The levels of NFAT isoforms co-
localized with nuclei were compared between the different groups. It should be noted that 
this assay is solely comparing the levels of nuclear-localized NFAT isoforms between the 
normal weight-bearing and overloaded condition in each mice group. This assay is not 
providing a comparison of the relative amounts of nuclear-localized NFAT isoforms in 
the plantaris muscle of different genetic background of mice. Also, the antibodies used in 
this study detected protein epitopes localized outside of the mutated region and hence 
these antibodies recognized mutant and wild-type proteins. All antibodies used were 









Figure 3.7: Nuclear trafficking of NFAT protein family members is altered in NFATc2-/- 
and NFATc3-/- mice. 
A, C and E) are representative immunofluorescence images that showed the overlay of images stained for 
nuclei (red) and specific NFAT isoforms (green) as indicated. Scale bar is 50 um. Arrows point to some of 
the nuclear-localized NFAT proteins (yellow). B, D and F) present the quantification of nuclear 
localization. A, B) are wild-type mice, C, D) are NFATc2 knockout mice and E, F) are NFATc3 knockout 
mice. All results are expressed as the mean ±SE. (* sig. diff. from respective CTL, n=3 per group, p≤0.05).  
 
In wild-type mice, following 7 days of functional overload, a significant 1.3 fold 
increase in nuclear-localized NFATc1 isoform was observed (Figure 3.7A and B). High 
amount of nuclear-localized NFATc2 also were observed but due to the high variability 
in the normal weight-bearing condition significance was not reached. Finally, the other 
NFAT isoforms did not display alteration in their nuclear localization in the wild-type 
mice. NFATc2 knockout mice also had a 1.5 fold increase in nuclear-localized NFATc1 
following functional overload. However, NFATc2-/- mice displayed an alteration in the 
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nuclear-localized levels of NFATc1 in the normal weight-bearing condition and, 
therefore, no significant change in nuclear translocation is observed after overload 
(Figure 3.7C and D). NFATc3 knockout mice displayed a 1.2 fold increase in nuclear-
localized NFATc1 and an interesting 1.4 fold increase in nuclear-localized NFATc4 
(Figure 3.7E and F). Collectively, these findings suggest that NFATc1 is the main 
isoform translocated to the nucleus in the overload response. These results also suggest 
that NFATc2 and NFATc3 may regulate the overload induced signaling by an indirect 
mechanism that depends on NFATc1 nuclear localization. In addition, these results imply 
a novel role for NFATc4 isoform in the overload response. 
 
3.5.5 NFATc2-/- and NFATc3-/- mice display an alteration in the expression of 
myogenic regulatory factors  
NFATc2 and NFATc3 knockout mice have been shown to display defects in 
various steps of myogenesis. While NFATc2 knockout mice display defects in the 
recruitment of myoblasts to fuse with multinucleated myofibers; a process required for 
postnatal myotube growth (Horsley et al., 2001), NFATc3 knockout  mice show defects 
in development of myoblasts; thus NFATc3 seems to regulate primary myogenesis 
(Kegley et al., 2001). To address these differences, the transcript levels of several 
members of the myogenic regulator factors were measured. The results described in this 
section are preliminary data that require a larger sample size to achieve statistical 
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significance, but that suggest important novel regulatory roles for NFATc2 and NFATc3 
transcription factors in the expression of muscle regulatory factors. 
Firstly, the amount of Pax7 was slightly increased in all genetic backgrounds of 
mice following 7 days of overload (Figure 3.8A and B). This suggests that all mice 
maintained the ability to carry out satellite cell self-renewal. The expression of Myf5 was 
increased 1.7 fold in both wild-type and NFATc3-/- mice in the overload condition as 
compared to normal weight bearing state, but this increase was blocked in NFATc2-/- 
mice (Figure 3.8A and C), implying that NFATc2 is important in the regulation of Myf5 
expression during adaptive muscle growth. The levels of MyoD mRNA were not altered 
following 7 days of functional overload in any genetic background of mice (Figure 3.8A 
and D). Finally, NFATc3 knockout mice displayed decrease levels of Mgn transcripts in 
the normal weight-bearing condition while maintaining the ability to promote the 
expression of Mgn transcript in the functional overload condition (Figure 3.8A and E).  
These results imply that NFATc2 and NFATc3 transcription factors can regulate 
the expression of myogenic regulatory factors. The data suggest that a larger block of 
overload induced hypertrophy observed in NFATc2-/- mice (Figure 3.2B) could be 
mediated by a decrease in Myf5 expression. Meanwhile, the decreased number of fibers 
seen in NFATc3-/- mice in normal weight-bearing muscles (Figure 3.2C) could be caused 





Figure 3.8: NFATc2 influences Myf5 levels while NFATc3 regulates Mgn levels. 
A) Representative agarose gel images of PCR products and quantifications comparing mRNA levels for B) 
Pax7, C) Myf5, D) MyoD and E) Mgn under normal weight-bearing or 7 days functional overload condition 
for all genetic background of mice investigated. All quantifications are standardized to ribosomal 28S 
RNA. Numbers above bars indicate the data value. Data are expressed as the mean ±SE.  




3.5.6 NFATc2-/- and NFATc3-/- mice do not exhibit modification in Akt signaling in 
the overload growth model 
The Akt signaling pathway is the best characterized skeletal muscle growth 
pathway and it has been shown important in the overload-induced muscle growth 
response (Bodine et al., 2001). Protein levels of pAkt and total Akt were measured since 
NFAT knockout mice displayed blunted overload induced muscle growth. In addition, 
the levels of the Akt downstream signaling target, GSK3β, were determined. The results 
described in this section are preliminary data that require a larger sample size to achieve 
statistical significance, but these data point out that Akt signaling pathway is most likely 
not altered in the adaptive muscle growth response of NFATc2-/- or NFATc3-/- mice, as 
compared to wild-type mice.  
First, results indicated a 2 fold increased in the level of pAkt in the overloaded 
wild-type muscles (Figure 3.9A and B). NFATc2 and NFATc3 knockout mice displayed 
similar amounts of pAkt as wild-type mice in the overloaded condition but these mice 
displayed larger variability in the amount of pAkt under normal weight-bearing 
conditions, particularly in the case of NFATc3-/- mice (Figure 3.9A and B). The levels of 
total Akt protein also display higher expression levels in the overloaded condition in all 
genetic backgrounds of mice (Figure 3.9A and C). Finally, pGSK3β or total GSK3β 
levels were not modified in the normal weight-bearing or overloaded conditions between 
mice investigated (Figure 3.9A, D and E). These findings suggest that reduced Akt 
activity is not responsible for the blunted growth in NFAT knockout mice in the adaptive 





Figure 3.9: Akt signaling is not responsible for altered growth in NFAT knockout mice. 
A) Representative Western blot images and quantification of protein levels for A) pAkt B) total Akt, C) 
pGSK3β and D) total GSK3β. Numbers above bars indicate the data value. All quantifications were 




Skeletal muscle fibers are composed of myofibers that can adapt to meet 
functional demands. Cn/NFAT signaling has been implicated in modulation of skeletal 
muscle fiber growth and remodeling (reviewed in (Olson & Williams, 2000; Bassel-Duby 
& Olson, 2003, 2006; Michel et al., 2007). In this study, the roles of the transcription 
factors NFATc2 and NFATc3, in the regulation of adaptive muscle growth, were 
investigated. The growth of the plantaris muscle was compared between wild-type and 
mice deficient for functional NFATc2 or NFATc3. This is the first study that explores the 
roles of NFATc2 and NFATc3 in functional compensatory muscle growth. The adaptive 
muscle growth was induced in this study using surgical synergistic muscle ablation, also 
called the overload model. This surgical model of muscle growth offers the advantage of 
inducing muscle adaptation by simultaneously increasing the nerve electrical activity and 
the muscle load. In addition, it offers the possibility of studying the malleability of adult 
muscle in a non-developmental setting. This muscle growth model has been characterized 
for promoting muscle fiber hypertrophy (Dunn & Michel, 1997; Dunn et al., 1999) and 
hyperplasia (Antonio & Gonyea, 1993; Kelley, 1996), as well as remodeling toward 
oxidative phenotype (Dunn & Michel, 1997). In this study, 28 days of overload was use 
to study fiber size and fiber type remodeling, while 7 days of overload was use to study 
changes in the biochemical signaling pathways. A complete time course analysis of all 
properties was not possible in this study, due to the limitation of knockout animals 
available. Calcineurin signaling has been shown to mediate overload-induced muscle 
remodeling and we hypothesized that an absence of downstream signaling partners 
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NFATc2 or NFATc3 would prevent or blunt overload induced muscle growth. NFATc2 
and NFATc3 knockout mice were chosen since these mice were previously described to 
display alteration in muscle mass (Horsley et al., 2001; Kegley et al., 2001).  
 
NFATc2-/- and NFATc3-/- mice exhibit an adaptive muscle growth characterized by 
hyperplasia and an absence of hypertrophy  
At first, plantaris muscle weights were compared between wild-type and NFATc2 
or NFATc3 knockout mice following 7 or 28 days of functional overload. The results 
were expressed as relative muscle weights to control for intrinsic body weight differences 
between mice used. The results (Figure 3.2A) indicated that NFATc2-/- and NFATc3/- 
mice displayed a reduced plantaris muscle growth as compared to wild-type mice. 
Notably, NFATc2 and NFATc3 knockout mice showed muscle weights comparable to 
wild-type mice in the initial phase (7 days) of the overload-induced remodeling. 
However, the greater muscle weight observed in the earlier phase of the overload period 
is probably caused by the surgical trauma that leads to muscle edema and an initial 
inflammatory response (Armstrong et al., 1979) which is not a direct muscle growth 
response.  
The growth of adult skeletal muscle can be described in two major steps. First, 
proliferating muscle precursor cells, called myoblasts, differentiate and fuse with one 
another to form nascent myotubes with a limited number of nuclei (Pavlath & Horsley, 
2003). Secondly, the formed nascent myotubes fuse with additional myoblasts. This 
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allows the multinucleated myotubes to grow in CSA while maintaining a constant 
myonuclear domain (i.e. “the quantity of cytoplasm regulated by a single myonuclei” 
(Roy et al., 1999)) (Roy et al., 1999; Pavlath & Horsley, 2003). The first growth response 
is identified by an increase in fiber number (hyperplasia), while the second phase of 
growth is characterized by simultaneous hyperplasia and hypertrophy (Pavlath & 
Horsley, 2003).  
Fiber size and fiber number were compared between wild-type and NFAT 
knockout mice after 28 days of functional overload to identify which step of muscle 
growth is compromised. The results indicated that hypertrophic fiber growth is inhibited 
in NFAT knockout mice and that this block is more pronounced in NFATc2-/- mice 
(Figure 3.2B). This severe block of fiber hypertrophy in NFATc2-/- mice is in agreement 
with published data that indicated that NFATc2-/- mice display defects in prenatal and 
postnatal fiber growth (Horsley et al., 2001). Specifically, using a model of muscle fiber 
regeneration following injury, NFATc2-/- mice were shown to be capable of forming 
new fibers but displayed defects in secondary fusion (Horsley et al., 2001; Mitchell & 
Pavlath, 2002; Pavlath, 2010). This lead to impaired nuclear addition and a block of fiber 
hypertrophy (Horsley et al., 2001). In our study, the number of myonuclei per fiber was 
not counted and thus impaired nuclear addition was not assessed, but a block of fiber 
hypertrophy was observed (Figure 3.2B). In addition, our data implicate Myf5 in this 
process since decrease levels of this myogenic regulator factor were detected in 
overloaded muscles of NFATc2-/- mice (Figure 3.8A and B).  
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In this study, normal weight-bearing NFATc2 knockout mice did not display 
smaller muscle fiber CSA when compared to wild-type mice (Figure 3.2B), in contrast to 
what has previously been shown (Horsley et al., 2001). Horsley et al. (2001) measured 
fiber size in NFATc2-/- mice and described a decrease in fiber CSA in the load-bearing, 
predominantly oxidative, soleus (SOL) muscle and in the not load-bearing, mainly 
glycolytic, extensor digitorum longus (EDL) muscle. However, the SOL and EDL 
muscles differ in biochemical and physiological properties from the plantaris muscle 
investigated in this study. The plantaris muscle is a load-bearing muscle formed by a 
mixture of fiber types, displaying all types of oxidative and glycolytic profiles. This is an 
important aspect to keep in mind since muscle types differ in intrinsic abilities to adapt 
resulting from distinct embryonic myoblast lineages (Schiaffino & Serrano, 2002). In 
addition, differences in age, gender, species, and growth model used (functional overload, 
growth after atrophy, maintenance, regeneration, stimulus like IGF) may explain 
discrepancies between results presented in different studies (Mitchell & Pavlath, 2002; 
Schiaffino & Serrano, 2002; Konhilas et al., 2004). Also, it was previously reported that 
calcineurin differentially influenced the growth of different muscle types (Mitchell et al., 
2002). More specifically, treatment of muscle with the pharmacological Cn inhibitor 
cyclosporine affected more severely the maintenance of growth in fast muscle plantaris 
than in slow muscle soleus (Mitchell et al., 2002). As a result, caution should be taken 
when comparing results from different studies and, as performed in this study, all 
comparison should be made using the same species, muscle type, gender and animal age.  
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Next, in response to functional overload, both NFATc2-/- and NFATc3-/- mice 
displayed an increase in the number of muscle fibers per midbelly area (Figure 3.2C). 
This indicates that NFAT deficient muscles are able to carry out fiber hyperplasia. A 
significant decrease in fiber number was observed in normal weight-bearing muscles of 
NFATc3-/- mice as compared to wild-type mice (Figure 3.2C) and as reported in the 
literature (Kegley et al., 2001) it is caused by a defect in primary myogenesis. This 
decrease in the number of fibers observed in NFATc3-/- mice (Figure 3.2C) could be 
mediated by decrease levels of Mgn in normal weight-bearing condition (Figure 3.8A and 
E). Nevertheless, following 28 days of functional overload, NFATc3 knockout mice 
reached a similar cell number as wild-type overloaded mice indicating that hyperplasia is 
not impaired (Figure 3.2C).  
This is the first study to investigate the role of NFATc2 and NFATc3 in the 
adaptive growth response of adult muscles. Overall, our findings demonstrate that in the 
plantaris muscle, functional overload-induced muscle growth is mediated by hypertrophy 
and hyperplasia in wild-type mice, whereas in mice lacking functional NFATc2 or 
NFATc3 the hypertrophic fiber growth is blocked. Also, the data illustrate a differential 






NFATc2-/- and NFATc3-/- mice maintain metabolic plasticity and display a block 
hypertrophic growth specific to glycolytic fibers 
 An analysis of fiber types was carried out and the size and percentage expression 
of each fiber type compared between normal weight-bearing and 28 days overloaded 
plantaris muscles in wild-type, NFATc2-/- and NFATc3-/- mice. This analysis seeks to 
determine if different NFAT isoforms may regulate the growth of different fiber types 
during adaptive muscle growth. The results indicated that NFATc2 and NFATc3 play 
important roles in the regulation of hypertrophic muscle growth predominantly in 
glycolytic fibers (Figure 3.3B and Figure 3.4B). Indeed, the overload-induced fiber 
hypertrophy of oxidative fibers expressing MyHC type IIa was maintained (Figure 3.3B) 
in knockout mice while the growth of glycolytic fibers expressing MyHC type IIb was 
blocked (Figure 3.4B). The blocked fiber size growth is in agreement with previous 
studies that implicated calcineurin signaling in the regulation of skeletal muscle 
hypertrophic growth (Dunn et al., 1999; Musaro et al., 1999; Semsarian et al., 1999; 
Mitchell et al., 2002; Miyazaki et al., 2006; Oishi et al., 2008; Sakuma et al., 2008). In 
addition, another study has implicated a Cn downstream signaling partner NFATc1, 
together with the four-and-a-half Lim protein 1 (FHL1), in the regulation of skeletal 
muscle hypertrophic growth (Cowling et al., 2008). In the latter study, it was shown that 
FHL1 complexes with NFATc1 and increases its transcriptional activity, promoting both 
skeletal muscle hypertrophy and oxidative fiber type remodeling (Cowling et al., 2008). 
In contrast, other groups have indicated that calcineurin is not involved in skeletal muscle 
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hypertrophy (Bodine et al., 2001; Rommel et al., 2001; Parsons et al., 2004) but 
numerous review papers (Schiaffino & Serrano, 2002; Bassel-Duby & Olson, 2003; 
Tidball, 2005; Sakuma & Yamaguchi, 2010) have provided possible explanations for the 
observed discrepancies between these two different conclusions. In our study, the 
divergent growth response of oxidative and glycolytic fibers in mice deficient for 
functional NFATc2 or NFATc3 serves to provide additional insight into the previously 
observed contrasting roles of Cn in muscle growth. Furthermore, the observed reduced 
growth of oxidative, MyHC IIa, fibers in NFATc2 knockout mice, as compared to wild-
type or NFATc3-/- mice (Figure 3.3B), is in agreement with impaired nuclear addition 
and a block of fiber hypertrophy observed previously in injury-induced regenerating 
fibers of NFATc2-/- mice (Horsley et al., 2001). In addition, the more pronounced block 
of fiber hypertrophy in NFATc2-/- mice, as compared to NFATc3-/- mice, suggests that 
NFAT proteins regulate distinct mechanisms. A differential regulation of the adaptive 
muscle growth response also is suggested by a different amount of Myf5 in the 
overloaded muscles of NFATc2-/- mice (Figure 3.8A and C)  The results suggest that 
different combinations of NFAT isoforms regulate the hypertrophy of specific fiber 
types, in the same way that previous research has shown that different combinations of 
NFAT isoforms are necessary for maintenance of both slow and fast muscle fibers 
(Calabria et al., 2009). Overall, these data reveal that NFATc2 and NFATc3 transcription 
factors can selectively regulate hypertrophy of glycolytic fibers.  
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  The comparison in the percentage expression of fibers compared between 
normal weight-bearing and 28 days overloaded plantaris muscles in wild-type, NFATc2-
/- and NFATc3-/- mice indicated that both NFATc2 and NFATc3 knockout mice 
maintain the ability of oxidative fiber type remodeling (Figure 3.3C and Figure 3.4C). 
Yet, the fiber type remodeling observed in our study did not produce a complete 
sequential transition of MyHC towards oxidative fiber types. The absence of a significant 
transition in MyHC profiles (i.e. a reduction in expression of MyHC IIa fibers and an 
increase in expression of MyHC IIb fibers) indicates that longer overload periods and/or 
forced exercise (Gregory et al., 1986) are necessary. The levels of mRNA encoding 
MyHC IIa and MyHC IIb were measured to corroborate an oxidative fiber type 
remodeling, that was implied by the histological assessments of fiber type expression. 
The preliminary data showed that, in the overloaded muscles of all animals investigated, 
the amount of MyHC IIb mRNA are decreased (Figure 3.5B) while the levels of MyHC 
IIa mRNA remained unchanged (Figure 3.5A). As a modification in the expression of 
muscle metabolic profiles often precedes changes in the expression of myosin heavy 
chain genes or proteins (Gundersen, 1998), the levels of mRNA encoding TnIs were 
measured. This contractile protein is associated with the expression of a slow muscle 
profile and its expression is promoted in conditions of oxidative muscle adaptation 
(Calvo et al., 1996; Nakayama et al., 1996; Chin et al., 1998; Dunn et al., 1999). As 
expected, an increase amount of TnIs mRNA was detected in overloaded muscles of all 
mice investigated (Figure 3.5C). Additionally, myogenin (Mgn), a gene recognized for its 
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roles in myogenesis, also has been implicated in mediating muscle remodeling toward 
oxidative metabolism (Hughes et al., 1999). All mice investigated displayed an up-
regulation in Mgn mRNA levels (Figure 3.8A and E). The ability of NFATc2 and 
NFATc3 knockout mice to experience oxidative fiber type remodeling under conditions 
of functional overload is in agreement with recent findings that indicated that a 
combination of different NFATs are required to mediate fiber type specification (Calabria 
et al., 2009). The research carried out by Calabria et al. (2009) indicated that NFAT 
transcription factors act synergistically to regulate specification of muscle fibers and that 
a combination of NFATc1, NFATc2, NFATc3 and NFATc4 act together to promote 
expression of oxidative MyHC muscle fibers. 
Overall, our results imply that the absence of one NFAT isoform does not prevent 
metabolic remodeling of muscles. Collectively these findings suggest that NFAT 
isoforms have a limited capacity to substitute for one another in muscle fiber type 
metabolic remodeling. Meanwhile, NFATc2 and NFATc3 isoforms are important in 
mediating skeletal muscle adaptive hypertrophic growth response of glycolytic muscle 
fibers. These findings provide new knowledge about the functions the different NFAT 






NFATc2-/- and NFATc3-/- mice display altered nuclear localization of surviving NFAT 
isoforms  
All four isoforms of calcium regulated NFAT are present in skeletal muscles 
(Hoey et al., 1995; Calabria et al., 2009). To assess the capacity of NFAT proteins to 
substitute for one another, the levels of mRNA encoding NFATs were compared between 
wild-type and knockout mice, in normal weight-bearing or 7 days overloaded conditions. 
This comparison did not show compensatory changes in the amounts of surviving NFAT 
mRNA in muscles of NFATc2 or NFATc3 knockout mice (Figure 3.6). This is in 
agreement with previous studies that investigated NFAT mRNA levels in normal weight-
bearing muscles or muscle cell cultures that lacked NFATc2 or NFATc3 expression 
(Horsley et al., 2001; Kegley et al., 2001). These findings indicate that compensatory 
regulation of surviving NFAT isoform mRNA is not occurring in NFATc2 or NFATc3 
knockout mice in normal weight-bearing or adaptive muscle growth conditions. 
NFAT proteins are transcription factors whose activities are regulated by 
dephosphorylation and subsequent localization to the nucleus. Previously, it has been 
reported that the translocation of some NFAT isoforms occurs at specific stages of 
muscle development (Abbott et al., 1998). In addition, more recently it was shown that in 
response to distinct muscle electrical activity patterns, different combinations of NFAT 
proteins translocate to the nucleus and act to regulate the expression of specific muscle 
fiber types (Calabria et al., 2009). It also has been described that nuclear shuttling of 
NFATc1 is linked to the activation of a slow muscle profile (Liu et al., 2001; Shen et al., 
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2006) and an increase in nuclear localization of NFATc1 was observed in the functional 
overload model (Dunn et al., 2000; Dunn et al., 2001). This study represents the first 
examination of the cellular distribution of all four calcium-regulated NFAT isoforms in 
conditions of adaptive muscle growth. Immunofluorescence was used to compare the 
nuclear localization of NFAT isoforms between normal weight-bearing and 7 days 
functional overloaded conditions in wild-type, NFATc2-/- and NFATc3-/- mice.  
In the wild-type mice an increase in nuclear-localized NFATc1 isoform was 
detected in the overloaded plantaris as compared to normal weight-bearing levels (Figure 
3.7A and B), corresponding to results previously reported in the literature (Dunn et al., 
2000; Dunn et al., 2001). While our data demonstrated that NFATc2 and NFATc3 
isoforms participate in muscle hypertrophic growth (Figure 3.2), these two isoforms did 
not show greater nuclear localization in response to overload in wild-type mice, versus 
the normal weight-bearing condition (Figure 3.7A and B). This finding suggests that 
nuclear shuttling of NFATc2 or NFATc3 might be implicated at earlier or later stages of 
the overload response. Consequently, future experiments should look at the expression of 
NFAT protein localization in a functional overload time course experiment. 
The assessment of nuclear localization of NFATc1 in NFATc2-/- mice did not 
indicate a significant increase in the nuclear localized NFATc1 in the overloaded muscle, 
but larger variability was detected for this isoform in the normal weight-bearing condition 
(Figure 3.7C and D). This may indicate that collaborative regulation occurs between 
NFATc1 and NFATc2 in wild-type mice hence the absence of functional NFATc2 in the 
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knockout mice leads to impaired nuclear shuttling of NFATc1 during the normal weight-
bearing condition. Structural analysis of the NFAT proteins (Hogan et al., 2003; Macian, 
2005) has indicated that they can form cooperative transcriptional complexes as homo- or 
hetero-dimers with other NFAT isoforms, or with other transcription factors. In the 
NFATc2-/- mice, the other NFAT isoforms did not exhibit alteration in nuclear 
localization in the overloaded condition (Figure 3.7C and D).  
Finally, NFATc3-/- mice displayed an increase in nuclear localization of both 
NFATc1 and NFATc4 isoforms (Figure 3.7E and F). This indicates that an absence of 
functional NFATc3 protein promotes a faster or greater nuclear trafficking of NFATc4. 
Notably, the nuclear import of NFATc1 with overload is reduced as compared to wild-
type mice (1.3 in wild-type versus 1.1 in NFATc3-/- mice) (Figure 3.7B and F) and 
NFATc4 might be recruited to substitute for NFATc1. NFATc4 is an isoform that has not 
been investigated in depth in skeletal muscles. NFATc4 knockout mice do not display 
defects in their muscle phenotype (Graef et al., 2001) and the expression of NFATc4 is 
very low in skeletal muscles (Hoey et al., 1995; McCullagh et al., 2004; Calabria et al., 
2009). Nevertheless, NFATc4 was shown to play roles in the specification of all four 
types of skeletal muscle fibers (Calabria et al., 2009) and results presented here also 
implicate NFATc4 in the regulation of adaptive muscle growth.   
In summary, these results imply that NFATc1 requires the presence of both 
NFATc2 and NFATc3 to fine tune its correct nuclear localization during the overload 
response. These data point out that more detailed analyses are required to elucidate the 
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exact mechanisms of NFAT nuclear trafficking in the functional overload model. Of 
foremost importance would be to carry out a detailed time-course investigation of NFAT 
localization over a large overload time period. In addition, immunoprecipitation 
experiments should be performed to study the formation of NFAT dimers in the nucleus, 
comparing wild-type and NFAT knockout mice in normal weight-bearing or overloaded 
conditions. It would also be interesting to compare the nuclear localization of NFATs in 
different fiber types since NFAT knockout mice displayed a block of growth of 
glycolytic (Figure 3.4B), but not oxidative fibers (Figure 3.3B). The latter experiments 
would strengthen the idea that NFATc2 and NFATc3 are essential to mediate 
hypertrophic growth in selected fiber types. Overall, immunofluorescence experiments 
suggest that a lack of functional NFATc2 or NFATc3 influences NFATc1 cellular 
distribution and suggest that NFAT isoforms might act collectively to influence muscle 
fiber hypertrophic growth. The absence of NFATc2 or NFATc3 could alter the 
import/export dynamics of surviving NFAT isoforms or it could affect the formation of 
NFAT cooperative transcriptional complexes. These results also imply distinct nuclear 
trafficking dynamics of surviving NFAT family members during the adaptive muscle 
growth in NFATc2-/- or NFATc3-/- mice. More detailed experiments are required to 
clearly elucidate the cellular distribution of NFAT isoforms and to better understand 





NFATc2 and NFATc3 regulate the expression of myogenic regulatory factors                   
As NFATc2 and NFATc3 knockout mice have been shown to display defects in 
various steps of developmental myogenesis (Horsley et al., 2001; Kegley et al., 2001), 
the mRNA coding for some myogenic factors were measured using RT-PCR. More 
precisely, in our study Pax7 was used as a marker of muscle precursor cells called 
satellite cells. Satellite cells become activated under conditions of muscle regeneration or 
growth. The transcription factor Pax7 is expressed in all satellite cells and it ensures 
survival of these cells (Seale et al., 2000; Kuang et al., 2006; Buckingham, 2007; 
Buckingham & Relaix, 2007). The myogenic factors Myf5 and MyoD served as markers 
of satellite cells activation and determination of the formation of myoblasts (Rudnicki et 
al., 1993; Megeney & Rudnicki, 1995; Sabourin & Rudnicki, 2000; Charge & Rudnicki, 
2004). Finally, Mgn was used as a marker of myoblast differentiation into myotubes that 
will form and grow into mature muscle fibers (Hasty et al., 1993; Nabeshima et al., 1993; 
Megeney & Rudnicki, 1995; Sabourin & Rudnicki, 2000). 
The levels of Pax7 gene showed a slight, but not significant, increase in the 
overloaded muscles of all mice investigated (Figure 3.8A and B). This result is in 
agreement with the literature since in the functional overload model the levels of this 
transcription factor displayed a rapid increase in the first 12 hours, peaked at 2 days and 
then exhibited a progressive decrease in expression (Hyatt et al., 2008). The lack of 
differential expression of the Pax7 gene between wild-type and NFAT knockout mice 
indicates that the expression of satellite cells is not altered in these animals. 
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Next, the levels of Myf5 and MyoD were determined and the results indicated an 
up-regulation of Myf5 levels in overloaded muscles of wild-type and NFATc3 knockout 
mice in comparison to normal weight-bearing muscles (Figure 3.8A and C). In contrast, a 
higher expression of Myf5 was not seen in overloaded muscles of NFATc2-/- mice. This 
finding could possibly relate to the impaired nuclear addition seen in NFATc2-/- mice 
(Horsley et al., 2001) since higher levels of Myf5 have been shown to promote satellite 
cell self-renewal (Charge & Rudnicki, 2004). An absence of satellite cells self-renewal 
could lead to impaired nuclear addition in growing muscle fibers and this would prevent 
the maintenance of a constant nuclear domain. In addition, Myf5 was shown to be 
regulated by a Cn/NFATc1 dependent mechanism in cell culture experiments (Friday & 
Pavlath, 2001) and our immunofluorescence assays suggested possible formation of 
cooperative transcriptional complexes between NFAT isoforms. 
  In contrast, the levels of MyoD did not show significant differences in the 
overloaded condition for all animals investigated (Figure 3.8A and D). This finding was 
expected since MyoD was shown to follow a similar time course of expression as the 
Pax7 gene in the functional overload; it thus returns to control expression levels after 7 
days of overload (Hyatt et al., 2008). It should also be noted that a difference in gene 
expression was not observed for Pax7, Myf5 or MyoD between animals, in normal 
weight-bearing conditions. This finding is consistent with previous reports that did not 
detect changes in the expression of MyoD in NFATc2-/- mice (Horsley et al., 2001). 
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Meanwhile, this study represents the first analysis of the expression levels of myogenic 
regulatory factors in NFATc3-/- mice.   
 Myogenin (Mgn) is a myogenic factor essential for the transition from 
proliferative myoblasts to differentiated cells that will fuse and form myotubes (Hasty et 
al., 1993; Nabeshima et al., 1993; Rawls et al., 1995). Analysis of the levels of Mgn 
indicated a large increase in Mgn mRNA levels in all mice investigated (Figure 3.8A and 
E) indicating that formation of nascent myotubes is not blocked in NFAT knockout mice 
and in good agreement with the observed hyperplasia in our model. It is also important to 
note a decrease in the amount of Mgn in normal weight-bearing muscle of NFATc3-/- 
mice (Figure 3.8A and E). This finding is consistent with a study that implicated NFATc3 
in the induction of myogenin expression (Armand et al., 2008) and supports the finding 
of a reduced number of fibers in NFATc3-/- mice in the normal weight-bearing condition 
(Figure 3.2C) and (Kegley et al., 2001). In the functional overloaded condition, the levels 
of Mgn are increased and this is also consistent with the ability of NFATc3-/- mice to 
display overload induced fiber hyperplasia (Figure 3.2C). These data indicate that Mgn is 
not regulated by NFATc2 or NFATc3 during adaptive muscle growth yet NFATc3 
controls Mgn expression during developmental myogenesis.   
  Collectively, these preliminary results suggest that during adaptive muscle 
growth, NFATc2 regulates the expression of Myf5, and this can possibly relate to the 
more pronounced block of fiber hypertrophy seen in NFATc2-/- mice (Figure 3.2B) 
Meanwhile, NFATc3 appears to influence the levels of Mgn during the developmental 
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growth of muscles, and this can be associated to the reduced number of fibers in 
NFATc3-/- mice (Figure 3.2C). 
   
Signaling via Akt pathway is not altered in overloaded NFATc2-/- or NFATc3-/- mice  
The Akt signaling pathway is well characterized in its role to promote skeletal 
muscle hypertrophy and prevent muscle atrophy (Bodine et al., 2001; Rommel et al., 
2001; Glass, 2005; Sandri, 2008; Glass, 2010). Akt becomes activated by 
phosphorylation and an increase in the expression of total Akt and phosphorylated protein 
have been reported in various models of muscle growth such as exercise (Nader & Esser, 
2001; Sakamoto et al., 2003; Sakamoto et al., 2004), electrical stimulation (Nader & 
Esser, 2001; Sakamoto et al., 2002) or the functional overload model (Bodine et al., 
2001; Miyazaki et al., 2011). The glycogen synthase kinase-3β (GSK-3β) is a target of 
Akt signaling and Akt-induced phosphorylation of GSK-3β leads to inhibition of GSK-3β 
activity (Cross et al., 1995; Proud & Denton, 1997; Harwood, 2001). GSK-3β is a 
negative regulator of protein translation and a reduction in its activity leads to muscle 
growth (Rommel et al., 2001; Vyas et al., 2002). In addition, GSK-3β has been shown to 
regulate NFAT transcription factors transcriptional activity during condition of muscle 
growth (Rommel et al., 2001; Vyas et al., 2002)   
The levels of phosphorylated and total Akt and GSK-3β proteins were measured 
using Western blotting and compared between normal weight-bearing and overloaded 
conditions in wild-type and 7 days functional overloaded animals (Figure 3.9). 
 126 
 
Quantification of these results indicated an increase in total and phosphorylated levels of 
Akt in the overloaded condition in all animals investigated. Meanwhile, total or 
phosphorylated levels of GSK-3β did not change in the overloaded condition. It is also 
interesting to observe a subtle increase in the levels of pAkt in NFATc3 knockout mice in 
the normal weight-bearing muscles as compared to wild-type and NFATc2-/- mice 
(Figure 3.9A and B). This could be a way for NFATc3-/- mice to compensate for a 
decreased number of fibers in the normal weight-bearing condition (Figure 3.2C).  
The results presented in this section should be re-confirmed and strengthened 
using a larger sample size to try to achieve statistically significant differences in the data. 
Nevertheless, these results indicate that Akt / GSK-3β signaling events are most likely 
not responsible for the reduced growth of glycolytic fibers in NFATc2 or NFATc3 
knockout mice in conditions of adaptive muscle growth.  
 
Summary 
This is the first study to use NFATc2 and NFATc3 knockout mice to investigate 
the roles of NFAT transcription factors in the adaptive muscle growth induced by 
surgical synergistic muscles ablation. The findings indicated that NFATc2 and NFATc3 
transcription factors are important in the regulation of glycolytic fiber hypertrophy. 
Furthermore, NFATc2 and NFATc3 knockout mice displayed differences in their 
adaptive growth responses. More precisely, the hypertrophic growth was more severely 
blunted in NFATc2-/- than NFATc3-/- mice. Meanwhile, both knockout mice maintained 
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the ability to carry out the overload-induced oxidative metabolic remodeling. The results 
demonstrated that NFATc2-/- and NFATc3-/- mice display alteration in nuclear shuttling 
of NFAT isoforms and implicated the less documented NFATc4 isoform in the regulation 
of muscle adaptive growth. The outcomes also showed that NFATc2 and NFATc3 
knockout mice differ in expression and regulation of myogenic factors Myf5 and Mgn and 
this provided insight into the different growth response of these animals. In short, 
NFATc2 may regulate the expression of Myf5 during adaptive muscle growth, while 
NFATc3 could influence the levels of Mgn during the developmental growth of muscles. 
Finally, mice deficient for functional NFATc2 or NFATc3 did not display impaired Akt 
signaling in response to the overload induced adaptive muscle growth.  
In conclusion, our findings illustrate the importance of NFATc2 and NFATc3 in 
the regulation of muscle hypertrophy. Although many questions still remain unanswered 
and require future study, these results demonstrate that both NFATc2 and NFATc3 
control adaptive growth of adult muscles. Our results also highlight the significance of 
different muscle growth models and distinct muscle and / or fiber types in decoding 
signaling events that stimulate muscle growth. A better understanding of molecular 
pathways regulating muscle growth can help identify future therapeutic targets for the 
treatment of various diseases displaying symptoms of muscle atrophy or wasting, such as 




3.7 Future Directions 
  Currently an ongoing project involves the investigation of muscle growth in mice 
deficient simultaneously for both functional NFATc2 and NFATc3 isoforms. Our 
laboratory is at this time breeding these transgenic mice, but as in the case of NFATc3-/- 
mice, the breeding success is very low. Indeed, it was reported that NFATc3-/- mice 
undergo fetal death and thus the chances of obtaining homozygous offspring is only 
about 12% (Oukka et al., 1998).  Furthermore, NFATc2-/-c3-/- mice are often sick and 
frail due to the weakness of their immune system, and this leads to younger death before 
surgery age or death following overload surgery. Nevertheless, it would be a very 
interesting to evaluate the response of these double null mice to the surgical overload 
model.   
In this chapter, due to the limited number of animals available, the signaling 
events were investigated following 7 days of functional overload, while histological 
phenotypic comparison were carried out after 28 days of functional overload. The future 
experiments should aim to evaluate a detailed time course of events for the observed data. 
As explained in the discussion, it appears important to investigate both the signaling and 
phenotypic alterations at 3 days, 1 week (7 days), 4 weeks (28 days) and 8 weeks. These 
experiments would require a large number of mutant mice and this is definitely a 
limitation to this study, but it would provide a clear and in depth understanding of NFAT 
roles in the regulation of adaptive muscle growth. 
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Finally, in the short-term it would also be important to perform an in depth 
immunofluorescent analysis of NFAT nuclear localization, not only at different overload 
time periods but also by fiber type. Our results indicated that NFATc2 or NFATc3 
knockout mice display defects in growth of glycolytic but not oxidative fiber types. In 
NFATc2-/- or NFATc3-/- mice alterations in the nuclear trafficking of NFATs proteins 
were detected hence a detailed time and fiber type analysis of the nuclear trafficking is 
important.  
Furthermore, Western blotting analysis of the expression of NFAT transcription 
factors in different cellular compartments is still pending due to the untidy results 
obtained in preliminary experiments. The analysis of Western blot detection is 
complicated by the presence of various splice variants of a single NFAT isoform, by the 
numerous phosphorylation sites present on NFAT proteins and by the detection of 
unspecific bands from other proteins containing a Rel homology domain. Additionally, 
immunoprecipitation experiments should be carried out to confirm the formation of 
transcriptional complexes between the different NFAT isoforms during muscle growth.  
Finally, the experiments carried out using semi-quantitative PCR should be re-
analyzed using real-time PCR. This equipment would provide a more precise and 
quantitative analysis of gene expression and would refine and support the results 
presented in this chapter. As an alternative, gene arrays could also be performed but 
caution should be taken in selecting gene array targets. The gene array assay would 
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provide a global analysis of possible changes in gene expression of numerous targets in a 
single experiment. 
Overall, to achieve a detail and clear understanding of the precise roles of 
NFATc2 and NFATc3 in the overload growth model more experiments are awaiting. An 
in depth understanding requires long term careful planning due to the limitations of the 
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4.1 Background  
In this Chapter the possibility that the trophic factor agrin can regulate skeletal 
muscle growth is explored. A recombinant neural agrin is injected directly into the tibialis 
anterior muscle of wild-type, aging and dystrophic mice. The results illustrate that agrin 
may regulate Akt signaling, a major muscle growth pathway. Yet, agrin failed to induce 
fiber hypertrophy in wild-type mice, it does not regulate Akt signaling in aging muscle, 
and it only showed a partial rescue of dystrophic muscle pathology.   
These results represent preliminary data that aim to discover novel roles for agrin. 
This protein is well recognized for its function in the maintenance and formation of NMJ 




The plasticity of skeletal muscle is a complex mechanism controlled by signals 
coming from the nerve and from within the muscle. Agrin is a large heparan sulfate 
proteoglycan released by the motor neuron. The best characterized function of agrin in 
skeletal muscle is its ability to form and stabilize the NMJ. Recent investigations indicate 
that agrin also has novel roles in muscles, beyond the maintenance of the NMJ. 
In this study, a recombinant neural agrin was injected in vivo into the tibialis 
anterior muscle of mice. In wild-type adult, healthy mice results showed that agrin may 
regulate Akt signaling, a major muscle growth pathway. Yet, histological assessment of 
wild-type muscle fibers did not indicate fiber hypertrophy or fiber type remodeling 
following agrin injection. In addition, the roles of agrin were assessed in two models 
displaying degeneration of skeletal muscles. Agrin administration failed to activate Akt 
signaling in mice displaying sarcopenia; the progressive decline of muscle mass and 
function that occurs with age. On the other hand, agrin treatment decreased the number of 
centrally nucleated fibers in a mouse model for Duchenne Muscular Dystrophy (DMD) 
indicating a modest rescue of muscle wasting.    
While these results are preliminary they suggest new functions for agrin in 
skeletal muscles. More in depth assessments of mechanical and biochemical properties of 
muscles are necessary to obtain a detailed picture of agrin’s roles in the regulation of 
muscle diseases and/or growth. Nevertheless, this investigation identifies novel research 




The plasticity of skeletal muscles is a complex mechanism controlled by signals 
coming from the nerve and from within the muscle. Agrin is a large heparan sulfate 
proteoglycan that exists in numerous different splice variants displaying different 
biological activities and tissue distributions (Ferns et al., 1993; Hoch et al., 1993). 
Currently, neural agrin, that contains an insert at splice site Z, is the sole isoform 
recognized to display biological activity (Ferns et al., 1993; Bezakova & Lomo, 2001; 
Williams et al., 2008). 
Agrin is released by the motor neuron into the presynaptic cleft and on the muscle 
surface agrin interacts with two receptors (Hoch, 1999). Firstly, the association of agrin 
with α-dystroglycan (α-DG) (Gee et al., 1994) serves to aggregate the dystrophin-
associated glycoprotein complex (DGC) (Campanelli et al., 1994; Hoch, 1999). The main 
functions of this complex are to stabilize the skeletal muscle structure and to serve as a 
scaffold for various signaling molecules (Pilgram et al., 2010). Secondly, agrin interacts 
with LDL-receptor related protein 4 (LRP4) (Kim et al., 2008; Zhang et al., 2008) that 
forms a complex with the muscle specific kinase (MuSK) and initiates a signaling 
cascade that drives the aggregation of AChR (DeChiara et al., 1996; Glass et al., 1996a; 
Glass et al., 1996b). 
Agrin is widely expressed in different tissues such as brain, spinal cord, retina, 
muscle, liver, kidney or lung (Ferns et al., 1993; Hoch et al., 1993) and its broad 
expression indicates that it also can regulate processes other than NMJ maintenance 
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(reviewed in (Bezakova & Ruegg, 2003; Williams et al., 2008)). Similarly, novel roles 
for agrin are emerging in the regulation of skeletal muscles. For instance, over-expression 
of agrin in mice was beneficial in the treatment of congenital muscular dystrophy (CMD) 
characterized by an absence of extracellular matrix structural protein laminin-α2  (Moll et 
al., 2001; Bentzinger et al., 2005; Qiao et al., 2005). In addition, agrin was shown to 
regulate properties of skeletal muscle cells in vitro by altering excitation-contraction 
coupling via regulation in the expression of various ion channels (Bandi et al., 2008; 
Jurdana et al., 2009). Finally, agrin was shown to enhance the contractile functions of an 
engineered aneural muscle tissue system (Bian & Bursac, 2011). These findings indicate 
that agrin might have novel roles in skeletal muscles, beyond its well characterized 
function in the maintenance of NMJ. 
In this study, two models displaying degeneration of skeletal muscles were used. 
Firstly, sarcopenia is the age-dependent progressive decline in skeletal muscle mass and 
contractile function (Balagopal et al., 1997). The average life-span of mice is about two 
years, thus animals older than 24 months are an adequate model to represent elderly mice. 
Secondly, Duchenne Muscular Dystrophy (DMD) is caused by the absence of a 
functional dystrophin. This dystrophin deficiency destabilizes the DGC and leads to 
progressive weakness and deterioration of skeletal muscle functions and structures. In 
research, mdx mice are commonly used as a model for DMD (Bulfield et al., 1984; 
Carnwath & Shotton, 1987; Coulton et al., 1988a; Coulton et al., 1988b; Pastoret & 
Sebille, 1995). The hypothesis explored in this study was that agrin can promote muscle 
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growth or it can prevent muscle decline. To investigate the roles of agrin in the regulation 
of skeletal muscles a direct intramuscular injection of a recombinant C-terminal half of 
neural agrin was performed in young, old and dystrophic mice. 
While preliminary data presented indicate that agrin may regulate the expression 
of Akt and S6K proteins, two major signaling targets of skeletal muscle growth, the data 
also suggest that agrin treatment does not improve the pathology observed in sarcopenic 
muscles. Meanwhile, deteriorating mdx muscles displayed a limited improvement in 
some of the disease symptoms. Taken together, these results illustrate innovative roles for 
the trophic factor agrin in skeletal muscles and demand further research to better 
understand agrin involvement in muscle plasticity.    
 
4.4 Methods  
4.4.1 Animal Care, Surgeries and Extractions 
All animal care and experimental procedures were performed in
 
accordance with 
the guidelines established by the Canadian Council
 
of Animal Care. These procedures 
were approved by the University Animal Research Ethics Committee (UAREC) of 
Concordia University. Animals were housed in temperature and humidity controlled 
conditions on a 14:10 hour light: dark cycle and had access to water and food ad libitum. 
In all experimental procedures male mice were used. Young and dystrophic mice were 3 
months old while aged mice were between 24 and 29 months of age.  
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4.4.2 Animal Surgeries and Extractions 
All surgical procedures were performed under aseptic conditions on animals 
anesthetized by intramuscular injection (1.2 μl / g) of 100 mg/ml ketamine hydrochloride 
and 10 mg/ml xylazine in a volume ratio of 1.6:1. A small incision was performed 
exposing the muscle surface, and the recombinant C-terminal half of rat agrin (R&D 
systems, Minneapolis, MN, USA) was injected directly into the tibialis anterior (TA) 
muscle. This ~90 kDa protein fragment contained an 8 amino acid insert at the Z site that 
induces clustering of AChRs at NMJ and is the neural isoform of agrin. Recombinant 
agrin was injected at a concentration of 10 μM in a sterile carrier solution consisting of 
25 mM PBS with 0.1% BSA. A single injection of 2.5 μl of recombinant agrin was 
performed in the left TA muscles and the contralateral limb served as a control and was 
injected with the carrier solution. The muscles of mice were extracted 7 days post-
injection, either frozen directly in liquid
 
nitrogen or embedded in OCT (Tissue-Tek, 
Torrance, CA, USA) and frozen in melting isopentane. Upon completion of tissues 
extraction, mice were euthanized by cervical dislocation under anesthesia and all tissues 
were stored at -86°C until processed. 
 
4.4.3 Immunohistochemistry 
To determine muscle fiber type and size, muscle cryosections (10 μm) were cut 
from TA muscle midbelly anatomical location. Sections were blocked for 30 minutes in 
5% goat serum in a carrier solution consisting of 0.5% bovine serum albumin (BSA) in 
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25 mM phosphate buffer solution (PBS) (pH = 7.4). Subsequently, the sections were 
incubated overnight at 4
o
C in carrier solution with a primary antibody raised against the 
appropriate MyHC type. All antibodies used (MyHC I: A4.840 using 1:25 dilution; 
MyHC IIa: SC71 using 2:25 dilution; MyHC IIx: 6H1 without dilution; MyHC IIb: BF-
F3 using 1:25 dilution) were from the Developmental Study Hybridoma Bank (DSHB, 
University of Iowa, Iowa city, IA). After three 10 minutes rinses in PBS, sections were 
incubated for two hours in secondary antibodies, horseradish peroxidase-conjugated goat 
anti-mouse IgG (MyHC type IIa) or IgM (MyHC type I, IIx, IIb) (Sigma-Aldrich, St-
Louis, MO, USA) using a 1:25 dilution. The sections then were rinsed three times with 
PBS for ten minutes, and the bound antibody complexes were visualized using 1 mg/ml 
of diaminobenzidine tetrahydrochloride (DAB). Additionally, hematoxylin and eosin 
staining was carried out to analyse fiber damage and central nucleation. Briefly, slides 
were incubated in 0.5% Harris haematoxylin (Sigma-Aldrich, MO, USA) for five 
minutes, rinsed with water, and immediately dipped in 1% HCl / 70% EtOH solution and 
rinsed again with water. Subsequently slides were incubated in 1% eosin (Fisher 
Scientific, ON, Canada) for three minutes, rinsed with water, incubated successively in 
70%, 80% and 90% EtOH solutions for two minutes each, and finally immersed in xylene 
(Fisher Scientific, ON, Canada) for thirty seconds. Slides were air dried and mounted in 
Permount (Fisher Scientific, ON, Canada). All slides were analyzed with an Olympus 
BX-60 light microscope. Three distinct regions were selected randomly from the 
midbelly of each TA muscle and images were captured across serial sections using a 
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Retiga SRV camera (QImaging, Surrey, ON, Canada). All fibers in those regions were 
classified according to the type of MyHC expressed and fiber cross sectional size was 
measured using ImagePro Plus version 6.2 software (Olympus, Markham, ON, Canada). 
In all analysis, the researcher was blinded to the experimental condition.   
 
4.4.4 Protein extraction and Western Blotting 
 Muscles were homogenized using a hand-held Tissue Tearor homogenizer 
(ColeParmer, Montreal, QC, Canada) in RIPA buffer consisting of 1XPBS, 1% igepal, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.001 M sodium 
orthovanadate, 0.01 M sodium fluoride, 0.01 mg/ml aprotinin, 0.01 mg/ml leupetin and 1 
mM phenylmethanesulfonyl fluoride (all reagents from Sigma-Aldrich, St-Louis, MO, 
USA). Homogenates were incubated on ice for 30 minutes followed by two 4
o
C 
centrifugations at 15 000 x g for 20 minutes. The supernatants were collected and the 
protein concentration determined using Quick Start Bradford dye reagent (Bio-Rad, 
Mississauga, ON, Canada).  
For protein expression analysis, 150 μg of protein were separated by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) on a gel consisting of a 5% stacking gel 
and an 8% separating gel. Samples were electrophoresed (buffer: 25 mM Tris, 192 mM 
glycine, 0.1% SDS, pH 8.3) at 120V and Amersham Full-Range Rainbow (GE 
Healthcare, Baie d’Urfe, QC, Canada) molecular weight markers were used to define the 
protein sizes. Subsequently, proteins were transferred (buffer: 25 mM Tris, 192 mM 
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glycine and 20% methanol) to a PVDF membrane (Millipore, Billerica, MA, USA) at 
100V for one hour and a successful transfer was confirmed using Ponceau S staining. 
Membranes were blocked for one hour using 5% non-fat milk in 0.1% Tween-Tris 
Buffered Saline (T-TBS) and incubated with primary antibody overnight at 4
o
C on a 
shaker as indicated in Table 3.2. The following day, the membranes were washed three 
times five minutes using 0.1% T-TBS and were then incubated with the appropriate 
horseradish peroxidase-conjugated secondary antibody: anti-rabbit IgG  #7074 (Cell 
Signaling Technology, Danvers, MA, USA) or anti-mouse IgG #A8924 (Sigma-Aldrich, 
St-Louis, MO, USA). Subsequently, membranes were developed using the 
chemiluminescent Immobilon HRP substrate kit (Millipore, MA, USA) as per the 
manufacturer’s instructions. Images were captured and protein expression quantified by 





SUPPLIER SIZE (kDa) 1OANTIBODY 2OANTIBODY 
α-tubulin Cell Signaling 
#2125 
52 1:2000 in 5% milk 1:2000 in 5% milk for 
1hr (anti-rabbit) 
pAkt (ser473) Cell Signaling 
#4060 





60 1:1000 in 5% milk 1:2000 in 5% milk for 
2hrs (anti-mouse) 
 
pS6K (thr389) Cell Signaling 
#9206 
70 1:1000 in 5% milk 1:2000 in 5% milk for 
2hrs (anti-mouse) 
 
S6K Santa Cruz 
#sc-230 
70 1:1000 in 5% milk 1:1000 in 5% milk for 
1hr (anti-rabbit) 
Table 4-1: Western Blotting Conditions 
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4.4.5 Statistical Analysis  
All data were analyzed using independent samples two-tailed Student’s T-test.  
All statistics were performed using SPSS statistics software version 17.0 (IBM SPSS, 
Chicago, IL, USA).  
  
4.5 Results 
4.5.1 Agrin injection is not regulating muscle fiber growth in healthy adult mice 
In this study, we seek to determine if agrin can regulate the growth of skeletal 
muscles. A recombinant C-terminal half of agrin (AGR), sufficient to carry out agrin 
induced AChR clustering in vivo (Bezakova et al., 2001), was injected directly into the 
TA muscle of adult, healthy mice. The contralateral limb was injected with a saline 
solution (PBS) and served as a control. A week post surgery, muscles were extracted and 
muscle weights, expressed relative to total body weight, were compared between PBS 
and AGR treated muscles. The data showed that agrin injection did not alter the relative 
muscle mass (Figure 4.1A). In addition, fiber typing was carried out based on the type of 
MyHC expressed. The cross sectional area (CSA) and percentage expression of muscle 
fibers were compared between PBS and AGR injected muscles.  Agrin injection did not 
modify the CSA of oxidative fibers expressing MyHC IIa or glycolytic muscle fibers 
expressing MyHC IIb as compared to PBS treated muscles (Figure 4.1Figure 4.1B). In 
addition, AGR treatment did not change the percentage expression of oxidative or 





Figure 4.1: Agrin is not promoting muscle growth in adult, healthy mice. 
A) Comparison of relative muscle weights between PBS (saline control) and AGR injected muscles of 
adult, healthy mice. Muscle fibers, classified to express MyHC IIa or MyHC IIb, were compared between 
PBS and AGR injected muscle. B) Quantification of fiber cross sectional area and C) quantification of fiber 
type’s percentage expression. All results are expressed as the mean ±SE. (p < 0.05, n=3 per group)  
 
4.5.2 Agrin may regulate Akt signaling in muscles of healthy adult mice 
 Akt signaling is the major signaling pathway described to regulate muscle growth. 
Akt expression and phosphorylation levels are rapidly activated in conditions of muscle 
growth (Bodine et al., 2001; Rommel et al., 2001; Pallafacchina et al., 2002) and this in 
turn leads to phosphorylation and activation of the downstream target S6K (ribosomal 
protein S6 kinase) (also known as p70
S6K
) (reviewed in (Glass, 2003a, b). Western 
blotting analysis indicated that injection of AGR in muscles of wild-type adult, healthy 
mice increased the expression of phosphorylated and total Akt protein by 1.6 fold 
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compared to PBS injected muscles (Figure 4.2A and B). In addition, the levels of 
phosphorylated and total S6K protein were measured. The administration of agrin did not 
alter the expression of phosphorylated S6K but levels of total S6K expression were 
increased 1.3 fold as compared to PBS treated muscles. It is essential to note that these 
findings are not significant and an analysis with a larger sample size is necessary. In 
summary, our data suggest that in adult, healthy mice agrin may regulate Akt signaling 
but it does not modify muscle fiber size.   
 
 
Figure 4.2: Agrin may regulate Akt signaling in muscles of adult, healthy mice. 
A) Representative Western blot images comparing protein expression in PBS (saline control) and AGR 
injected wild-type muscle of adult, healthy mice. B) Quantification of protein levels. All quantifications 
were standardized to tubulin loading control and are expressed as the mean ±SE (p < 0.05, n=3 per group). 
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4.5.3 Agrin does not activate Akt signaling in a sarcopenia model 
Next the ability of agrin to rescue the progressive muscle decline observed in 
sarcopenia was investigated. Firstly, aging mice were characterized to confirm the 
phenotypic changes normally observed in sarcopenia. Aging mice displayed a marked 
increase in total body weight (Figure 4.3A) and a notable decrease in absolute muscle 
weight (Figure 4.3B), but these results were not significant. The relative muscle weights 
were compared between young and old mice and a significant 40% decrease was 
measured in sarcopenia (Figure 4.3C). In addition, sarcopenia is characterized by a 
decrease in fiber CSA size. In this study, mice displayed a 45% decrease in fiber size 
(Figure 4.3D and E). These results confirmed a decline of muscle mass in the aging mice 
used in this study. 
Next, to determine if agrin can prevent the progressive muscle atrophy observed 
in sarcopenia, this trophic factor was injected into aging muscles. The comparison of the 
relative muscle weights between PBS and AGR injected muscles did not show a recovery 
of muscle mass (Figure 4.4A). Furthermore, Akt activated signaling can not only induce 
muscle hypertrophy, but it also prevents muscle atrophy (Bodine et al., 2001). Agrin’s 
ability to regulate Akt signaling in sarcopenia was assessed using immunoblotting. The 
results indicated that AGR administration did not change the expression of total or 
phosphorylated Akt or S6K protein in comparison to PBS injected muscles (Figure 4.4B 
and C). Overall, these preliminary data failed to show a role for agrin in the regulation of 







Figure 4.3: Characterization of the sarcopenia model 
A) Quantification of total mouse body weight, B) absolute TA muscle weight and C) TA muscle weight 
relative to total body weight comparing young (3 months) and aging (>24months) mice D) Representative 
images stained for H&E illustrating the progressive atrophy observed in aging muscles. E) Quantification 
of muscle fiber size comparing young and aging muscles. All quantifications are expressed as mean ± SE 






Figure 4.4:  Agrin does not activate Akt signaling in aging muscles 
A) Representative Western blot images comparing protein expression in PBS (saline control) and AGR 
injected wild-type muscles of old mice displaying symptoms of sarcopenia. B) Quantification of protein 
levels. All quantifications were standardized to tubulin loading control and are expressed as the mean ±SE 




4.5.4 Agrin treatment regulates central nucleation in dystrophic muscles 
Previous research has shown that agrin can improve the pathology observed in 
CMD (Moll et al., 2001; Bentzinger et al., 2005; Qiao et al., 2005), yet the roles of agrin 
in DMD were not investigated. In the next experiments, a preliminary analysis of agrin’s 
role in DMD was carried out using mdx mice. Previously, histological parameters that are 
hallmarks of DMD have been characterized in mdx mice (Briguet et al., 2004). They 
included a large number of muscle fibers displaying central nucleation and an increase in 
fiber CSA variability versus healthy mice. In this investigation, a histological assay 
confirmed a large number of centrally nucleated fibers in dystrophic muscles of mdx mice 
(Figure 4.5A), in contrast to the absence of centrally nucleated fibers in wild-type mice. 
The presence of centrally nucleated fibers confirms that muscle regeneration is occurring 
in the diseased muscles. In addition, a frequency distribution of fiber CSA indicated a 
significant increase in small (<1000 μm2) fibers in muscles of dystrophic mice but failed 
to demonstrate a major increase in fiber size variability (Figure 4.5B). The smaller-sized 
fibers are most likely new regenerating fibers. Finally, a quantitative measurement of the 
coefficient of variation (ratio of standard deviation to the mean) showed that mdx mice 
display a larger variability in their fiber size in comparison to wild-type mice (Figure 
4.5C). The coefficient of variation is a normalized measure of fiber size dispersion as 






Figure 4.5: Characterization of the dystrophic model 
A) Representative images stained for H&E illustrating the higher fiber size variability and the increased 
central nucleation observed in muscles of mdx mice. The arrows point to some centrally nucleated fibers. 
B) Frequency distribution of fiber size comparing wild-type and dystrophic muscles. C) Quantification of 
fiber size variability expressed using the coefficient of variation. All quantifications are expressed as mean 
± SE (* sig. diff. from wild-type, p < 0.05, n=3 per group). 
 
 
 Next, these same histological parameters were used to assess the hallmarks of 
DMD in mdx mice that were administered an intramuscular injection of agrin. The 
frequency distribution of fibers CSA failed to identify changes between PBS and AGR 
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injected muscles (Figure 4.6A). Similarly, the coefficient of variation did not show 
alterations between PBS and AGR administrated dystrophic muscles (Figure 4.6B). In 
addition, a fiber typing analysis (based on the expression of MyHC) did not show 





Figure 4.6: Agrin decrease central nucleation in mdx mice 
A) Frequency distribution of fiber size comparing PBS (control saline) and AGR injected dystrophic 
muscles. B) Quantification of fiber size variability expressed using the coefficient of variation. C) 
Quantification of the number of fibers displaying central nucleation. All quantifications are expressed as 




injection (data not shown). Finally, fibers displaying central nucleation were counted and 
compared between PBS and AGR treated muscles. The administration of AGR promoted 
a subtle, yet significant decrease in central nucleation: from 66% ±5 in PBS muscles to 
56% ±1 in AGR treated muscles (Figure 4.6C). These results suggest that agrin could be 
beneficial in the treatment of DMD. 
 
4.6 Discussion 
The roles of the nerve-derived factor agrin in the regulation of NMJ development 
and maintenance are well documented. Recent research has also illustrated novel 
functions for agrin in skeletal muscles (Moll et al., 2001; Bentzinger et al., 2005; Qiao et 
al., 2005; Bandi et al., 2008; Jurdana et al., 2009; Bian & Bursac, 2011). In addition, 
agrin injection in vivo is able to rescue overload-induced muscle growth in a surgical 
model displaying a blocked transport of trophic factors from the nerve to the muscle 
(Michel & Kulig, 2008). In this investigation, we sought to determine if agrin can 
regulate muscle mass in adult mice. Furthermore, roles for agrin in the improvement of 
muscle wasting observed in sarcopenia and DMD were investigated.  
A recombinant C-terminal half of rat agrin was injected directly into the tibialis 
anterior (TA) muscle of wild-type, healthy, adult mice. The injected protein contained an 
8 amino acid insert at the Z site sufficient to induce clustering of AChRs at NMJ. This 
recombinant protein was a fragment of the “neural agrin”; the sole agrin isoform 
currently characterized to display biological activity (Ferns et al., 1993; Bezakova & 
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Lomo, 2001; Williams et al., 2008). In this study, the TA muscle of one side was injected 
with AGR while the contralateral TA muscle served as a control and was injected with a 
saline PBS solution. This permitted controlling for intrinsic differences that might exist 
between animals and it allowed for the minimization of both animal and recombinant 
protein usage. The TA muscle was chosen because of its ease of access and 
compartmentalized localization in mice hind limbs. A week post-injection, muscle 
weights were compared and the data failed to show a change following agrin treatment 
(Figure 4.1A). The results were expressed as relative muscle weights to control for 
intrinsic body weight differences between mice. Since the measurement of muscle 
weights is a crude method that cannot detect subtle alterations in muscle fiber growth, 
fiber typing analysis was performed based on MyHC expression. The fiber typing 
analysis allowed the comparison of fiber cross sectional area (CSA) and the percentage 
expression of different fiber types. Yet again, a comparison between PBS and AGR 
injected muscles did not indicate a remodeling in muscle fiber size (Figure 4.1B) or fiber 
type (Figure 4.1C).  
The major pathway shown to regulate muscle growth is the Akt signaling cascade. 
This pathway is rapidly activated under conditions of muscle growth and the activity of 
this pathway persists for many days to promote muscle fiber hypertrophy (Bodine et al., 
2001; Rommel et al., 2001; Pallafacchina et al., 2002). Briefly, this pathway is activated 
through insulin growth factor (IGF-1) signaling that phosphorylates and triggers the 
activation of Akt via the phosphatidyl inositol 3-kinase (PI3K). This signaling leads to 
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downstream phosphorylation and activation of S6K (p70
S6K
) a positive regulator of 
protein translation (reviewed in (Glass, 2003a, b, 2005, 2010). The results presented here 
indicated that AGR injection may increase the levels of phosphorylated and total Akt 
protein in comparison to PBS treated muscles (Figure 4.2A and B). Yet, the 
phosphorylation of Akt’s downstream signaling partner S6K was not observed following 
AGR administration (Figure 4.2A and B). This finding indicates that protein synthesis via 
S6K signaling is probably not regulated by agrin in adult mice. However, since an 
increase in the expression of total S6K protein was observed in agrin treated muscles, this 
could indicate a delayed activation of this signaling partner. Alternatively, Akt signaling 
could block protein degradation mediated by ubiquitin ligases (Stitt et al., 2004).  Indeed, 
Akt phosphorylates forkhead box (FOXO) transcription factors preventing their entry into 
the nucleus (Stitt et al., 2004). Normally, FOXO transcription factors induce the 
expression of ubiquitin liagases MuRF1 (muscle specific ring finger protein 1) and 
MAFbx (muscle specific F-box protein; also called atrogin-1) leading to protein 
degradation and muscle atrophy (Stitt et al., 2004). This signaling was not investigated in 
this study but should be considered in future experiments.  
Also, it cannot be ruled out that a longer agrin treatment period and/or increased 
dosage of agrin are necessary to observe a hypertrophic muscle growth response. In this 
study, the dosage used was previously shown to induce AChR clustering in vivo 
(Bezakova et al., 2001). In addition, the recombinant agrin used in this study had a 
similar size to a mini-agrin that when over-expressed in mice had a half-life of 4.5 days 
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(Meinen et al., 2007). This suggests that agrin was biologically active in our model over 
the experimental time course. In spite of that, it is possible that muscles require a longer 
time period to display fiber type remodeling and/or fiber growth following intramuscular 
agrin injection. Future studies should carry out a time course investigation of possible 
roles for agrin in the regulation of muscle mass. In addition, in future experiments 
recombinant agrin should be fluorescent-labeled, prior to injection, to permit the tracking 
of the recombinant protein expression and localization. Collectively, the results presented 
indicate that a week post-agrin injection, skeletal muscles are not displaying fiber growth, 
yet agrin may modulate the signaling of Akt pathway. Future agrin injection experiments 
should be performed using a larger sample size and with consideration of the above 
mentioned improvements.     
 Numerous critical events such as muscle fiber atrophy, oxidative fiber type 
remodeling and alteration in NMJ structure, occur during skeletal muscle aging (reviewed 
in (Nair, 2005; Doran et al., 2009). This investigation examines the possibility that an 
intramuscular injection of recombinant agrin could rescue the progressive muscle decline 
observed in sarcopenia. Firstly, measurements of body and muscle weights were 
compared between young adult (3 months) and older mice (< 24 months). The older mice 
displayed subtle increases in overall body weights (Figure 4.3A) mediated by an increase 
in fat accumulation due to a reduced activity of aging animals. Meanwhile, the absolute 
and relative muscle weights were both reduced in old mice in comparison to young mice 
(Figure 4.3B and C). In addition, histological analysis confirmed muscle fiber atrophy 
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(Figure 4.3E) and other symptoms of sarcopenia (reviewed in (Nair, 2005; Doran et al., 
2009) were noted such as fibers with central nucleation and an increase infiltration of fat 
and connective tissue between fibers (Figure 4.3D). Subsequently, the activation of Akt 
signaling was compared between PBS and AGR injected muscle. The results indicated 
that agrin administration did not trigger, or that it delayed, the activation of Akt signaling 
in sarcopenia (Figure 4.4B and C). These results are in agreement with an investigation 
that used the overload induced muscle growth model and showed a reduced or delayed 
activation of Akt signaling in older mice (Hwee & Bodine, 2009). A time course 
experiment would differentiate between a blocked or delayed activation of this signaling 
pathway. Alternatively, these explorative results may indicate that agrin administration is 
not beneficial in the treatment of sarcopenia. This conclusion would concur with a recent 
study that used transgenic over-expression of agrin and, by means of fiber size 
measurements, indicated that agrin did not prevent skeletal muscle atrophy (Butikofer et 
al., 2011). Yet, other recent studies illustrated agrin’s ability to regulate excitation-
contraction coupling (Bandi et al., 2008; Jurdana et al., 2009) and agrin’s ability to 
regulate contractile properties of muscle fibers (Bian & Bursac, 2011). In future 
experiments, measurements of muscle fiber strength and fatigability should be performed 
in sarcopenic muscles injected with agrin. The likelihood exists that agrin does not induce 
the hypertrophy or prevent the atrophy of aging skeletal muscles, but it might be capable 
of improving muscles mechanical properties.  
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 Next, previous research indicated that transgenic over-expression of agrin in mice 
was beneficial in the treatment of congenital muscular dystrophy (CMD) characterized by 
an absence of extracellular matrix structural protein laminin-α2  (Moll et al., 2001; 
Bentzinger et al., 2005; Qiao et al., 2005). In CMD mice, agrin improved muscle 
structure, whole body growth, mouse motility and lifespan (Moll et al., 2001; Bentzinger 
et al., 2005; Qiao et al., 2005). Since agrin expression levels are decreased in the muscles 
(Eusebio et al., 2003) and  brain (Nico et al., 2010) of mdx mice, in the next experiments, 
agrin was injected into the TA muscle of this mouse model of DMD. Firstly, using 
histological parameters that are hallmarks of dystrophy in mdx mice (Briguet et al., 
2004), dystrophy-induced muscle wasting was confirmed in animals used in this study. 
The results indicated a large number of centrally nucleated fibers and an increased 
variability in fiber size in the TA muscles of mdx mice, in comparison to wild-type mice 
(Figure 4.5). Subsequently, using the same histological comparison parameters, the data 
indicated that while AGR injection did not modify the fiber size variability (Figure 4.6A 
and B), AGR administration led to a decrease in the number of centrally nucleated fibers 
in mdx muscles versus PBS treated muscles (Figure 4.6C). This finding suggests a partial 
improvement of the dystrophic phenotype. A reduction in centrally nucleated fibers 
suggests a decrease in fiber regeneration. This could indicate a reduce speed in the cyclic 
events of fiber degeneration/regeneration observed in mdx mice. Previously, agrin was 
shown to promote the expression of the utrophin gene in cell cultures (Gramolini et al., 
1998; Gramolini et al., 1999). Utrophin is a dystrophin homologue that has been shown 
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to be naturally upregulated in dystrophic models and a genetic over-expression of 
utrophin improves biochemical and morphological aspects of DMD (reviewed in 
(Gramolini & Jasmin, 1998; Jasmin et al., 2002). Agrin intramuscular injection could 
regulate utrophin expression in mdx mice or, alternatively, agrin may stabilize the DAC 
and thus improve muscle strengthen in disease mice. In light of these points, future 
experiments should focus on assessing muscle fiber regeneration, damage and 
mechanical properties, in addition to determining the expression of utrophin in agrin 
injected muscles of mdx mice. 
 In conclusion, results presented here provide an explorative assessment of 
potential novel roles for agrin in skeletal muscles. The data presented serve as a survey of 
possible research targets and indicate that agrin may regulate muscle signaling. In this 
study, the results suggested that agrin regulates the activation of Akt signaling in adult, 
healthy muscles. In addition, a partial improvement of the dystrophic phenotype was 
observed in mdx mice administrated with agrin. Since recent studies have shown that 
activation of Akt attenuates dystrophic symptoms (Blaauw et al., 2008; Kim et al., 2011), 
this path should be investigated in detail in mdx mice. Agrin signaling via Akt could be a 
novel therapeutic avenue for the treatment of DMD. 
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4.7 Future Directions 
Currently, a project has been initiated that involves the blocking of agrin 
expression in skeletal muscles. The hypothesis is that blocking agrin expression will 
prevent or reduce muscle growth. Muscle growth can be induced using the functional 
overload model. Meanwhile, agrin expression can be reduced in skeletal muscles by 
electroporation of plasmids that would generate short hairpin RNAs (shRNA) that target 
agrin (McCroskery et al., 2006; McCroskery et al., 2009). Alternatively, the expression 
of agrin could be decreased via injection of an antibody against agrin (although 
preliminary experiments using this model lead to mice death).     
As indicated previously, the involvement of agrin in the regulation of DMD 
pathology is an interesting research path. Agrin has the potential to promote expression of 
the dystrophin homologue utrophin (Gramolini et al., 1998; Gramolini et al., 1999) and 
in addition agrin can activate Akt signaling (this study). Both utrophin (reviewed in 
(Gramolini & Jasmin, 1998; Jasmin et al., 2002) and Akt (Blaauw et al., 2008; Kim et 
al., 2011) are potential therapeutic targets for the treatment of DMD. The investigation of 






Chapter 5: Conclusion 
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Skeletal muscles play a central role in the overall health of individuals. Defects in 
muscles lead to various diseases, and in addition numerous disease symptoms include a 
progressive wasting of muscles called cachexia. A better understanding of muscle 
plasticity can help in the prevention and treatment of a vast number of diseases.     
Skeletal muscle can adapt its properties to respond to various demands such as 
mechanical loads, neural activity, hormones circulation and availability of nutrients 
and/or growth factors. This ability of adult muscle to change in response to various 
stimuli is called muscle plasticity and it can lead to alterations in muscle fiber type, size 
and signaling. Furthermore, skeletal muscles are in continuous communication with 
nerves by means of the NMJ, and the properties of the motor neuron can be remodel to 
match the properties of the muscle fibers it innervates. Collectively, neuromuscular 
plasticity is influenced by both anterograde (from the nerve) and retrograde (from the 
muscle fiber) mechanisms illustrating the importance of the communication that occurs at 
the NMJ. 
Animal models are frequently used to study molecular and cellular mechanisms 
that regulate muscle growth. The research presented in this thesis illustrates the use of 
diverse mouse models to explore various events that influence neuromuscular plasticity. 
In this first study, the adaptability of NMJ to muscle’s signals is illustrated using 
transgenic mice displaying compromised calmodulin signaling in skeletal muscles. These 
mice adapt by changing the organization of AChRs at their NMJ. A change in density or 
structure of NMJ can remodel synaptic communication. Abnormally localized AChRs 
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could represent fragmented endplates mediated by a loss of nerve terminals followed by 
novel nerve sprouting. Furthermore, a dysregulation in synaptic communication leads to 
muscle disease, such as Myasthenia Gravis were a loss of AChR leads to muscle fatigue 
and wasting. In the second study, mice knockout for NFATc2 or NFATc3 are used. 
These mouse models demonstrate the importance of NFAT transcription factors in 
compensatory muscle growth and illustrate the ability of muscle to fine tune its growth 
response. This work also shows that signaling partners described to have important 
function in other tissues, can regulate muscle mass. A better understanding of the 
signaling that regulates muscle growth serves to identify therapeutic targets to improve 
deteriorating muscles mass observed in numerous diseases. Finally, the third study 
explored the roles of the nerve-derived trophic factor agrin in the modulation of muscle 
fiber mass. Agrin may regulate signaling pathways that mediate muscle growth or it 
could improve muscle contractile functions by stabilizing the DGC. A large number of 
muscle disorders, such as Duchenne Muscular Dystrophy or sarcopenia, are awaiting 
treatment and original research can help pinpoint novel beneficial therapeutic strategies.  
Collectively, the research presented in this thesis illustrates the inter-dependence 
between the motor nerve and skeletal muscle fibers. In addition, this work highlights the 
complexity of skeletal muscle plasticity and shows that research in this field is an 
ongoing process. As new discoveries are made, new signaling targets are identified, novel 
links between signaling pathways emerge and the original roles for old signaling targets 
are revealed. The research in the field of neuromuscular plasticity has a double objective 
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of providing a better understanding of signaling pathways in skeletal muscles and 
identifying novel pharmacological targets for the treatment of neuromuscular disorders. 
Appropriate synaptic communication and normal muscle function are key aspects in the 









e N Mean Std. Deviation Std. Error Mean 
HDAC4 WT 5 1.0000 .29536 .13209 
TG 5 1.0732 .13422 .06002 
Dach2 WT 5 1.0000 .42455 .18986 
TG 5 1.0737 .19736 .08826 
Mgn WT 5 1.0000 .24936 .11152 
TG 5 .9012 .33058 .14784 
AGR WT 3 1.0000 .18047 .10419 
TG 4 .7341 .25136 .12568 
MuSK WT 3 1.0000 .24558 .14179 
TG 4 1.1226 .19054 .09527 
NRG WT 3 1.0000 .42430 .24497 
TG 4 1.0347 .20012 .10006 
GABP WT 3 1.0001 .36040 .20808 
TG 3 .9611 .13812 .07975 
AChRalpha WT 3 1.0000 .17670 .10202 
TG 4 1.0204 .27341 .13670 
AChRgamma WT 3 1.0000 .16402 .09470 
TG 4 1.0918 .18677 .09339 
AChRepsilon WT 3 1.0000 .17946 .10361 
TG 4 .8108 .30122 .15061 




Levene's Test for 




Interval of the 
Difference 
  








e Lower Upper 
HDAC4 Equal variances 
assumed 
3.020 .120 -.505 8 .627 -.07323 .14509 -.40780 .26134 
Equal variances 
not assumed 
  -.505 5.584 .633 -.07323 .14509 -.43475 .28828 
Dach2 Equal variances 
assumed 
2.407 .159 -.352 8 .734 -.07367 .20938 -.55649 .40915 
Equal variances 
not assumed 
  -.352 5.652 .738 -.07367 .20938 -.59374 .44640 
Mgn Equal variances 
assumed 
.155 .704 .533 8 .608 .09879 .18518 -.32825 .52582 
Equal variances 
not assumed 
  .533 7.439 .609 .09879 .18518 -.33392 .53149 
AGR Equal variances 
assumed 
.257 .633 1.543 5 .184 .26595 .17237 -.17715 .70905 
Equal variances 
not assumed 
  1.629 4.999 .164 .26595 .16325 -.15373 .68563 
MuSK Equal variances 
assumed 
.423 .544 -.749 5 .488 -.12256 .16365 -.54322 .29811 
Equal variances 
not assumed 
  -.717 3.710 .516 -.12256 .17082 -.61185 .36674 
NRG Equal variances 
assumed 
4.299 .093 -.147 5 .889 -.03474 .23669 -.64318 .57370 
Equal variances 
not assumed 
  -.131 2.673 .905 -.03474 .26462 -.93817 .86868 
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GABP Equal variances 
assumed 
4.171 .111 .175 4 .870 .03897 .22284 -.57972 .65767 
Equal variances 
not assumed 





.657 .455 -.112 5 .915 -.02047 .18289 -.49061 .44966 
Equal variances 
not assumed 





1.162 .330 -.675 5 .529 -.09183 .13597 -.44134 .25768 
Equal variances 
not assumed 





2.634 .166 .955 5 .384 .18921 .19817 -.32021 .69863 
Equal variances 
not assumed 
  1.035 4.874 .349 .18921 .18281 -.28439 .66282 
 
 
Chapter 2: Western Blotting 
Group Statistics 
 
Genotype N Mean Std. Deviation Std. Error Mean 
pCaMKII SOL WT 3 .2111 .02155 .01244 
SOL TG 3 .1488 .02710 .01565 
CaMKII SOL WT 3 .2352 .07221 .04169 
SOL TG 3 .2477 .05618 .03244 
Independent Samples Test 
  
Levene's Test for 




















.146 .722 3.116 4 .036 .06230 .01999 .00679 .11781 
Equal variances 
not assumed 





.254 .641 -.235 4 .825 -.01243 .05282 -.15909 .13423 
Equal variances 
not assumed 




Genotype N Mean Std. Deviation Std. Error Mean 
pCaMKII EDL WT 3 .4398 .04666 .02694 
EDL TG 3 .3165 .10597 .06118 
CaMKII EDL WT 3 .3445 .11453 .06612 
EDL TG 3 .3069 .11390 .06576 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  











2.480 .190 1.844 4 .139 .12327 .06685 -.06233 .30886 
Equal variances 
not assumed 










Genotype N Mean Std. Deviation Std. Error Mean 
pCaMKII EDL WT 3 .4398 .04666 .02694 
EDL TG 3 .3165 .10597 .06118 
CaMKII EDL WT 3 .3445 .11453 .06612 
Equal variances 
not assumed 




Genotype N Mean Std. Deviation Std. Error Mean 
pERK1 SOL WT 3 .5179 .03731 .02154 
SOL TG 3 .7058 .12551 .07246 
ERK1 SOL WT 3 .8937 .12331 .07119 
SOL TG 3 .9271 .10545 .06088 
pERK2 SOL WT 3 .7978 .06000 .03464 
SOL TG 3 .9606 .17381 .10035 
ERK2 SOL WT 3 .9996 .12355 .07133 
SOL TG 3 1.0355 .13157 .07596 
pJNK SOL WT 3 .6514 .13902 .08026 
SOL TG 3 .5039 .07491 .04325 
JNK SOL WT 3 .7476 .39373 .22732 
SOL TG 3 .4702 .05132 .02963 
AChRalpha SOL WT 3 .8614 .29267 .16897 
SOL TG 3 .8788 .21610 .12477 
Independent Samples Test 
  
Levene's Test for 






Interval of the 
Difference 
  






Difference Lower Upper 
pERK1 Equal variances 
assumed 
4.390 .104 -2.485 4 .068 -.18787 .07560 -.39775 .02202 
Equal variances 
not assumed 
  -2.485 2.351 .112 -.18787 .07560 -.47077 .09503 
ERK1 Equal variances 
assumed 
.135 .732 -.357 4 .739 -.03340 .09367 -.29348 .22668 
Equal variances 
not assumed 
  -.357 3.906 .740 -.03340 .09367 -.29597 .22917 
pERK2 Equal variances 
assumed 
6.032 .070 -1.533 4 .200 -.16277 .10616 -.45752 .13198 
Equal variances 
not assumed 
  -1.533 2.470 .241 -.16277 .10616 -.54559 .22005 
ERK2 Equal variances 
assumed 
.119 .748 -.345 4 .748 -.03593 .10420 -.32525 .25338 
Equal variances 
not assumed 
  -.345 3.984 .748 -.03593 .10420 -.32570 .25383 
pJNK Equal variances 
assumed 
1.975 .233 1.618 4 .181 .14753 .09117 -.10560 .40067 
Equal variances 
not assumed 
  1.618 3.071 .202 .14753 .09117 -.13885 .43392 
JNK Equal variances 
assumed 
5.517 .079 1.210 4 .293 .27740 .22924 -.35908 .91388 
Equal variances 
not assumed 










Genotype N Mean Std. Deviation Std. Error Mean 
pERK1 SOL WT 3 .5179 .03731 .02154 
SOL TG 3 .7058 .12551 .07246 
ERK1 SOL WT 3 .8937 .12331 .07119 
SOL TG 3 .9271 .10545 .06088 
pERK2 SOL WT 3 .7978 .06000 .03464 
SOL TG 3 .9606 .17381 .10035 
ERK2 SOL WT 3 .9996 .12355 .07133 
SOL TG 3 1.0355 .13157 .07596 
pJNK SOL WT 3 .6514 .13902 .08026 
SOL TG 3 .5039 .07491 .04325 
JNK SOL WT 3 .7476 .39373 .22732 
SOL TG 3 .4702 .05132 .02963 
AChRalpha SOL WT 3 .8614 .29267 .16897 
Equal variances 
not assumed 
  -.083 3.681 .938 -.01737 .21005 -.62102 .58629 
 
 
Chapter 3: Muscle Weights 
Descriptives 
Relative Muscle Weight 
 
N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 6 .5717 .03764 .01537 .5322 .6112 .52 .62 
WT 7dOV 3 .8533 .00577 .00333 .8390 .8677 .85 .86 
WT 28dOV 4 1.2000 .09309 .04655 1.0519 1.3481 1.07 1.29 
NFATc2-/- CTL 7 .5171 .04271 .01614 .4776 .5566 .45 .58 
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NFATc2-/- 7dOV 3 .6833 .14012 .08090 .3353 1.0314 .57 .84 
NFATc2-/- 
28dOV 
4 .8775 .12393 .06196 .6803 1.0747 .80 1.06 
NFATc3-/- CTL 5 .5020 .02950 .01319 .4654 .5386 .46 .53 
NFATc3-/- 7dOV 3 .7967 .09018 .05207 .5726 1.0207 .71 .89 
NFATc3-/- 
28dOV 
3 .9600 .19157 .11060 .4841 1.4359 .83 1.18 
Total 38 .7303 .24077 .03906 .6511 .8094 .45 1.29 
Test of Homogeneity of Variances 
Relative Muscle Weight 
Levene Statistic df1 df2 Sig. 
4.423 8 29 .001 
Robust Tests of Equality of Means 




 df1 df2 Sig. 
Welch 114.999 8 9.771 .000 
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:Relative Muscle Weight 
 
(I) Genotype (J) Genotype 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
 
Lower Bound Upper Bound 
Dunnett T3 WT CTL WT 7dOV -.28167
*
 .01572 .000 -.3608 -.2026 
WT 28dOV -.62833
*
 .04902 .004 -.9331 -.3236 
NFATc2-/- CTL .05452 .02229 .495 -.0352 .1443 
NFATc2-/- 7dOV -.11167 .08234 .936 -.9240 .7007 
NFATc2-/- 28dOV -.30583 .06384 .125 -.7255 .1138 
NFATc3-/- CTL .06967 .02025 .147 -.0160 .1553 
NFATc3-/- 7dOV -.22500 .05429 .252 -.7093 .2593 
NFATc3-/- 28dOV -.38833 .11167 .370 -1.5316 .7550 
WT 7dOV WT CTL .28167
*





 .04667 .044 -.6788 -.0146 
NFATc2-/- CTL .33619
*
 .01648 .000 .2589 .4135 
NFATc2-/- 7dOV .17000 .08097 .708 -.6940 1.0340 
NFATc2-/- 28dOV -.02417 .06205 1.000 -.4673 .4190 
NFATc3-/- CTL .35133
*
 .01361 .000 .2762 .4264 
NFATc3-/- 7dOV .05667 .05217 .980 -.4969 .6102 
NFATc3-/- 28dOV -.10667 .11065 .992 -1.2897 1.0764 
WT 28dOV WT CTL .62833
*
 .04902 .004 .3236 .9331 
WT 7dOV .34667
*
 .04667 .044 .0146 .6788 
NFATc2-/- CTL .68286
*
 .04927 .003 .3805 .9853 
NFATc2-/- 7dOV .51667 .09333 .086 -.1061 1.1395 
NFATc2-/- 28dOV .32250 .07750 .105 -.0638 .7088 
NFATc3-/- CTL .69800
*
 .04838 .003 .3870 1.0090 
NFATc3-/- 7dOV .40333
*
 .06984 .041 .0200 .7867 
NFATc3-/- 28dOV .24000 .12000 .739 -.6959 1.1759 
NFATc2-/- CTL WT CTL -.05452 .02229 .495 -.1443 .0352 
WT 7dOV -.33619
*
 .01648 .000 -.4135 -.2589 
WT 28dOV -.68286
*
 .04927 .003 -.9853 -.3805 
NFATc2-/- 7dOV -.16619 .08249 .735 -.9734 .6411 
NFATc2-/- 28dOV -.36036 .06403 .078 -.7778 .0571 
NFATc3-/- CTL .01514 .02085 1.000 -.0707 .1009 
NFATc3-/- 7dOV -.27952 .05451 .162 -.7577 .1987 
NFATc3-/- 28dOV -.44286 .11178 .299 -1.5821 .6963 
NFATc2-/- 7dOV WT CTL .11167 .08234 .936 -.7007 .9240 
WT 7dOV -.17000 .08097 .708 -1.0340 .6940 
WT 28dOV -.51667 .09333 .086 -1.1395 .1061 
NFATc2-/- CTL .16619 .08249 .735 -.6411 .9734 
NFATc2-/- 28dOV -.19417 .10190 .782 -.7860 .3977 
NFATc3-/- CTL .18133 .08197 .671 -.6443 1.0070 
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NFATc3-/- 7dOV -.11333 .09621 .983 -.7404 .5137 
NFATc3-/- 28dOV -.27667 .13703 .732 -1.1286 .5753 
NFATc2-/- 28dOV WT CTL .30583 .06384 .125 -.1138 .7255 
WT 7dOV .02417 .06205 1.000 -.4190 .4673 
WT 28dOV -.32250 .07750 .105 -.7088 .0638 
NFATc2-/- CTL .36036 .06403 .078 -.0571 .7778 
NFATc2-/- 7dOV .19417 .10190 .782 -.3977 .7860 
NFATc3-/- CTL .37550 .06335 .072 -.0500 .8010 
NFATc3-/- 7dOV .08083 .08094 .998 -.3428 .5044 
NFATc3-/- 28dOV -.08250 .12678 1.000 -.9403 .7753 
NFATc3-/- CTL WT CTL -.06967 .02025 .147 -.1553 .0160 
WT 7dOV -.35133
*
 .01361 .000 -.4264 -.2762 
WT 28dOV -.69800
*
 .04838 .003 -1.0090 -.3870 
NFATc2-/- CTL -.01514 .02085 1.000 -.1009 .0707 
NFATc2-/- 7dOV -.18133 .08197 .671 -1.0070 .6443 
NFATc2-/- 28dOV -.37550 .06335 .072 -.8010 .0500 
NFATc3-/- 7dOV -.29467 .05371 .152 -.7951 .2058 
NFATc3-/- 28dOV -.45800 .11139 .283 -1.6119 .6959 
NFATc3-/- 7dOV WT CTL .22500 .05429 .252 -.2593 .7093 
WT 7dOV -.05667 .05217 .980 -.6102 .4969 
WT 28dOV -.40333
*
 .06984 .041 -.7867 -.0200 
NFATc2-/- CTL .27952 .05451 .162 -.1987 .7577 
NFATc2-/- 7dOV .11333 .09621 .983 -.5137 .7404 
NFATc2-/- 28dOV -.08083 .08094 .998 -.5044 .3428 
NFATc3-/- CTL .29467 .05371 .152 -.2058 .7951 
NFATc3-/- 28dOV -.16333 .12225 .952 -1.0791 .7524 
NFATc3-/- 28dOV WT CTL .38833 .11167 .370 -.7550 1.5316 
WT 7dOV .10667 .11065 .992 -1.0764 1.2897 
WT 28dOV -.24000 .12000 .739 -1.1759 .6959 
 172 
 
NFATc2-/- CTL .44286 .11178 .299 -.6963 1.5821 
NFATc2-/- 7dOV .27667 .13703 .732 -.5753 1.1286 
NFATc2-/- 28dOV .08250 .12678 1.000 -.7753 .9403 
NFATc3-/- CTL .45800 .11139 .283 -.6959 1.6119 
NFATc3-/- 7dOV .16333 .12225 .952 -.7524 1.0791 
 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 1758.00 383.313 221.306 805.80 2710.20 1341 2095 
WT OV 4 2403.75 201.888 100.944 2082.50 2725.00 2200 2622 
NFATc2-/- CTL 4 1636.75 179.673 89.836 1350.85 1922.65 1383 1798 
NFATc2-/- OV 4 1803.00 299.744 149.872 1326.04 2279.96 1590 2244 
NFATc3-/- CTL 3 1889.00 318.679 183.989 1097.36 2680.64 1559 2195 
NFATc3-/- OV 3 2283.00 176.570 101.943 1844.38 2721.62 2139 2480 
Total 21 1960.19 374.348 81.689 1789.79 2130.59 1341 2622 
Test of Homogeneity of Variances 
Fiber Size 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups 1754735.738 5 350947.148 5.023 .007 
Within Groups 1047987.500 15 69865.833 
  
Total 2802723.238 20 
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Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:Fiber Size 
 
(I) Group (J) Group 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
 
Lower Bound Upper Bound 
Tukey HSD WT CTL WT OV -645.750 201.879 .055 -1301.65 10.15 
NFATc2-/- CTL 121.250 201.879 .989 -534.65 777.15 
NFATc2-/- OV -45.000 201.879 1.000 -700.90 610.90 
NFATc3-/- CTL -131.000 215.818 .989 -832.18 570.18 
NFATc3-/- OV -525.000 215.818 .206 -1226.18 176.18 
WT OV WT CTL 645.750 201.879 .055 -10.15 1301.65 
NFATc2-/- CTL 767.000
*
 186.903 .010 159.76 1374.24 
NFATc2-/- OV 600.750 186.903 .053 -6.49 1207.99 
NFATc3-/- CTL 514.750 201.879 .171 -141.15 1170.65 
NFATc3-/- OV 120.750 201.879 .990 -535.15 776.65 
NFATc2-/- CTL WT CTL -121.250 201.879 .989 -777.15 534.65 
WT OV -767.000
*
 186.903 .010 -1374.24 -159.76 
NFATc2-/- OV -166.250 186.903 .943 -773.49 440.99 
NFATc3-/- CTL -252.250 201.879 .806 -908.15 403.65 
NFATc3-/- OV -646.250 201.879 .055 -1302.15 9.65 
NFATc2-/- OV WT CTL 45.000 201.879 1.000 -610.90 700.90 
WT OV -600.750 186.903 .053 -1207.99 6.49 
NFATc2-/- CTL 166.250 186.903 .943 -440.99 773.49 
NFATc3-/- CTL -86.000 201.879 .998 -741.90 569.90 
NFATc3-/- OV -480.000 201.879 .225 -1135.90 175.90 
NFATc3-/- CTL WT CTL 131.000 215.818 .989 -570.18 832.18 
WT OV -514.750 201.879 .171 -1170.65 141.15 
NFATc2-/- CTL 252.250 201.879 .806 -403.65 908.15 
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NFATc2-/- OV 86.000 201.879 .998 -569.90 741.90 
NFATc3-/- OV -394.000 215.818 .480 -1095.18 307.18 
NFATc3-/- OV WT CTL 525.000 215.818 .206 -176.18 1226.18 
WT OV -120.750 201.879 .990 -776.65 535.15 
NFATc2-/- CTL 646.250 201.879 .055 -9.65 1302.15 
NFATc2-/- OV 480.000 201.879 .225 -175.90 1135.90 
NFATc3-/- CTL 394.000 215.818 .480 -307.18 1095.18 
 




N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 659.33 109.464 63.199 387.41 931.26 533 726 
WT OV 4 864.25 62.334 31.167 765.06 963.44 786 938 
NFATc2-/- CTL 4 730.75 114.284 57.142 548.90 912.60 637 890 
NFATc2-/- OV 4 1016.25 93.578 46.789 867.35 1165.15 921 1145 
NFATc3-/- CTL 3 444.67 58.046 33.513 300.47 588.86 394 508 
NFATc3-/- OV 3 891.67 76.350 44.081 702.00 1081.33 805 949 
Total 21 782.48 199.891 43.620 691.49 873.47 394 1145 
Test of Homogeneity of Variances 
Fiber Number 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups 679656.988 5 135931.398 17.066 .000 
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Within Groups 119472.250 15 7964.817 
  
Total 799129.238 20 
   
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:Fiber Number 
 
(I) Group (J) Group 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
 
Lower Bound Upper Bound 
Tukey HSD WT CTL WT OV -204.917 68.163 .078 -426.37 16.54 
NFATc2-/- CTL -71.417 68.163 .894 -292.87 150.04 
NFATc2-/- OV -356.917
*
 68.163 .001 -578.37 -135.46 
NFATc3-/- CTL 214.667 72.869 .087 -22.08 451.42 
NFATc3-/- OV -232.333 72.869 .056 -469.08 4.42 
WT OV WT CTL 204.917 68.163 .078 -16.54 426.37 
NFATc2-/- CTL 133.500 63.106 .331 -71.53 338.53 
NFATc2-/- OV -152.000 63.106 .214 -357.03 53.03 
NFATc3-/- CTL 419.583
*
 68.163 .000 198.13 641.04 
NFATc3-/- OV -27.417 68.163 .998 -248.87 194.04 
NFATc2-/- CTL WT CTL 71.417 68.163 .894 -150.04 292.87 
WT OV -133.500 63.106 .331 -338.53 71.53 
NFATc2-/- OV -285.500
*
 63.106 .004 -490.53 -80.47 
NFATc3-/- CTL 286.083
*
 68.163 .008 64.63 507.54 
NFATc3-/- OV -160.917 68.163 .231 -382.37 60.54 
NFATc2-/- OV WT CTL 356.917
*
 68.163 .001 135.46 578.37 
WT OV 152.000 63.106 .214 -53.03 357.03 
NFATc2-/- CTL 285.500
*
 63.106 .004 80.47 490.53 
NFATc3-/- CTL 571.583
*
 68.163 .000 350.13 793.04 
NFATc3-/- OV 124.583 68.163 .478 -96.87 346.04 





 68.163 .000 -641.04 -198.13 
NFATc2-/- CTL -286.083
*
 68.163 .008 -507.54 -64.63 
NFATc2-/- OV -571.583
*
 68.163 .000 -793.04 -350.13 
NFATc3-/- OV -447.000
*
 72.869 .000 -683.75 -210.25 
NFATc3-/- OV WT CTL 232.333 72.869 .056 -4.42 469.08 
WT OV 27.417 68.163 .998 -194.04 248.87 
NFATc2-/- CTL 160.917 68.163 .231 -60.54 382.37 
NFATc2-/- OV -124.583 68.163 .478 -346.04 96.87 
NFATc3-/- CTL 447.000
*
 72.869 .000 210.25 683.75 
 
Chapter 3: Analysis of MyHC IIa fibers  
Descriptives 
MyHC IIa Size 
 
N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 1223.00 398.270 229.941 233.64 2212.36 900 1668 
WT 28dOV 4 2079.75 319.265 159.633 1571.73 2587.77 1805 2531 
NFATc2-/- CTL 4 944.50 166.442 83.221 679.65 1209.35 743 1097 
NFTAc2-/- 
28dOV 
4 1479.75 180.469 90.234 1192.58 1766.92 1221 1641 
NFATc3-/- CTL 3 1113.33 63.815 36.844 954.81 1271.86 1042 1165 
NFATc3-/- 
28dOV 
3 1995.67 120.608 69.633 1696.06 2295.27 1888 2126 
Total 21 1476.76 491.219 107.193 1253.16 1700.36 743 2531 
Test of Homogeneity of Variances 
MyHC IIa Size 
Levene Statistic df1 df2 Sig. 




MyHC IIa Size 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 3984837.976 5 796967.595 14.213 .000 
Within Groups 841081.833 15 56072.122 
  
Total 4825919.810 20 
   
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:MyHC IIa Size 
 
(I) Group (J) Group 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
 
Lower Bound Upper Bound 
Tukey HSD WT CTL WT 28dOV -856.750
*
 180.856 .003 -1444.34 -269.16 
NFATc2-/- CTL 278.500 180.856 .646 -309.09 866.09 
NFTAc2-/- 28dOV -256.750 180.856 .716 -844.34 330.84 
NFATc3-/- CTL 109.667 193.343 .992 -518.50 737.83 
NFATc3-/- 28dOV -772.667
*
 193.343 .012 -1400.83 -144.50 
WT 28dOV WT CTL 856.750
*
 180.856 .003 269.16 1444.34 
NFATc2-/- CTL 1135.250
*
 167.440 .000 591.24 1679.26 
NFTAc2-/- 28dOV 600.000
*
 167.440 .027 55.99 1144.01 
NFATc3-/- CTL 966.417
*
 180.856 .001 378.82 1554.01 
NFATc3-/- 28dOV 84.083 180.856 .997 -503.51 671.68 
NFATc2-/- CTL WT CTL -278.500 180.856 .646 -866.09 309.09 
WT 28dOV -1135.250
*
 167.440 .000 -1679.26 -591.24 
NFTAc2-/- 28dOV -535.250 167.440 .055 -1079.26 8.76 
NFATc3-/- CTL -168.833 180.856 .931 -756.43 418.76 
NFATc3-/- 28dOV -1051.167
*
 180.856 .000 -1638.76 -463.57 
NFTAc2-/- 28dOV WT CTL 256.750 180.856 .716 -330.84 844.34 
WT 28dOV -600.000
*
 167.440 .027 -1144.01 -55.99 
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NFATc2-/- CTL 535.250 167.440 .055 -8.76 1079.26 
NFATc3-/- CTL 366.417 180.856 .373 -221.18 954.01 
NFATc3-/- 28dOV -515.917 180.856 .102 -1103.51 71.68 
NFATc3-/- CTL WT CTL -109.667 193.343 .992 -737.83 518.50 
WT 28dOV -966.417
*
 180.856 .001 -1554.01 -378.82 
NFATc2-/- CTL 168.833 180.856 .931 -418.76 756.43 
NFTAc2-/- 28dOV -366.417 180.856 .373 -954.01 221.18 
NFATc3-/- 28dOV -882.333
*
 193.343 .004 -1510.50 -254.17 
NFATc3-/- 28dOV WT CTL 772.667
*
 193.343 .012 144.50 1400.83 
WT 28dOV -84.083 180.856 .997 -671.68 503.51 
NFATc2-/- CTL 1051.167
*
 180.856 .000 463.57 1638.76 
NFTAc2-/- 28dOV 515.917 180.856 .102 -71.68 1103.51 
NFATc3-/- CTL 882.333
*
 193.343 .004 254.17 1510.50 
 
Descriptives 
MyHC IIa Percentage 
 
N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 47.33 24.420 14.099 -13.33 108.00 20 67 
WT 28dOV 4 61.00 6.831 3.416 50.13 71.87 52 68 
NFATc2-/- CTL 4 35.25 13.500 6.750 13.77 56.73 18 46 
NFTAc2-/- 
28dOV 
4 57.25 9.215 4.608 42.59 71.91 47 66 
NFATc3-/- CTL 3 41.67 15.631 9.025 2.84 80.50 25 56 
NFATc3-/- 
28dOV 
3 52.67 24.007 13.860 -6.97 112.30 29 77 
Total 21 49.48 16.711 3.647 41.87 57.08 18 77 
Test of Homogeneity of Variances 
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MyHC IIa Percentage 
Levene Statistic df1 df2 Sig. 
1.560 5 15 .231 
ANOVA 
MyHC IIa Percentage 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 1809.738 5 361.948 1.438 .267 
Within Groups 3775.500 15 251.700 
  
Total 5585.238 20 
   
 
Chapter 3: Analysis of MyHC IIb fibers 
Descriptives 
MyHC IIb Size 
 
N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 2366.00 442.569 255.517 1266.60 3465.40 1919 2804 
WT 28dOV 4 3426.50 542.245 271.123 2563.67 4289.33 2914 4190 
NFATc2-/- CTL 4 2109.75 242.625 121.313 1723.68 2495.82 1916 2460 
NFTAc2-/- 
28dOV 
4 2378.75 241.956 120.978 1993.74 2763.76 2247 2741 
NFATc3-/- CTL 3 2658.00 298.608 172.402 1916.22 3399.78 2335 2924 
NFATc3-/- 
28dOV 
3 3208.67 223.768 129.193 2652.79 3764.54 3075 3467 
Total 21 2683.71 588.759 128.478 2415.71 2951.71 1916 4190 
Test of Homogeneity of Variances 
MyHC IIb Size 
Levene Statistic df1 df2 Sig. 




MyHC IIb Size 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 5028211.119 5 1005642.224 7.920 .001 
Within Groups 1904531.167 15 126968.744 
  
Total 6932742.286 20 
   
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable:MyHC IIb Size 
 
(I) Group (J) Group 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
 
Lower Bound Upper Bound 
Tukey HSD WT CTL WT 28dOV -1060.500
*
 272.149 .015 -1944.70 -176.30 
NFATc2-/- CTL 256.250 272.149 .929 -627.95 1140.45 
NFTAc2-/- 28dOV -12.750 272.149 1.000 -896.95 871.45 
NFATc3-/- CTL -292.000 290.940 .910 -1237.25 653.25 
NFATc3-/- 28dOV -842.667 290.940 .095 -1787.92 102.59 
WT 28dOV WT CTL 1060.500
*
 272.149 .015 176.30 1944.70 
NFATc2-/- CTL 1316.750
*
 251.961 .001 498.14 2135.36 
NFTAc2-/- 28dOV 1047.750
*
 251.961 .009 229.14 1866.36 
NFATc3-/- CTL 768.500 272.149 .107 -115.70 1652.70 
NFATc3-/- 28dOV 217.833 272.149 .963 -666.37 1102.04 
NFATc2-/- CTL WT CTL -256.250 272.149 .929 -1140.45 627.95 
WT 28dOV -1316.750
*
 251.961 .001 -2135.36 -498.14 
NFTAc2-/- 28dOV -269.000 251.961 .887 -1087.61 549.61 
NFATc3-/- CTL -548.250 272.149 .379 -1432.45 335.95 
NFATc3-/- 28dOV -1098.917
*
 272.149 .011 -1983.12 -214.71 
NFTAc2-/- 28dOV WT CTL 12.750 272.149 1.000 -871.45 896.95 
WT 28dOV -1047.750
*
 251.961 .009 -1866.36 -229.14 
NFATc2-/- CTL 269.000 251.961 .887 -549.61 1087.61 
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NFATc3-/- CTL -279.250 272.149 .902 -1163.45 604.95 
NFATc3-/- 28dOV -829.917 272.149 .072 -1714.12 54.29 
NFATc3-/- CTL WT CTL 292.000 290.940 .910 -653.25 1237.25 
WT 28dOV -768.500 272.149 .107 -1652.70 115.70 
NFATc2-/- CTL 548.250 272.149 .379 -335.95 1432.45 
NFTAc2-/- 28dOV 279.250 272.149 .902 -604.95 1163.45 
NFATc3-/- 28dOV -550.667 290.940 .443 -1495.92 394.59 
NFATc3-/- 28dOV WT CTL 842.667 290.940 .095 -102.59 1787.92 
WT 28dOV -217.833 272.149 .963 -1102.04 666.37 
NFATc2-/- CTL 1098.917
*
 272.149 .011 214.71 1983.12 
NFTAc2-/- 28dOV 829.917 272.149 .072 -54.29 1714.12 
NFATc3-/- CTL 550.667 290.940 .443 -394.59 1495.92 
 
Descriptives 
MyHC IIb Percentage 
 
N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 27.67 27.209 15.709 -39.92 95.26 10 59 
WT 28dOV 4 10.50 6.191 3.096 .65 20.35 5 19 
NFATc2-/- CTL 4 40.75 19.363 9.681 9.94 71.56 23 58 
NFTAc2-/- 
28dOV 
4 24.00 10.801 5.401 6.81 41.19 15 38 
NFATc3-/- CTL 3 28.00 10.583 6.110 1.71 54.29 20 40 
NFATc3-/- 
28dOV 
3 23.00 11.136 6.429 -4.66 50.66 13 35 
Total 21 25.57 16.482 3.597 18.07 33.07 5 59 
Test of Homogeneity of Variances 
MyHC IIb Percentage 
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Levene Statistic df1 df2 Sig. 
5.658 5 15 .004 
Robust Tests of Equality of Means 




 df1 df2 Sig. 
Welch 2.281 5 6.284 .167 
 




N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 1.9858 .74707 .43132 .1300 3.8417 1.15 2.60 
WT 7dOV 3 1.7996 .43826 .25303 .7109 2.8883 1.30 2.11 
NFATc2-/- CTL 3 2.2801 .71211 .41114 .5111 4.0490 1.48 2.86 
NFATc2-/- 
7dOV 
3 2.0279 .79692 .46010 .0482 4.0075 1.11 2.57 
NFATc3-/- CTL 3 2.2445 .61708 .35627 .7116 3.7775 1.62 2.86 
NFATc3-/- 
7dOV 
3 1.7750 .56608 .32683 .3687 3.1812 1.44 2.43 
Total 18 2.0188 .58766 .13851 1.7266 2.3110 1.11 2.86 
Test of Homogeneity of Variances 
MyHC IIa 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
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Between Groups .684 5 .137 .316 .894 
Within Groups 5.187 12 .432 
  
Total 5.871 17 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 1.2049 .63337 .36568 -.3685 2.7783 .51 1.75 
WT 7dOV 3 .4870 .18648 .10766 .0237 .9502 .29 .66 
NFATc2-/- CTL 3 .9739 .76771 .44324 -.9332 2.8810 .22 1.75 
NFATc2-/- 
7dOV 
3 .3618 .22167 .12798 -.1888 .9125 .11 .53 
NFATc3-/- CTL 3 .9551 1.05378 .60840 -1.6626 3.5729 .17 2.15 
NFATc3-/- 
7dOV 
3 .4024 .26542 .15324 -.2569 1.0618 .13 .66 
Total 18 .7309 .61470 .14489 .4252 1.0366 .11 2.15 
Test of Homogeneity of Variances 
MyHC IIb 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups 1.913 5 .383 1.018 .449 
Within Groups 4.511 12 .376 
  
Total 6.424 17 







N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .4924 .35159 .20299 -.3810 1.3658 .13 .83 
WT 7dOV 3 1.9996 1.32512 .76506 -1.2921 5.2914 .95 3.49 
NFATc2-/- CTL 3 .5501 .63934 .36912 -1.0381 2.1383 .17 1.29 
NFATc2-/- 
7dOV 
3 1.7446 1.91822 1.10748 -3.0206 6.5097 .33 3.93 
NFATc3-/- CTL 3 .2701 .11430 .06599 -.0138 .5541 .15 .37 
NFATc3-/- 
7dOV 
3 1.5501 1.48259 .85597 -2.1329 5.2330 .39 3.22 
Total 18 1.1011 1.20589 .28423 .5015 1.7008 .13 3.93 
Test of Homogeneity of Variances 
TnIs 
Levene Statistic df1 df2 Sig. 
4.376 5 12 .017 





 df1 df2 Sig. 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 1.6998 .23523 .13581 1.1154 2.2841 1.48 1.95 
WT 7dOV 3 1.5797 .09236 .05332 1.3503 1.8091 1.48 1.67 





3 1.5745 .25109 .14497 .9507 2.1982 1.43 1.86 
NFATc3-/- CTL 3 1.5644 .34671 .20017 .7031 2.4256 1.23 1.93 
NFATc3-/- 
7dOV 
3 1.5891 .09519 .05496 1.3527 1.8256 1.48 1.67 
Total 18 1.6512 .22739 .05360 1.5382 1.7643 1.23 2.17 
Test of Homogeneity of Variances 
NFATc1 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups .260 5 .052 1.007 .455 
Within Groups .619 12 .052 
  
Total .879 17 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 1.3871 .40840 .23579 .3726 2.4016 1.00 1.81 
WT 7dOV 3 1.0971 .09206 .05315 .8684 1.3258 1.02 1.20 
NFATc2-/- CTL 3 .7902 .39137 .22596 -.1821 1.7624 .35 1.10 
NFATc2-/- 
7dOV 
3 .7884 .45559 .26303 -.3433 1.9202 .35 1.26 
NFATc3-/- CTL 3 .7402 .66261 .38256 -.9058 2.3862 .18 1.47 
NFATc3-/- 
7dOV 






N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 1.3871 .40840 .23579 .3726 2.4016 1.00 1.81 
WT 7dOV 3 1.0971 .09206 .05315 .8684 1.3258 1.02 1.20 
NFATc2-/- CTL 3 .7902 .39137 .22596 -.1821 1.7624 .35 1.10 
NFATc2-/- 
7dOV 
3 .7884 .45559 .26303 -.3433 1.9202 .35 1.26 
NFATc3-/- CTL 3 .7402 .66261 .38256 -.9058 2.3862 .18 1.47 
NFATc3-/- 
7dOV 
3 .6315 .35142 .20289 -.2414 1.5045 .27 .97 
Total 18 .9057 .44664 .10527 .6836 1.1279 .18 1.81 
Test of Homogeneity of Variances 
NFATc2 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups 1.194 5 .239 1.305 .325 
Within Groups 2.197 12 .183 
  
Total 3.391 17 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
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WT CTL 3 .6413 .05750 .03320 .4984 .7841 .58 .70 
WT 7dOV 3 .5076 .04693 .02709 .3911 .6242 .48 .56 
NFATc2-/- CTL 3 .7174 .28080 .16212 .0199 1.4150 .51 1.04 
NFATc2-/- 
7dOV 
3 .4957 .28280 .16327 -.2068 1.1983 .29 .82 
NFATc3-/- CTL 3 .3177 .09897 .05714 .0718 .5635 .23 .42 
NFATc3-/- 
7dOV 
3 .3488 .08717 .05033 .1322 .5653 .29 .45 
Total 18 .5048 .20769 .04895 .4015 .6080 .23 1.04 
Test of Homogeneity of Variances 
NFATc3 
Levene Statistic df1 df2 Sig. 
4.911 5 12 .011 





 df1 df2 Sig. 
Welch 5.207 5 5.406 .041 




(I) Group (J) Group 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
 
Lower Bound Upper Bound 
Dunnett T3 WT CTL WT 7dOV .13361 .04285 .239 -.0929 .3601 
NFATc2-/- CTL -.07617 .16548 1.000 -1.4761 1.3238 
NFATc2-/- 7dOV .14551 .16661 .981 -1.2656 1.5567 
NFATc3-/- CTL .32358 .06608 .087 -.0695 .7166 
NFATc3-/- 7dOV .29246 .06029 .079 -.0479 .6329 
WT 7dOV WT CTL -.13361 .04285 .239 -.3601 .0929 
NFATc2-/- CTL -.20978 .16437 .886 -1.6414 1.2218 
NFATc2-/- 7dOV .01190 .16550 1.000 -1.4308 1.4546 
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NFATc3-/- CTL .18997 .06324 .311 -.2216 .6015 
NFATc3-/- 7dOV .15885 .05716 .350 -.1927 .5104 
NFATc2-/- CTL WT CTL .07617 .16548 1.000 -1.3238 1.4761 
WT 7dOV .20978 .16437 .886 -1.2218 1.6414 
NFATc2-/- 7dOV .22168 .23009 .981 -.9670 1.4104 
NFATc3-/- CTL .39975 .17190 .505 -.8626 1.6621 
NFATc3-/- 7dOV .36863 .16975 .558 -.9324 1.6697 
NFATc2-/- 7dOV WT CTL -.14551 .16661 .981 -1.5567 1.2656 
WT 7dOV -.01190 .16550 1.000 -1.4546 1.4308 
NFATc2-/- CTL -.22168 .23009 .981 -1.4104 .9670 
NFATc3-/- CTL .17807 .17298 .958 -1.0955 1.4516 
NFATc3-/- 7dOV .14695 .17085 .984 -1.1654 1.4593 
NFATc3-/- CTL WT CTL -.32358 .06608 .087 -.7166 .0695 
WT 7dOV -.18997 .06324 .311 -.6015 .2216 
NFATc2-/- CTL -.39975 .17190 .505 -1.6621 .8626 
NFATc2-/- 7dOV -.17807 .17298 .958 -1.4516 1.0955 
NFATc3-/- 7dOV -.03112 .07614 1.000 -.4281 .3659 
NFATc3-/- 7dOV WT CTL -.29246 .06029 .079 -.6329 .0479 
WT 7dOV -.15885 .05716 .350 -.5104 .1927 
NFATc2-/- CTL -.36863 .16975 .558 -1.6697 .9324 
NFATc2-/- 7dOV -.14695 .17085 .984 -1.4593 1.1654 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .8499 .29932 .17281 .1063 1.5934 .50 1.03 
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WT 7dOV 3 1.4535 .17955 .10366 1.0075 1.8995 1.25 1.58 
NFATc2-/- CTL 3 .7882 .50879 .29375 -.4757 2.0521 .26 1.27 
NFATc2-/- 
7dOV 
3 1.0078 .91951 .53088 -1.2764 3.2920 .39 2.06 
NFATc3-/- CTL 3 .4593 .41810 .24139 -.5794 1.4979 .17 .94 
NFATc3-/- 
7dOV 
3 .6113 .54834 .31658 -.7509 1.9734 .25 1.24 
Total 18 .8617 .55352 .13047 .5864 1.1369 .17 2.06 
Test of Homogeneity of Variances 
NFATc4 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups 1.805 5 .361 1.273 .337 
Within Groups 3.403 12 .284 
  
Total 5.209 17 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .9331 .23267 .13433 .3551 1.5110 .67 1.13 
WT 7dOV 3 1.2585 .34455 .19893 .4026 2.1144 .94 1.62 
NFATc2-/- CTL 3 .7583 .27745 .16019 .0690 1.4475 .51 1.06 
NFATc2-/- 
7dOV 
3 .8883 .15187 .08768 .5111 1.2656 .71 .99 





3 1.0381 .26049 .15039 .3910 1.6852 .83 1.33 
Total 17 .9470 .27837 .06752 .8039 1.0901 .51 1.62 
Test of Homogeneity of Variances 
Pax7 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups .523 5 .105 1.608 .237 
Within Groups .716 11 .065 
  
Total 1.240 16 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .8830 .32480 .18752 .0762 1.6898 .51 1.10 
WT 7dOV 3 1.4918 .52584 .30359 .1856 2.7981 1.04 2.07 
NFATc2-/- CTL 3 .7026 .45708 .26390 -.4329 1.8381 .40 1.23 
NFATc2-/- 
7dOV 
3 1.0183 .67495 .38968 -.6584 2.6949 .26 1.55 
NFATc3-/- CTL 3 .7624 .06431 .03713 .6027 .9222 .69 .81 
NFATc3-/- 
7dOV 
3 1.4059 .49678 .28681 .1718 2.6399 .93 1.92 
Total 18 1.0440 .50038 .11794 .7952 1.2928 .26 2.07 




Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups 1.662 5 .332 1.537 .251 
Within Groups 2.595 12 .216 
  
Total 4.256 17 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .6845 .12082 .06976 .3844 .9847 .55 .77 
WT 7dOV 3 .7291 .09047 .05223 .5043 .9538 .64 .82 
NFATc2-/- CTL 3 .5103 .11967 .06909 .2131 .8076 .42 .65 
NFATc2-/- 
7dOV 
3 .6774 .13775 .07953 .3352 1.0196 .58 .84 
NFATc3-/- CTL 2 .6415 .44350 .31360 -3.3432 4.6262 .33 .96 
NFATc3-/- 
7dOV 
3 .4396 .04540 .02621 .3268 .5524 .41 .49 
Total 17 .6121 .17759 .04307 .5208 .7034 .33 .96 
Test of Homogeneity of Variances 
MyoD 
Levene Statistic df1 df2 Sig. 
13.302 5 11 .000 
 







 df1 df2 Sig. 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .6625 .44554 .25723 -.4442 1.7693 .22 1.11 
WT 7dOV 3 1.6539 .57196 .33022 .2331 3.0747 1.09 2.24 
NFATc2-/- CTL 3 .7238 .54871 .31680 -.6393 2.0868 .28 1.34 
NFATc2-/- 
7dOV 
3 1.5083 1.26092 .72799 -1.6240 4.6406 .72 2.96 
NFATc3-/- CTL 3 .3417 .33676 .19443 -.4949 1.1782 .00 .67 
NFATc3-/- 
7dOV 
3 .8238 .53297 .30771 -.5001 2.1478 .33 1.39 
Total 18 .9523 .75183 .17721 .5785 1.3262 .00 2.96 
Test of Homogeneity of Variances 
Myogenin 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups 3.981 5 .796 1.698 .210 
Within Groups 5.628 12 .469 
  
Total 9.609 17 










N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
NFATc1 WT CTL 3 1.0200 .06557 .03786 .8571 1.1829 .96 1.09 
WT 7dOV 3 1.3400 .03000 .01732 1.2655 1.4145 1.31 1.37 
Total 6 1.1800 .18111 .07394 .9899 1.3701 .96 1.37 
NFATc2 WT CTL 3 .9967 .48336 .27907 -.2041 2.1974 .47 1.42 
WT 7dOV 3 1.3033 .28711 .16576 .5901 2.0166 1.06 1.62 
Total 6 1.1500 .39324 .16054 .7373 1.5627 .47 1.62 
NFATc3 WT CTL 3 1.0000 .52849 .30512 -.3128 2.3128 .68 1.61 
WT 7dOV 3 1.0033 .23714 .13691 .4143 1.5924 .75 1.22 
Total 6 1.0017 .36636 .14956 .6172 1.3861 .68 1.61 
NFATc4 WT CTL 3 .9833 .20841 .12032 .4656 1.5010 .80 1.21 
WT 7dOV 3 1.1433 .36460 .21050 .2376 2.0491 .75 1.47 
Total 6 1.0633 .27969 .11418 .7698 1.3569 .75 1.47 
Test of Homogeneity of Variances 
 
Levene Statistic df1 df2 Sig. 
NFATc1 1.600 1 4 .275 
NFATc2 .915 1 4 .393 
NFATc3 3.796 1 4 .123 
NFATc4 .950 1 4 .385 
ANOVA 
  
Sum of Squares df Mean Square F Sig. 
NFATc1 Between Groups .154 1 .154 59.077 .002 
Within Groups .010 4 .003 
  
Total .164 5 
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NFATc2 Between Groups .141 1 .141 .893 .398 
Within Groups .632 4 .158 
  
Total .773 5 
   
NFATc3 Between Groups .000 1 .000 .000 .993 
Within Groups .671 4 .168 
  
Total .671 5 
   
NFATc4 Between Groups .038 1 .038 .435 .545 
Within Groups .353 4 .088 
  
Total .391 5 







Deviation Std. Error 




Lower Bound Upper Bound 
NFATc1 NFATc2-/- 
CTL 
3 1.0200 .74223 .42852 -.8238 2.8638 .17 1.54 
NFATc2-/- 
7dOV 
3 1.5300 .06557 .03786 1.3671 1.6929 1.46 1.59 
Total 6 1.2750 .54782 .22365 .7001 1.8499 .17 1.59 
NFATc2 NFATc2-/- 
CTL 
3 1.0233 .44837 .25887 -.0905 2.1371 .61 1.50 
NFATc2-/- 
7dOV 
3 .6800 .43486 .25106 -.4002 1.7602 .34 1.17 
Total 6 .8517 .43751 .17861 .3925 1.3108 .34 1.50 
NFATc3 NFATc2-/- 
CTL 
3 .9700 .46776 .27006 -.1920 2.1320 .69 1.51 
NFATc2-/- 
7dOV 
3 1.0767 .58398 .33716 -.3740 2.5274 .64 1.74 





3 .9833 .22189 .12811 .4321 1.5345 .80 1.23 
NFATc2-/- 
7dOV 
3 1.1167 .31565 .18224 .3326 1.9008 .91 1.48 
Total 6 1.0500 .25472 .10399 .7827 1.3173 .80 1.48 
Test of Homogeneity of Variances 
 
Levene Statistic df1 df2 Sig. 
NFATc1 11.545 1 4 .027 
NFATc2 .003 1 4 .959 
NFATc3 .281 1 4 .624 
NFATc4 .894 1 4 .398 
ANOVA 
  
Sum of Squares df Mean Square F Sig. 
NFATc1 Between Groups .390 1 .390 1.405 .301 
Within Groups 1.110 4 .278 
  
Total 1.501 5 
   
NFATc2 Between Groups .177 1 .177 .906 .395 
Within Groups .780 4 .195 
  
Total .957 5 
   
NFATc3 Between Groups .017 1 .017 .061 .817 
Within Groups 1.120 4 .280 
  
Total 1.137 5 
   
NFATc4 Between Groups .027 1 .027 .358 .582 
Within Groups .298 4 .074 
  
Total .324 5 
   




 df1 df2 Sig. 
NFATc1 Welch 1.405 1 2.031 .356 
NFATc2 Welch .906 1 3.996 .395 
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NFATc3 Welch .061 1 3.818 .818 







Deviation Std. Error 




Lower Bound Upper Bound 
NFATc1 NFATc3-/- CTL 3 .9900 .05292 .03055 .8586 1.1214 .95 1.05 
NFATc3-/- 
7dOV 
3 1.1567 .07024 .04055 .9822 1.3311 1.09 1.23 
Total 6 1.0733 .10690 .04364 .9612 1.1855 .95 1.23 
NFATc2 NFATc3-/- CTL 3 .9800 .13115 .07572 .6542 1.3058 .84 1.10 
NFATc3-/- 
7dOV 
3 1.0833 .06506 .03756 .9217 1.2450 1.02 1.15 
Total 6 1.0317 .10852 .04430 .9178 1.1456 .84 1.15 
NFATc3 NFATc3-/- CTL 3 .9900 .21284 .12288 .4613 1.5187 .76 1.18 
NFATc3-/- 
7dOV 
3 .8867 .09866 .05696 .6416 1.1317 .82 1.00 
Total 6 .9383 .15880 .06483 .7717 1.1050 .76 1.18 
NFATc4 NFATc3-/- CTL 3 1.0067 .18717 .10806 .5417 1.4716 .87 1.22 
NFATc3-/- 
7dOV 
3 1.4400 .07000 .04041 1.2661 1.6139 1.37 1.51 
Total 6 1.2233 .26890 .10978 .9411 1.5055 .87 1.51 
Test of Homogeneity of Variances 
 
Levene Statistic df1 df2 Sig. 
NFATc1 .136 1 4 .731 
NFATc2 1.327 1 4 .314 
NFATc3 1.620 1 4 .272 





Sum of Squares Df Mean Square F Sig. 
NFATc1 Between Groups .042 1 .042 10.776 .030 
Within Groups .015 4 .004 
  
Total .057 5 
   
NFATc2 Between Groups .016 1 .016 1.495 .289 
Within Groups .043 4 .011 
  
Total .059 5 
   
NFATc3 Between Groups .016 1 .016 .582 .488 
Within Groups .110 4 .028 
  
Total .126 5 
   
NFATc4 Between Groups .282 1 .282 14.107 .020 
Within Groups .080 4 .020 
  
Total .362 5 
   
 




N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .6608 .06565 .03790 .4977 .8239 .61 .73 
WT 7dOV 3 1.3100 .39947 .23063 .3176 2.3023 .85 1.57 
NFATc2-/- CTL 3 .8425 .30226 .17451 .0916 1.5933 .59 1.18 
NFATc2-/- 
7dOV 
3 1.2575 .48792 .28170 .0455 2.4696 .73 1.69 
NFATc3-/- CTL 3 1.0658 .45049 .26009 -.0533 2.1849 .57 1.45 
NFATc3-/- 
7dOV 






N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
WT CTL 3 .6608 .06565 .03790 .4977 .8239 .61 .73 
WT 7dOV 3 1.3100 .39947 .23063 .3176 2.3023 .85 1.57 
NFATc2-/- CTL 3 .8425 .30226 .17451 .0916 1.5933 .59 1.18 
NFATc2-/- 
7dOV 
3 1.2575 .48792 .28170 .0455 2.4696 .73 1.69 
NFATc3-/- CTL 3 1.0658 .45049 .26009 -.0533 2.1849 .57 1.45 
NFATc3-/- 
7dOV 
3 1.2235 .66370 .38319 -.4252 2.8722 .65 1.95 
Total 18 1.0600 .43914 .10351 .8416 1.2784 .57 1.95 
Test of Homogeneity of Variances 
pAKT 
Levene Statistic df1 df2 Sig. 




Sum of Squares Df Mean Square F Sig. 
Between Groups 1.005 5 .201 1.061 .428 
Within Groups 2.273 12 .189 
  
Total 3.278 17 





N Mean Std. Deviation Std. Error 




Lower Bound Upper Bound 
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WT CTL 3 1.0556 .19975 .11532 .5594 1.5518 .87 1.27 
WT 7dOV 3 1.5712 .48768 .28156 .3597 2.7827 1.16 2.11 
NFATc2-/- CTL 3 1.0642 .17061 .09850 .6404 1.4880 .87 1.19 
NFATc2-/- 
7dOV 
3 1.4178 .45754 .26416 .2812 2.5544 .92 1.82 
NFATc3-/- CTL 3 1.1514 .30967 .17879 .3822 1.9207 .80 1.38 
NFATc3-/- 
7dOV 
3 1.4351 .54303 .31352 .0862 2.7841 .81 1.79 
Total 18 1.2826 .38636 .09107 1.0904 1.4747 .80 2.11 
Test of Homogeneity of Variances 
AKT 
Levene Statistic df1 df2 Sig. 




Sum of Squares df Mean Square F Sig. 
Between Groups .724 5 .145 .958 .480 
Within Groups 1.814 12 .151 
  
Total 2.538 17 
   
 
Chapter 4: Agrin in adult healthy mice 
Group Statistics 
 
Mice Category N Mean Std. Deviation Std. Error Mean 
Relative Muscle Weight Adult PBS 3 187.00 13.892 8.021 
Adult AGR 3 189.67 3.055 1.764 
Independent Samples Test 
  
Levene's Test for 
Equality of 






Interval of the 
Difference 
  













8.818 .041 -.325 4 .762 -2.667 8.212 -25.468 20.135 
Equal variances 
not assumed 




Mice Category N Mean Std. Deviation Std. Error Mean 
Size MyHC IIa Adult PBS 2 1112.50 289.207 204.500 
Adult AGR 3 897.67 36.116 20.851 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  






















Mice Category N Mean Std. Deviation Std. Error Mean 
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Size MyHC IIb Adult PBS 3 3578.33 369.522 213.343 
Adult AGR 3 3308.00 280.343 161.856 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  





















Mice Category N Mean Std. Deviation Std. Error Mean 
Percentage MyHC IIa Adult PBS 3 6.33 7.767 4.485 
Adult AGR 3 2.67 1.155 .667 
 
 
Independent Samples Test 
  
Levene's Test for 
Equality of 






























Mice Category N Mean Std. Deviation Std. Error Mean 
Percentage MyHC IIb Adult PBS 3 38.00 5.568 3.215 
Adult AGR 3 41.67 10.408 6.009 
Independent Samples Test 
  
Levene's Test for 
Equality of 




Interval of the 
Difference 
  






















Category N Mean Std. Deviation Std. Error Mean 
pAKT Adult PBS 3 .6257 .15581 .08996 
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Adult AGR 3 .9923 .27832 .16069 
Total AKT Adult PBS 3 .4747 .14650 .08458 
Adult AGR 3 .7627 .35205 .20325 
pS6K Adult PBS 3 .4920 .16865 .09737 
Adult AGR 3 .5090 .09657 .05575 
Total S6K Adult PBS 3 .7297 .23276 .13438 
Adult AGR 3 .9760 .18385 .10614 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  






Difference Lower Upper 
pAKT Equal variances 
assumed 
1.323 .314 -1.991 4 .117 -.36667 .18416 -.87797 .14463 
Equal variances 
not assumed 





3.751 .125 -1.308 4 .261 -.28800 .22015 -.89924 .32324 
Equal variances 
not assumed 
  -1.308 2.673 .292 -.28800 .22015 -1.03978 .46378 
pS6K Equal variances 
assumed 
1.340 .311 -.152 4 .887 -.01700 .11220 -.32853 .29453 
Equal variances 
not assumed 





.456 .536 -1.438 4 .224 -.24633 .17125 -.72179 .22912 
Equal variances 
not assumed 




Chapter 4: Characterization of sarcopenia 
Group Statistics 
 
Mice Category N Mean Std. Deviation Std. Error Mean 
Body Weight Young 3 26.000 2.2913 1.3229 
Old 3 32.733 4.8336 2.7907 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  











1.714 .261 -2.180 4 .095 -6.7333 3.0883 -15.3079 1.8412 
Equal variances 
not assumed 




Mice Category N Mean Std. Deviation Std. Error Mean 
Absolute Muscle Weight Young 3 46.900 4.8962 2.8268 
Old 3 42.700 3.1749 1.8330 
Independent Samples Test 
  
Levene's Test for 
Equality of 






















.723 .443 1.247 4 .281 4.2000 3.3691 -5.1541 13.5541 
Equal variances 
not assumed 




Mice Category N Mean Std. Deviation Std. Error Mean 
Relative Muscle Weight Young 3 180.33 2.887 1.667 
Old 3 131.33 10.693 6.173 
Independent Samples Test 
  
Levene's Test for 
Equality of 




Interval of the 
Difference 
  














7.797 .049 7.663 4 .002 49.000 6.394 31.246 66.754 
Equal variances 
not assumed 




Mice Category N Mean Std. Deviation Std. Error Mean 





Mice Category N Mean Std. Deviation Std. Error Mean 
Mean Fiber Size Young 3 1674.55 136.824 78.995 
Old 3 1154.41 65.863 38.026 
Independent Samples Test 
  
Levene's Test for 
Equality of 




Interval of the 
Difference 
  













.944 .386 5.933 4 .004 520.137 87.671 276.723 763.552 
Equal variances 
not assumed 
  5.933 2.880 .011 520.137 87.671 234.413 805.862 
 




Category N Mean Std. Deviation Std. Error Mean 
Relative Muscle Weight Old PBS 6 130.17 11.771 4.806 
Old AGR 3 131.00 13.892 8.021 
Independent Samples Test 
  
Levene's Test for 
Equality of 






Interval of the 
Difference 
  













.103 .757 -.095 7 .927 -.833 8.778 -21.591 19.924 
Equal variances 
not assumed 





Category N Mean Std. Deviation Std. Error Mean 
pAKT Old PBS 3 .5627 .06357 .03670 
Old AGR 3 .6140 .03236 .01868 
Total AKT Old PBS 3 .5720 .22188 .12810 
Old AGR 3 .5643 .24553 .14176 
pS6K Old PBS 3 .4033 .14066 .08121 
Old AGR 3 .4473 .17957 .10367 
Total S6K Old PBS 3 .8073 .05181 .02991 
Old AGR 3 .6957 .18874 .10897 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  






Difference Lower Upper 
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pAKT Equal variances 
assumed 
2.588 .183 -1.246 4 .281 -.05133 .04118 -.16568 .06301 
Equal variances 
not assumed 





.094 .775 .040 4 .970 .00767 .19106 -.52281 .53815 
Equal variances 
not assumed 
  .040 3.960 .970 .00767 .19106 -.52495 .54029 
pS6K Equal variances 
assumed 
.465 .533 -.334 4 .755 -.04400 .13169 -.40964 .32164 
Equal variances 
not assumed 





4.536 .100 .988 4 .379 .11167 .11300 -.20207 .42540 
Equal variances 
not assumed 
  .988 2.300 .415 .11167 .11300 -.31858 .54192 
 




Category N Mean Std. Deviation Std. Error Mean 
< 1000 Wild-type 3 7.88 2.309 1.333 
Dystrophic 3 22.53 7.765 4.483 
1000 - 2000 Wild-type 3 41.15 9.201 5.312 
Dystrophic 3 31.69 2.168 1.252 
2000 - 3000 Wild-type 3 18.77 2.138 1.235 
Dystrophic 3 20.16 2.233 1.289 
3000 - 4000 Wild-type 3 20.26 4.589 2.649 
Dystrophic 3 13.58 8.402 4.851 






Category N Mean Std. Deviation Std. Error Mean 
< 1000 Wild-type 3 7.88 2.309 1.333 
Dystrophic 3 22.53 7.765 4.483 
1000 - 2000 Wild-type 3 41.15 9.201 5.312 
Dystrophic 3 31.69 2.168 1.252 
2000 - 3000 Wild-type 3 18.77 2.138 1.235 
Dystrophic 3 20.16 2.233 1.289 
3000 - 4000 Wild-type 3 20.26 4.589 2.649 
Dystrophic 3 13.58 8.402 4.851 
> 4000 Wild-type 3 11.95 6.069 3.504 
Dystrophic 3 12.04 6.481 3.742 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  






Difference Lower Upper 
< 1000 Equal variances 
assumed 
6.985 .057 -3.132 4 .035 -14.650 4.677 -27.636 -1.664 
Equal variances 
not assumed 





8.681 .042 1.733 4 .158 9.460 5.457 -5.692 24.613 
Equal variances 
not assumed 















1.995 .231 1.208 4 .294 6.677 5.527 -8.668 22.023 
Equal variances 
not assumed 
  1.208 3.096 .311 6.677 5.527 -10.609 23.963 
> 4000 Equal variances 
assumed 
.020 .895 -.017 4 .987 -.089 5.126 -14.322 14.144 
Equal variances 
not assumed 





Category N Mean Std. Deviation Std. Error Mean 
Coefficient Variation Wild-type 3 .4869 .02217 .01280 
Dystrophic 3 .6891 .05448 .03146 
Independent Samples Test 
  
Levene's Test for 
Equality of 




Interval of the 
Difference 
  













3.617 .130 -5.955 4 .004 -.20223 .03396 -.29652 -.10794 
Equal variances 
not assumed 










Category N Mean Std. Deviation Std. Error Mean 
< 1000 MDX PBS 3 22.53 7.765 4.483 
MDX AGR 3 32.51 17.707 10.223 
1000 - 2000 MDX PBS 3 31.69 2.168 1.252 
MDX AGR 3 32.04 5.507 3.179 
2000 - 3000 MDX PBS 3 20.16 2.233 1.289 
MDX AGR 3 16.07 7.010 4.047 
3000 - 4000 MDX PBS 3 13.58 8.402 4.851 
MDX AGR 3 7.32 2.813 1.624 
> 4000 MDX PBS 3 12.04 6.481 3.742 
MDX AGR 3 12.07 5.711 3.297 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  






Difference Lower Upper 
< 1000 Equal variances 
assumed 
3.281 .144 -.894 4 .422 -9.974 11.163 -40.967 21.019 
Equal variances 
not assumed 















4.150 .111 .965 4 .389 4.098 4.248 -7.695 15.892 
Equal variances 
not assumed 





5.036 .088 1.224 4 .288 6.259 5.115 -7.943 20.462 
Equal variances 
not assumed 
  1.224 2.443 .326 6.259 5.115 -12.337 24.855 
> 4000 Equal variances 
assumed 
.000 .993 -.006 4 .995 -.032 4.987 -13.880 13.815 
Equal variances 
not assumed 






Category N Mean Std. Deviation Std. Error Mean 
Coefficient Variation MDX PBS 3 .6891 .05448 .03146 
MDX AGR 3 .7872 .10927 .06309 
Independent Samples Test 
  
Levene's Test for 
Equality of 




Interval of the 
Difference 
  



















Category N Mean Std. Deviation Std. Error Mean 
Coefficient Variation MDX PBS 3 .6891 .05448 .03146 
Equal variances 
not assumed 





Category N Mean Std. Deviation Std. Error Mean 
Central Nuclei Mdx PBS 3 66.00 5.568 3.215 
Mdx AGR 3 56.33 1.155 .667 
Independent Samples Test 
  
Levene's Test for 




Interval of the 
Difference 
  













4.062 .114 2.945 4 .042 9.667 3.283 .552 18.782 
Equal variances 
not assumed 
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